



US007985554B2

(12) **United States Patent**  
Chapman et al.

(10) **Patent No.:** US 7,985,554 B2  
(45) **Date of Patent:** Jul. 26, 2011

(54) **BOTULINUM NEUROTOXIN A RECEPTOR AND THE USE THEREOF**

(75) Inventors: **Edwin R. Chapman**, Madison, WI (US); **Min Dong**, Madison, WI (US)

(73) Assignee: **Wisconsin Alumni Research Foundation**, Madison, WI (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 771 days.

(21) Appl. No.: **11/546,880**

(22) Filed: **Oct. 12, 2006**

(65) **Prior Publication Data**

US 2010/0249372 A1 Sep. 30, 2010

**Related U.S. Application Data**

(60) Provisional application No. 60/726,879, filed on Oct. 14, 2005.

(51) **Int. Cl.**

**G01N 33/53** (2006.01)

**C08G 63/66** (2006.01)

(52) **U.S. Cl.** ..... **435/7.1; 530/300; 530/324; 435/7.2;**  
..... **435/7.21**

(58) **Field of Classification Search** ..... None  
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2004/0106147 A1\* 6/2004 Lynch et al. .... 435/7.1

FOREIGN PATENT DOCUMENTS

WO 2005/016233 A2 2/2005  
WO 2007/048638 A2 5/2007

OTHER PUBLICATIONS

Mahrhold et al (FEBS Letters, 580(8):2011-2014, Apr. 3, 2006).\*  
GenBank Accession No. L10362 first publicly available Jun. 7, 1993, image in office action.\*

GenBank Accession No. NM-057210 first publically available Nov. 21, 2001, image in office action.\*

GenBank Accession No. NM\_022030 first publically available Dec. 4, 2000, image in office action.\*

GenBank Accession No. NM\_153579 publically available Dec. 19, 2002, image in office action.\*

GenBank Accession No. XM\_127490 publically available Oct. 30, 2003, image in office action.\*

GenBank Accession No. NM\_014849 first publically available Apr. 27, 2000, image in office action.\*

GenBank Accession No. BC030011 first publically available Aug. 2, 2005, image in office action.\*

GenBank Accession No. BC100827 first publically available Aug. 2, 2005, image in office action.\*

Bajjalieh SM et al., J. Neurosci., 1994, 14:5223-5235.

Bajjalieh SM et al., Proc. Natl. Acad. Sci. USA, 1993, 90:2150-2154.

Feany MB et al., Cell, 1992, 70:861-867.

Janz R and Sudhof TC, Neuroscience, 1999, 94:1279-1290.

Janz R et al., Neuron, 1999, 24:1003-1016.

Scranton TW et al., J Neurochem, 1993, 61:29-44.

Bindra PS et al., Gene, 1993, 137:299-302.

Database Genesequence: Jun. 5, 2002, "Novel Central Nervous System Protein #308".

Database UnitProt: Oct. 11, 2005, "12 Days Embryo Embryonic Body Between Diaphragm Region and Neck cDNA, RIKEN Full-Length Enriched Library, Clone:9430053C09 Product:Synaptic Vesicle Glycoprotein 2c, Full Insert Sequence. (Fragment)."

Robinson Renee F et al, The Annals of Pharmacotherapy, 2003, (37)1:127-131.

Dong Min et al. Science, 2006, 28:592-596.

Marhold Stefan et al., FEBS Letters, 2006, (580)8:2011-2014.

Buckley K et al., Journal of Cell Biology, 1985, 100:1284-1294.

ISR Jul. 26, 2007 PCT/US2006/040685.

\* cited by examiner

*Primary Examiner* — Patricia A Duffy

(74) *Attorney, Agent, or Firm* — Quarles & Brady, LLP

(57) **ABSTRACT**

The present invention is based on the identification of synaptic vessel glycoprotein SV2 as the BoNT/A receptor and the further identification of various BoNT/A-binding fragments of SV2. The disclosure here provides new tools for diagnosing and treating botulism.

**12 Claims, 9 Drawing Sheets**  
**(7 of 9 Drawing Sheet(s) Filed in Color)**




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8

Y Y G L T V W F P D M I R H L Q S D E Y	Majority
-----+-----+-----	
450	460
-----+-----+-----	
447 Y Y G L S V W F P D V I K H L Q S D E Y	SV2C-rat-protein
461 Y Y G L T V W F P D M I R H L Q A V D Y	SV2A-human-protein
404 Y Y G L T V W F P D M I R Y F Q D E E Y	SV2B-human-protein
447 Y Y G L S V W F P D V I K P L Q S D E Y	SV2C-human-protein
461 Y Y G L T V W F P D M I R H L Q A V D Y	SV2A-mouse-protein
404 Y Y G L T V W F P D M I R Y F Q D E E Y	SV2B-mouse-protein
447 Y Y G L S V W F P D V I K H L Q S D E Y	sv2c-mice-protein
-----+-----+-----	
A L L T K V F Q G E K V A N F T I N F T	Majority
-----+-----+-----	
470	480
-----+-----+-----	
467 A L L T R N V Q K D K Y A N F S I N F T	SV2C-rat-protein
481 A S R T K V F P G E R V E H V T F N F T	SV2A-human-protein
424 K S K M K V F F G E H V Y G A T I N F T	SV2B-human-protein
467 A L L T R N V R E D K Y A N F T I N F T	SV2C-human-protein
481 A A R T K V F P G E R V E H V T F N F T	SV2A-mouse-protein
424 K S K M K V F F G E H V H G A T I N F T	SV2B-mouse-protein
467 A L L T R N V Q K D K Y A N F S I N F T	sv2c-mice-protein
-----+-----+-----	
M E N Q I H T G G E Y V N D K F I G V K	Majority
-----+-----+-----	
490	500
-----+-----+-----	
487 M E N Q V H T G M E Y D N G R F L G V K	SV2C-rat-protein
501 L E N Q I H R G G Q Y F N D K F I G L R	SV2A-human-protein
444 M E N Q I H Q H G K L V N D K F T R M Y	SV2B-human-protein
487 M E N Q I H T G M E Y D N G R F I G V K	SV2C-human-protein
501 L E N Q I H R G G Q Y F N D K F I G L R	SV2A-mouse-protein
444 M E N Q I H Q H G K L V N D K F I K M Y	SV2B-mouse-protein
487 M E N Q I H T G M E Y E N G R F L G V K	sv2c-mice-protein
-----+-----+-----	
F K S V T F E D S V F K S C Y F E D V T	Majority
-----+-----+-----	
510	520
-----+-----+-----	
507 F K S V T F K D S V F K S C T F D D V T	SV2C-rat-protein
521 L K S V S F E D S L F E E C Y F E D V T	SV2A-human-protein
464 F K H V L F E D T F F D E C Y F E D V T	SV2B-human-protein
507 F K S V T F K D S V F K S C T F E D V T	SV2C-human-protein
521 L K S V S F E D S L F E E C Y F E D V T	SV2A-mouse-protein
464 F K H V L F E D T F F D K C Y F E D V T	SV2B-mouse-protein
507 F K S V T F K D S V F K S C T F D D V T	sv2c-mice-protein
-----+-----+-----	
S V N T Y F K N C T F I D T V F Y N T D	Majority
-----+-----+-----	
530	540
-----+-----+-----	
527 S V N T Y F K N C T F I D T L F E N T D	SV2C-rat-protein
541 S S N T F F R N C T F I N T V F Y N T D	SV2A-human-protein
484 S T D T Y F K N C T I E S T I F Y N T D	SV2B-human-protein
527 S V N T Y F K N C T F I D T V F D N T D	SV2C-human-protein
541 S S N T F F R N C T F I N T V F Y N T D	SV2A-mouse-protein
484 S T D T Y F K N C T I E S T T F Y N T D	SV2B-mouse-protein
527 S V N T Y F K N C T F I D T L F D N T D	sv2c-mice-protein
-----+-----+-----	
L E E Y K F I N S R F I N S T F L H N K	Majority
-----+-----+-----	
550	560
-----+-----+-----	
547 F E P Y K F I D S E F Q N C S F L H N K	SV2C-rat-protein
561 L F E Y K F V N S R L I N S T F L H N K	SV2A-human-protein
504 L Y E H K F I N C R F I N S T F L E Q K	SV2B-human-protein
547 F E P Y K F I D S E F K N C S F F H N K	SV2C-human-protein
561 L F E Y K F V N S R L V N S T F L H N K	SV2A-mouse-protein
504 L Y K H K F I N C R F I N S T F L E Q K	SV2B-mouse-protein
547 F E P Y K F I D S E F Q N C S F L H N K	sv2c-mice-protein

1

**BOTULINUM NEUROTOXIN A RECEPTOR  
AND THE USE THEREOF**

**CROSS-REFERENCE TO RELATED  
APPLICATIONS**

This application claims the benefit of U.S. Patent Application No. 60/726,879, filed on Oct. 14, 2005, which is herein incorporated by reference in its entirety.

**STATEMENT REGARDING FEDERALLY  
SPONSORED RESEARCH OR DEVELOPMENT**

This invention was made with United States government support awarded by the following agencies: NIH AI057153 and AI057744. The United States government has certain rights in this invention.

**BACKGROUND OF THE INVENTION**

Botulinum neurotoxin A (BoNT/A) is one of seven botulinum neurotoxins (designated BoNT/A-G) produced by the anaerobic bacteria strain *Clostridium botulinum* (Schiavo G et al., *Physiol. Rev.* 80:717-766, 2000). BoNTs block neurotransmitter release by cleaving members of the membrane fusion machinery composed of SNAP-25, vamp-2/synaptobrevin (Syb), and syntaxin (Jahn R and Niemann H, *Ann. NY Acad. Sci.* 733:245-255, 1994; Schiavo G et al., *supra*, 2000). Cleavage of these proteins in motor nerve terminals blocks acetylcholine release at the neuromuscular junction (NMJ) which causes paralysis and may lead to death due to respiratory failure (Schiavo G. et al., *supra*, 2000; Simpson L L, *Ann. Rev. Pharmacol. Toxicol.* 44:167-193, 2004). Due to extreme potency and lethality as well as ease of use and transport, BoNTs are considered one of the six most dangerous potential bioterrorism threats (designated by Center for Disease Control of United States) (Amon S S et al., *JAMA* 285:1059-1070, 2001). According to the American Medical Society, as little as one gram of crystalline toxin is sufficient to kill one million people.

Currently, the standard test for BoNTs is the mouse bioassay available at the Centers for Disease Control and Prevention (CDC) and select laboratories across the country. The test involves treating mice with clinical samples suspected of carrying one of the BoNTs. The mice are immunized against the various BoNTs, and only those mice immunized against the specific BoNT present in the sample will survive. Although the test is sensitive in that it can detect as little as 0.03 ng of a BoNT, it is expensive and takes days to complete. On the treatment side, equine antitoxin containing antibodies against a BoNT is the therapy of choice and its effectiveness depends on timely treatment. This treatment, however, has all the disadvantages of a horse serum product such as the risks of anaphylaxis and serum sickness. Many times, treatment begins before botulism is confirmed as the diagnostic test takes days which is too long to wait for effective treatment. Therefore, there is a need in the art for alternative detection and treatment strategies.

**BRIEF SUMMARY OF THE INVENTION**

The present invention is based on the identification of synaptic vessel glycoprotein SV2 as the BoNT/A receptor and the further identification of various BoNT/A-binding fragments of SV2. The disclosure here provides new tools for diagnosing and treating botulism.

2

**BRIEF DESCRIPTION OF THE SEVERAL  
VIEWS OF THE DRAWINGS**

The file of this patent contains at least one drawing executed in color. Copies of this patent with color drawings will be provided by the Patent and Trademark Office upon request and payment of the necessary fee.

FIG. 1 shows that stimulating synaptic vesicle exocytosis increases BoNT/A binding to diaphragm motor nerve terminals and cultured hippocampal neurons. Panel a: Mouse hemi-diaphragm preparations were exposed to BoNT/A (25 nM) in either resting conditions (control buffer) or stimulated conditions (High K<sup>+</sup> buffer: 45 mM KCl). The tissue was fixed and permeabilized. Neuromuscular junctions (NMJs) were labeled with Alexa-488 conjugated α-BTX. BoNT/A was detected with a polyclonal BoNT/A antibody and a Cy3-conjugated secondary antibody. The overlay of regions indicated by rectangles was enlarged to show that BoNT/A staining mirrors α-BTX staining at individual NMJs. Right panel: BoNT/A binding to NMJs was quantified. NMJ regions (region of interest, ROI) were defined by α-BTX signals. The intensity of BoNT/A staining was normalized to α-BTX signals and the ratios were plotted on the Y-axis. Stimulation with high K<sup>+</sup> buffer resulted in an approximate 6-fold increase in BoNT/A intensity. Error bars represent SEM (n=27-28 images). Panel b: Cultured rat hippocampal neurons were exposed to BoNT/A (10 nM) and an antibody against the luminal domain of synaptotagmin I (Syt I<sub>N</sub> Ab; CI604.4, 1:40) for 1 min in three different buffer conditions: (1) Normal buffer (PBS), (2) High K<sup>+</sup> (56 mM KCl), and (3) High K<sup>+</sup>/No Ca<sup>2+</sup> (without Ca<sup>2+</sup>). Stimulating neurons with high K<sup>+</sup> increased Syt I<sub>N</sub> Ab immunofluorescence signals. This increase was not seen without extracellular Ca<sup>2+</sup>. BoNT/A signals largely co-localize with Syt I<sub>N</sub> Ab signals. The third image column on the right shows images obtained from differential interference contrast microscopy (DIC). Panel c: Rat hippocampal neurons pretreated with BoNT/B (30 nM, 24 h) were exposed to BoNT/A (10 nM) for 10 min in High K<sup>+</sup> buffer. Cells were fixed and immunostained for Syb II and BoNT/A. BoNT/A binding is abolished by BoNT/B treatment, which cleaves Syb II in neurons. Neurons that were not treated with BoNT/B served as controls. The third image column on the right shows images obtained from DIC microscopy.

FIG. 2 shows that BoNT/A binds directly to SV2 luminal domains. Panel a: Monoclonal antibodies against the synaptic vesicle proteins synaptophysin (Syp, CI7.2) and SV2 (pan-SV2), were used to co-immunoprecipitate BoNT/A (100 nM) from rat brain detergent extract. Control samples without antibodies (No Ab) were carried out in parallel. Immunoprecipitated toxin and vesicle proteins were detected by western blot. BoNT/A co-immunoprecipitated with SV2, but not Syp. Panel b: Co-immunoprecipitations of BoNT/A from mouse brain detergent extract were carried out with pan-SV2 antibodies, with or without exogenous gangliosides (mixture of bovine brain gangliosides, 0.6 mg/ml), at the indicated BoNT/A concentrations. Adding gangliosides increased the amount of BoNT/A co-immunoprecipitated by SV2 antibodies. Panel c: The 4<sup>th</sup> luminal domains of all three SV2 isoforms (see panel d for SV2 topology) were purified as GST-tagged proteins and immobilized on glutathione-sepharose beads. Pull down assay were carried out using 8 µg immobilized proteins and 100 nM toxins (BoNT/A, B or E). Bound materials were analyzed by western blot with anti-BoNT/A, B,E antibodies. BoNT/A binds directly to all SV2 isoforms with the luminal domain of SV2C showing the highest apparent affinity. Panel d: Schematic view of putative SV2 topol-

ogy. Each circle represents a residue. Filled circles indicate conserved residues in all SV2A, B and C isoforms, gray circles are residues conserved in two of SV2 isoforms, and open circles represent non-conserved residues. SV2 contains 12 transmembrane domains with its N- and C-terminus facing the cytoplasm. The 4<sup>th</sup> luminal domain (L4) lies inside vesicles and contains three putative N-glycosylation sites, indicated. The critical region in SV2C for BoNT/A binding is indicated by arrows (see panel e for details). Panel e: A series of truncation mutants within SV2C-L4 were generated as GST fusion proteins and tested for BoNT/A binding. Binding assays were performed as described in panel b and analyzed by western blot. The critical region for BoNT/A binding was mapped to a short fragment (residues 529-566 in SV2C), which alone maintains the ability to bind BoNT/A. Immobilized GST fusion proteins were shown by Ponceau S staining to ensure that equal amount of immobilized protein were used in the assay. The protein sequence of this region is aligned with regions of SV2A and B (all are rat sequences), with putative N-glycosylation sites indicated by asterisks.

FIG. 3 shows the block of BoNT/A binding and entry into hippocampal neurons and motor nerve terminals by an SV2C luminal fragment. Panel a, left panel: hippocampal neurons were exposed to BoNT/A (10 nM) and Syt I<sub>N</sub> Ab in High K<sup>+</sup> buffers for 10 min, with the presence of either control protein (soluble GST, 10 μM) or SV2C-L4 (soluble GST tagged SV2C-L4 fragment, 10 μM). Cells were washed and fixed. Binding and uptake of Syt I<sub>N</sub> Ab and BoNT/A were analyzed through subsequent immunostaining. SV2C-L4 did not affect Syt I<sub>N</sub> Ab uptake into neurons, but reduced BoNT/A binding to the same neurons. Panel a, right panel: The experiment was carried out as described above except using BoNT/B instead of BoNT/A. SV2C-L4 did not affect BoNT/B binding to neurons. Panel b: Hippocampal neurons were incubated with BoNT/A (10 nM), in the presence of either GST proteins or SV2C-L4, for 10 min in High K<sup>+</sup> buffers. Cells were washed three times and further incubated for 6 hrs in culture medium. Cells were then fixed and permeabilized. Cleavage of SNAP-25 was detected using a monoclonal antibody (anti-SNAP-25-C) that only recognizes cleaved SNAP-25 (but not intact full-length SNAP-25). SV2C-L4 prevented the cleavage of native SNAP-25 by BoNT/A. The third image column on the right shows images obtained from DIC microscopy. Panel c: Mouse hemi-diaphragm preparations were exposed to BoNT/A (10 nM) or BoNT/B (10 nM) in the presence of either GST protein or SV2C-L4 for 30 min in High K<sup>+</sup> buffer. Tissues were washed, fixed and permeabilized. NMJs were labeled with α-BTX. BoNT/A and B were detected with their polyclonal antibodies, respectively. SV2C-L4 specifically reduced binding of BoNT/A to NMJs, while it has no effect on BoNT/B binding. Panel d: Binding of BoNT/A and B to NMJs, based on images collected in panel c, were quantified as described in FIG. 1a. SV2C-L4 significantly reduced BoNT/A binding (65% reduction compared to control, P<0.0001, t-test, n=76-90 images), but did not affect BoNT/B binding (P>0.05, t-test, n=49-55 images). Error bars represent SEM.

FIG. 4 shows that BoNT/A binding is abolished in SV2A and B knockout hippocampal neurons. Panel a: Hippocampal neurons from SV2B knockout (SV2B(−/−)) mice and wild-type (WT) littermate controls were cultured. Neurons were exposed to BoNT/A (15 nM) and BoNT/B (7.5 nM) in High K<sup>+</sup> for 10 min. They were washed three times to reduce surface bound toxins, fixed and permeabilized. Immunofluorescence signals for BoNT/A and B were detected and quantified, and plotted as normalized intensity ratios (% WT signals). SV2B(−/−) neurons displayed significantly reduced

BoNT/A uptake (28% reduction compared to WT, P<0.0001, t-test, n=18 images). BoNT/B uptake level remained the same for SV2B(−/−) and WT neurons (P>0.05, t-test, n=22 images). Error bars represent SD. Panel b: Hippocampal neurons from littermates with the following genotypes: SV2A (+/+SV2B(−/−)), SV2A(+/+SV2B(−/−)), and double knockout SV2A(−/−)SV2B(−/−) were cultured. Cultures were exposed to BoNT/A (10 nM) and BoNT/B (7.5 nM) simultaneously for 10 min. Cells were washed three times, fixed and permeabilized. Triple immunostaining was performed (BoNT/B: rabbit anti-BoNT/B; BoNT/A: human anti-BoNT/A; SV2: mouse pan-SV2). Binding of BoNT/B to neurons was not altered between different genotypes. SV2B knockout and SV2A heterozygotes (SV2A(+−)SV2B(−/−)) showed reduced BoNT/A binding. SV2A/B double knockouts showed no binding of BoNT/A. Panel c: Images collected in panel b were thresholded to only include neurons. The average intensity (background subtracted) was plotted as normalized data (% of SV2A(+/+)). SV2A(+−)SV2B(−/−) neurons displayed a 53% reduction compared to SV2A(+/+SV2B(−/−)), and SV2A/B double knockouts showed no binding of BoNT/A. The binding of BoNT/B remained the same for all genotypes (P>0.05, t-test, n=11 images).

FIG. 5 shows that introducing SV2A, B or C in SV2A/B double knockout neurons rescues BoNT/A binding. Rat SV2A, B and C were subcloned into a lentiviral vector under control of a neuronal specific synapsin promoter, and were used to transfect hippocampal neurons from SV2A/B double knockout mice. Forty-eight hrs after transfection, neurons were exposed to BoNT/A (10 nM) for 10 min. Cells were washed three times, fixed, and permeabilized. Immunostaining for SV2 and BoNT/A were performed as described in FIG. 4b. Transfected neurons were identified by GFP expression, which is under control of a separated synapsin promoter in the vector. Expression of exogenous un-tagged SV2 isoforms were confirmed by SV2 staining, and BoNT/A selectively bound to transfected cells. The overlay images of regions indicated by white rectangles are enlarged to show the high degree of colocalization between SV2 expression and BoNT/A signals.

FIG. 6 shows that SV2 knockout mice have reduced BoNT/A binding at diaphragm motor nerve terminals and are more resistant to BoNT/A. Panel a: Mouse diaphragms were prepared from wild-type (WT) and SV2A(+−)SV2B(−/−) mice. Half of the diaphragm was exposed to BoNT/A (25 nM) in stimulated conditions for 1 hr. The tissue was fixed and immunostained with α-BTX and BoNT/A antibody as described in FIG. 1a. The other half of the diaphragm was exposed to BoNT/B (25 nM), and immunostained in parallel. Representative images are shown. Panel b: Images collected in panel a were quantified as described in FIG. 1a. SV2A(+−)SV2B(−/−) mice showed significantly less BoNT/A binding compared to WT (72% reduction, P<0.001, t-test, n=47 images), while BoNT/B binding is the same (P>0.05, t-test, n=20 images). Panel c: The susceptibility of SV2B(−/−) mice and their WT littermates to BoNT/A was determined by a rapid time-to-death assay. The same amount of BoNT/A was injected into each mouse, and their survival time (time-to-death) recorded. The average effective toxicity (LD<sub>50</sub>/ml) were estimated from time-to-death data using a standard curve. SV2B(−/−) mice live significantly longer than WT mice (43 min versus 33 min, P<0.05, paired t-test). The effective toxicity of injected BoNT/A in WT mice is about 2.5-fold greater than SV2B knockout mice.

FIG. 7 shows that a peptide containing the BoNT/B binding site specifically inhibits BoNT/B, but not BoNT/A binding to hippocampal neurons, and SV2C-L4 does not affect

BoNT/E binding. Panel a: Peptide P21 is derived from the synaptotagmin II luminal domain (Dong M et al., *J. Cell. Biol.* 162:1293-1303, 2003). P21S is a scrambled version of P21 that serves as a control (Dong M et al., *supra*, 2003). Cultured hippocampal neurons were exposed to BoNT/B (10 nM) and Syt I<sub>N</sub> Ab in High K<sup>+</sup> buffers for 10 min, in the presence of P21 (30 μM) or P21S. Cells were washed and fixed. Binding and uptake of Syt I<sub>N</sub> Ab and BoNT/B were analyzed through subsequent immunostaining as described in FIG. 3a. P21 inhibited BoNT/B binding to neurons, while uptake of Syt I<sub>N</sub> Ab is not affected. Panel b: Experiments were carried out as described in panel a with BoNT/A instead of BoNT/B. P21 peptide did not affect BoNT/A binding to hippocampal neurons. Panel c: Hippocampal neurons were exposed to BoNT/E (10 nM) and Syt I<sub>N</sub> Ab in High K<sup>+</sup> buffers for 10 min, in the presence of GST (10 μM) or SV2C-L4 (10 μM). Binding of BoNT/E was detected with a polyclonal anti-BoNT/E antibody. SV2C-L4 did not affect BoNT/E binding to neurons.

FIG. 8 shows that motor nerve terminals at mouse diaphragm express SV2A, B and C. Mouse hemi-diaphragms were excised, immediately fixed in 4% paraformaldehyde for 30 min, permeabilized, and blocked. Expression of SV2A, B or C was detected by their specific polyclonal antibodies (1:1000). NMJs were labeled with α-BTX. All SV2 isoforms were observed at NMJs, presumably at presynaptic nerve terminals.

FIG. 9 shows an alignment of partial sequences of rat SV2C (SEQ ID NO:6), human SV2A (SEQ ID NO:14), human SV2B (SEQ ID NO:16), human SV2C (SEQ ID NO:18), mouse SV2A (SEQ ID NO:8), mouse SV2B (SEQ ID NO:10), and mouse SV2C (SEQ ID NO:12).

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention is based on the identification of synaptic vesicle glycoprotein SV2 as the BoNT/A receptor as well as the identification of various BoNT/A-binding fragments of SV2. The disclosure here provides new prevention and treatment strategies for BoNT/A toxicity and the botulism disease. The disclosure here also provides new tools for identifying agents that can reduce SV2-BoNT/A binding, BoNT/A cellular entry, and BoNT/A toxicity.

In some species (e.g., human, rat, and mouse), three SV2 isoforms, namely SV2A, SV2B, and SV2C, have been identified. Using rat SV2 as an example, the inventors found that all three isoforms are capable of binding to and serve as the receptor for BoNT/A. In other species such as bovine and electric ray (*Discopyge ommatta*), only one isoform has been identified so far. The bovine SV2 cDNA is closer to SV2A than SV2B and SV2C, and the electric ray SV2 cDNA is closer to SV2C than SV2A and SV2B. It is known in the art that the function and amino acid sequences of SV2A, SV2B, and SV2C are conserved across animal species (mammalian species in particular). At protein level, there is at least 62% identity among known SV2 proteins (human, mouse, rat, bovine, and electric ray) and at least 57% identity among the luminal domains of known SV2 proteins. For known SV2A and bovine SV proteins, the amino acid sequence identity is over 98% for the whole protein and 100% for the luminal domain. For known SV2B proteins, the amino acid sequence identity is over 94% for the whole protein and over 96% for the luminal domain. For known SV2C and electric ray SV proteins, the amino acid sequence identity is over 79% (over 96% for mammalian species) for the whole protein and over 76% (over 97% for mammalian species) for the luminal domain. The amino acid sequence identity among rat SV2A,

B, and C luminal domains is 76% and the amino acid sequence identity among mouse SV2A, B, and C luminal domains is 75%. Although the disclosure here is based on the discovery made with rat SV2A, SV2B, and SV2C, it applies to all animal species including all mammalian species. For example, while certain rat SV2C fragments have been shown to be capable of binding to BoNT/A, corresponding fragments from rat SV2A, rat SV2B as well as corresponding fragments from other SV2 homologs are expected to be capable of binding to BoNT/A. Corresponding domains and fragments among all SV2 proteins can be identified using any alignment program familiar to a skilled artisan. For example, the GCG software from Accelrys (San Diego, Calif.) can be used for this purpose (e.g., the MegaAlign program with default parameters).

An SV2 protein typically contains 12 transmembrane domains, 7 cytoplasmic domains, and one large luminal domain (luminal domain 4, L4) (Janz R and Sudhof T C, *Neuroscience* 94:1279-1290, 1999). In the case of rat SV2A, SV2B, and SV2C, the luminal domain spans from amino acid 468 to amino acid 595, amino acid 411 to amino acid 536, and amino acid 454 to amino acid 580, respectively. The inventors have determined that BoNT/A binds to an SV2 protein at its luminal domain. In particular, the inventors have demonstrated that rat SV2C luminal domain fragments amino acids 529-562 and amino acids 454-546 and various other fragments containing the above fragments are capable of binding to BoNT/A. Fragment amino acids 529-566 binds almost as efficiently as the luminal domain itself. Fragments shorter than that spanning amino acids 529-562 or 454-546 may also be able to bind to BoNT/A and a skilled artisan can readily identify these fragments by routine truncation experiments.

Furthermore, a peptide that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% identical to any of the BoNT/A-binding fragments of an SV2 protein discussed above and any such binding fragments with one or more conservative substitutions are expected to be able to bind to BoNT/A. It is well known in the art that the amino acids within the same conservative group can typically substitute for one another without substantially affecting the function of a protein. For the purpose of the present invention, such conservative groups are set forth in Table 1 based on shared properties.

TABLE 1

Conservative substitution.	
Original Residue	Conservative Substitution
Ala (A)	Val, Leu, Ile
Arg (R)	Lys, Gln, Asn
Asn (N)	Gln, His, Lys, Arg
Asp (D)	Glu
Cys (C)	Ser
Gln (Q)	Asn
Glu (E)	Asp
His (H)	Asn, Gln, Lys, Arg
Ile (I)	Leu, Val, Met, Ala, Phe
Leu (L)	Ile, Val, Met, Ala, Phe
Lys (K)	Arg, Gln, Asn

TABLE 1-continued

Conservative substitution.	
Original Residue	Conservative Substitution
Met (M)	Leu, Phe, Ile
Phe (F)	Leu, Val, Ile, Ala
Pro (P)	Gly
Ser (S)	Thr
Thr (T)	Ser
Trp (W)	Tyr, Phe
Tyr (Y)	Trp, Phe, Thr, Ser
Val (V)	Ile, Leu, Met, Phe, Ala

The cDNA and amino acid sequences for rat SV2A (cDNA sequence is set forth in SEQ ID NO:1 and amino acid sequence is set forth in SEQ ID NO:2), SV2B (cDNA sequence is set forth in SEQ ID NO:3 and amino acid sequence is set forth in SEQ ID NO:4), and SV2C (cDNA sequence is set forth in SEQ ID NO:5 and amino acid sequence is set forth in SEQ ID NO:6) can be found at GenBank Accession Nos. NM\_057210, L10362, and NM\_031593, respectively. The cDNA and amino acid sequences for mouse SV2A (cDNA sequence is set forth in SEQ ID NO:7 and amino acid sequence is set forth in SEQ ID NO:8), SV2B (cDNA sequence is set forth in SEQ ID NO:9 and amino acid sequence is set forth in SEQ ID NO:10), and SV2C (cDNA sequence is set forth in SEQ ID NO:11 and amino acid sequence is set forth in SEQ ID NO:12) can be found at GenBank Accession Nos. NM\_022030, NM\_153579, and XM\_991257, respectively. The cDNA and amino acid sequences for human SV2A (cDNA sequence is set forth in SEQ ID NO:13 and amino acid sequence is set forth in SEQ ID NO:14), SV2B (cDNA sequence is set forth in SEQ ID NO:15 and amino acid sequence is set forth in SEQ ID NO:16), and SV2C (cDNA sequence is set forth in SEQ ID NO:17 and amino acid sequence is set forth in SEQ ID NO:18) can be found at GenBank Accession Nos. NM\_014849, BC030011, and BC100827, respectively. The cDNA and amino acid sequences for bovine SV2 (cDNA sequence is set forth in SEQ ID NO:19 and amino acid sequence is set forth in SEQ ID NO:20) can be found at GenBank Accession No. NM\_173962. The cDNA and amino acid sequences for electric ray (*Discopyge ommatta*) SV2 (cDNA sequence is set forth in SEQ ID NO:21 and amino acid sequence is set forth in SEQ ID NO:22) can be found at GenBank Accession No. L23403.

#### Polypeptides, Nucleic Acids, Vectors, and Host Cells

The term "isolated polypeptide" or "isolated nucleic acid" used herein means a polypeptide or nucleic acid isolated from its natural environment or prepared using synthetic methods such as those known to one of ordinary skill in the art. Complete purification is not required in either case. The polypeptides and nucleic acids of the invention can be isolated and purified from normally associated material in conventional ways such that in the purified preparation the polypeptide or nucleic acid is the predominant species in the preparation. At the very least, the degree of purification is such that the extraneous material in the preparation does not interfere with use of the polypeptide or nucleic acid of the invention in the manner disclosed herein. The polypeptide or nucleic acid is

preferably at least about 85% pure, more preferably at least about 95% pure and most preferably at least about 99% pure.

Further, an isolated nucleic acid has a structure that is not identical to that of any naturally occurring nucleic acid or to that of any fragment of a naturally occurring genomic nucleic acid spanning more than one gene. An isolated nucleic acid also includes, without limitation, (a) a nucleic acid having a sequence of a naturally occurring genomic or extrachromosomal nucleic acid molecule but which is not flanked by the coding sequences that flank the sequence in its natural position; (b) a nucleic acid incorporated into a vector or into a prokaryote or eukaryote genome such that the resulting molecule is not identical to any naturally occurring vector or genomic DNA; (c) a separate molecule such as a cDNA, a genomic fragment, a fragment produced by polymerase chain reaction (PCR), or a restriction fragment; and (d) a recombinant nucleotide sequence that is part of a hybrid gene, i.e., a gene encoding a fusion protein. Specifically excluded from this definition are nucleic acids present in mixtures of clones, e.g., as these occur in a DNA library such as a cDNA or genomic DNA library. An isolated nucleic acid can be modified or unmodified DNA or RNA, whether fully or partially single-stranded or double-stranded or even triple-stranded. A nucleic acid can be chemically or enzymatically modified and can include so-called non-standard bases such as inosine.

As used in this application, "percent identity" between amino acid or nucleotide sequences is synonymous with "percent homology," which can be determined using the algorithm of Karlin and Altschul (*Proc. Natl. Acad. Sci. USA* 87, 2264-2268, 1990), modified by Karlin and Altschul (*Proc. Natl. Acad. Sci. USA* 90, 5873-5877, 1993), or other methods familiar to a skilled artisan. The noted algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al. (*J. Mol. Biol.* 215, 403-410, 1990). BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12, to obtain nucleotide sequences homologous to a polynucleotide of interest. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3, to obtain amino acid sequences homologous to a reference polypeptide. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (*Nucleic Acids Res.* 25, 3389-3402, 1997). When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. An example of another program for aligning two amino acid sequences (MegaAlign, GCG) is provided earlier in the specification.

In one aspect, the present invention relates to an isolated polypeptide containing an amino acid sequence that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% identical to that of a BoNT/A-binding fragment of an SV2 protein over the entire length of the binding fragment or an amino acid sequence of a BoNT/A-binding fragment of an SV2 protein with one or more conservative substitutions. Preferably, the above isolated polypeptide is capable of binding to BoNT/A. Specifically excluded from the polypeptide of the present invention is one that contains a full length SV2 protein. In one embodiment, an isolated polypeptide that consists of an SV2 luminal domain or that contains an SV2 luminal domain wherein the domain is flanked at one or both ends by a non-native flanking amino acid sequence is also excluded from the present invention. Examples of BoNT/A binding fragments of SV2 proteins include but are not limited to (i) amino acids 529-562 of rat SV2C, (ii) amino acids 486 to 519 of rat SV2B, (iii) amino acids 543 to 576 of rat SV2A, (iv) a fragment of a homolog of the rat SV2C, SV2B, or SV2A

wherein the fragment corresponds to amino acids 529-562 of rat SV2C, amino acids 486 to 519 of rat SV2B, or amino acids 543 to 576 of rat SV2A, respectively (see FIG. 9 for examples), (v) amino acids 454-546 of rat SV2C, (vi) amino acids 411 to 503 of rat SV2B, (vii) amino acids 468 to 560 of rat SV2A, and (viii) a fragment of a homolog of the rat SV2C, SV2B, or SV2A wherein the fragment corresponds to amino acids 454-546 of rat SV2C, amino acids 411 to 503 of rat SV2B, or amino acids 468 to 560 of rat SV2A, respectively (see FIG. 9 for examples).

Preferred BoNT/A binding fragments of SV2 proteins include but are not limited to (i) amino acids 529-566 of rat SV2C, (ii) amino acids 486 to 523 of rat SV2B, (iii) amino acids 543 to 580 of rat SV2A, (iv) a fragment of a homolog of the rat SV2C, SV2B, or SV2A wherein the fragment corresponds to amino acids 529-566 of rat SV2C, amino acids 486 to 523 of rat SV2B, or amino acids 543 to 580 of rat SV2A, respectively. Other preferred BoNT/A binding fragments include the luminal domains of SV2 proteins.

In one embodiment, the polypeptide of the present invention is about the size of an SV2 luminal domain or shorter. For example, the polypeptide of the present invention can be shorter than 129, 128, 127, or 126 amino acids. In another embodiment, the polypeptide of the present invention is shorter than 125, 120, 110, 100, 90, 80, 70, 60, 50, or 40 amino acids.

In another embodiment, the polypeptide of the present invention is soluble in an aqueous solvent (e.g., water with or without other additives). By soluble in an aqueous solvent, we mean that the polypeptide exhibits a solubility of at least 10 µg/ml, preferably at least 50 µg/ml or 100 µg/ml, more preferably at least 500 µg/ml, and most preferably at least 1,000 µg/ml in an aqueous solvent. Whether a polypeptide is soluble in an aqueous solution can be readily determined by a skilled artisan based on its amino acid sequence or through routine experimentation. Examples of soluble polypeptides of the present invention include those that contain all or part of the luminal domain of an SV2 protein but lack at least part of and preferably the entire adjacent transmembrane domain(s). Soluble polypeptides are typically more suitable than insoluble polypeptides for intravenous administration.

The isolated polypeptide of the invention can include one or more amino acids at either or both N-terminal and C-terminal ends of a BoNT/A-binding sequence of an SV2 protein, where the additional amino acid(s) do not materially affect the BoNT/A binding function. Any additional amino acids can, but need not, have advantageous use in purifying, detecting, or stabilizing the polypeptide.

In order to improve the stability and/or binding properties of a polypeptide, the molecule can be modified by the incorporation of non-natural amino acids and/or non-natural chemical linkages between the amino acids. Such molecules are called peptidomimics (H. U. Saragovi et al., *Bio/Technology* 10:773-778, 1992; S. Chen et al., *Proc. Nat'l. Acad. Sci. USA* 89:5872-5876, 1992). The production of such compounds is restricted to chemical synthesis. It is understood that a polypeptide of the present invention can be modified into peptidomimics without abolishing its function. This can be readily achieved by a skilled artisan.

In another aspect, the present invention relates to an isolated nucleic acid containing a coding polynucleotide or its complement wherein the coding polynucleotide has an uninterrupted coding sequence that encodes a polypeptide of the invention as set forth above. A nucleic acid containing a polynucleotide that can hybridize to the coding polynucleotide or its complement, under either stringent or moderately stringent hybridization conditions, is useful for detecting the

coding polypeptide and thus is within the scope of the present invention. Stringent hybridization conditions are defined as hybridizing at 68° C. in 5×SSC/5×Denhardt's solution/1.0% SDS, and washing in 0.2×SSC/0.1% SDS/+100 µg/ml denatured salmon sperm DNA at room temperature, and moderately stringent hybridization conditions are defined as washing in the same buffer at 42° C. Additional guidance regarding such conditions is readily available in the art, for example, by Sambrook et al., 1989, *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Press, N.Y.; and Ausubel et al. (eds.), 1995, *Current Protocols in Molecular Biology*, (John Wiley & Sons, N.Y.) at Unit 2.10. A nucleic acid containing a polynucleotide that is at least 80%, 85%, 90%, or 95% identical to the coding polynucleotide or its complement over the entire length of the coding polynucleotide can also be used as a probe for detecting the coding polynucleotide and is thus within the scope of the present invention. Specifically excluded from the present invention is a nucleic acid that contains a nucleotide sequence encoding a full length SV2 protein. In one embodiment, a nucleic acid that consists of a polynucleotide that encodes an SV2 luminal domain and a nucleic acid that comprises a polynucleotide that encodes a polypeptide having an SV2 luminal domain wherein the domain is flanked at one or both ends by a non-native amino acid sequence are excluded.

In a related aspect, any nucleic acid of the present invention described above can be provided in a vector in a manner known to those skilled in the art. The vector can be a cloning vector or an expression vector. In an expression vector, the polypeptide-encoding polynucleotide is under the transcriptional control of one or more non-native expression control sequences which can include a promoter not natively found adjacent to the polynucleotide such that the encoded polypeptide can be produced when the vector is provided in a compatible host cell or in a cell-free transcription and translation system. Such cell-based and cell-free systems are well known to a skilled artisan. Cells comprising a vector containing a nucleic acid of the invention are themselves within the scope of the present invention. Also within the scope of the present invention is a host cell having the nucleic acid of the present invention integrated into its genome at a non-native site.

#### Ligand-Polypeptide Complexes

In another aspect, the present invention relates to a complex of a ligand and a polypeptide, wherein the polypeptide comprises a member to which the ligand binds, the member being selected from (i) amino acids 529-562 of rat SV2C, (ii) amino acids 486 to 519 of rat SV2B, (iii) amino acids 543 to 576 of rat SV2A, (iv) a fragment of a homolog of the rat SV2C, SV2B, or SV2A wherein the fragment corresponds to amino acids 529-562 of rat SV2C, amino acids 486 to 519 of rat SV2B, or amino acids 543 to 576 of rat SV2A, respectively, (v) amino acids 454-546 of rat SV2C, (vi) amino acids 411 to 503 of rat SV2B, (vii) amino acids 468 to 560 of rat SV2A, (viii) a fragment of a homolog of the rat SV2C, SV2B, or SV2A wherein the fragment corresponds to amino acids 454-546 of rat SV2C, amino acids 411 to 503 of rat SV2B, or amino acids 468 to 560 of rat SV2A, respectively, (ix) an amino acid sequence that is at least 70% identical to any of the amino acid sequences in (i) to (viii) and is capable of binding to BoNT/A, and (x) an amino acid sequence from (i) to (viii) with conservative substitutions and is capable of binding to BoNT/A, with the proviso that where the polypeptide is a full length SV2 protein, the ligand is not a botulinum toxin. The complexes disclosed herein include both those formed in vitro and in vivo.

**11**

In one embodiment, the polypeptide in the complex is a full length SV2 protein.

In another embodiment, the polypeptide in the complex is one of the BoNT/A-binding polypeptides of the present invention provided in the section of "polypeptides, polynucleotides, vectors, and host cells."

In a preferred embodiment, the polypeptide in the complex comprises a member selected from (i) amino acids 529-566 of rat SV2C, (ii) amino acids 486 to 523 of rat SV2B, (iii) amino acids 543 to 580 of rat SV2A, (iv) a fragment of a homolog of the rat SV2C, SV2B, or SV2A wherein the fragment corresponds to amino acids 529-566 of rat SV2C, amino acids 486 to 523 of rat SV2B, or amino acids 543 to 580 of rat SV2A, respectively, (v) amino acids 454-546 of rat SV2C, (vi) amino acids 411 to 503 of rat SV2B, (vii) amino acids 468 to 560 of rat SV2A, and (viii) a fragment of a homolog of the rat SV2C, SV2B, or SV2A wherein the fragment corresponds to amino acids 454-546 of rat SV2C, amino acids 411 to 503 of rat SV2B, or amino acids 468 to 560 of rat SV2A, respectively.

The polypeptide in the complex may be a synthetic or recombinant peptide and it may contain an affinity tag and/or a ganglioside binding site.

In one embodiment, the ligand in the complex is an antibody against the polypeptide or a BoNT/A fragment that binds to the polypeptide. Such an antibody and BoNT/A fragment can reduce the binding between the polypeptide and BoNT/A.

#### Methods for Reducing BoNT/A Neuro-Toxicity

In another aspect, the present invention relates to a method for reducing BoNT/A cellular toxicity in target cells such as neurons. As a result, botulism disease can be prevented or treated. In one embodiment, the method is used to reduce BoNT/A toxicity in a human or non-human animal by administering to the human or non-human animal an agent that can reduce BoNT/A toxicity.

The term "reducing BoNT/A cellular toxicity" encompasses any level of reduction in BoNT/A toxicity. The BoNT/A toxicity can be reduced by reducing the level of an SV2 protein in target cells, by inhibiting BoNT/A-related cellular functions of an SV2 protein in target cells, or by reducing the binding between BoNT/A and an SV2 protein located on the cellular surface of target cells. The binding between BoNT/A and an SV2 protein can be reduced by either blocking the binding directly or by reducing the amount of SV2 proteins available for binding.

There are many methods by which cellular protein levels such as the level of an SV2 protein can be reduced. The present invention is not limited to a particular method in this regard. As an example, the cellular level of an SV2 protein can be reduced by using the antisense technology. For instance, a 20-25mer antisense oligonucleotide directed against the 5' end of an SV2 mRNA can be generated. Phosphorothioate derivatives can be employed on the last three base pairs on the 3' and 5' ends of the antisense oligonucleotide to enhance its half-life and stability. A carrier such as a cationic liposome can be employed to deliver the antisense oligonucleotide. In this regard, the oligonucleotide is mixed with the cationic liposome prepared by mixing 1-alpha dioleylphatidylcelthanolamine with dimethyldioctadecylammonium bromide in a ratio of 5:2 in 1 ml of chloroform. The solvent is evaporated and the lipids resuspended by sonication in 10 ml of saline. Another way to use an antisense oligonucleotide is to engineer it into a vector so that the vector can produce an antisense cRNA that blocks the translation of an SV2 mRNA. Similarly, RNAi techniques, which are now being applied to mammalian systems, are also suited for inhibiting the expression of an

**12**

SV2 protein. (See Zamore, *Nat. Struct. Biol.* 8:746-750, 2001, incorporated herein by reference as if set forth in its entirety).

#### Dominant Negative SV2

In another aspect, the present invention relates to identifying a dominant negative SV2 that can negate the effects of BoNT/A on cells that express the corresponding wild-type SV2. A dominant negative SV2 can be identified by introducing a mutation into a wild-type SV2 gene, expressing the mutated SV2 and the wild-type SV2 in the same host cell and determining the effect of the mutated SV2 on parameters that relate to BoNT/A toxicity, which include but are not limited to susceptibility of the host cell to BoNT/A, integration of newly formed SV2 into the host cell membrane, binding of wild-type SV2 to BoNT/A, and uptake of BoNT/A into the cells. The wild-type SV2 expressed in the host cell can be the endogenous SV2 or an SV2 introduced into the host cell. Any dominant negative SV2 identified is within the scope of the present invention. The identified dominant negative SV2 can be used to negate the effect of BoNT/A.

#### Blocking the Binding Between BoNT/A and SV2

The identification of SV2 as the BoNT/A receptor as well as the BoNT/A-binding sequences on SV2 enable those skilled in the art to block the binding between BoNT/A and its receptor through many strategies available in the art. One strategy involves the use of monoclonal and polyclonal antibodies specific for the BoNT/A-binding sequences on SV2. It is well within the capability of a skilled artisan to generate such monoclonal and polyclonal antibodies. The antibodies so generated are within the scope of the present invention.

Another strategy involves the use of a BoNT/A-binding polypeptide, preferably a soluble BoNT/A-binding polypeptide, to compete with the receptor for BoNT/A binding. For example, the BoNT/A-binding polypeptide of the present invention described above in the section of "polypeptides, polynucleotides, vectors, and host cells" can be employed for this purpose. Other polypeptides that can be employed include those that comprise a full length SV2 protein, those that consist of an SV2 luminal domain, and those that comprise an SV2 luminal domain wherein the domain is flanked at one or both ends by a non-native flanking amino acid sequence.

To block the binding between BoNT/A and its receptor in an animal (human or non-human), a BoNT/A-binding polypeptide from both the same and a different species can be used. The polypeptide can be introduced into the animal by administering the polypeptide directly or by administering a vector that can express the polypeptide in the animal.

Those skilled in the art understand that mutations such as substitutions, insertions and deletions can be introduced into a BoNT/A-binding sequence of an SV2 protein without abolishing their BoNT/A binding activity. Some mutations may even enhance the binding activity. A polypeptide containing such modifications can be used in the method of the present invention. Such polypeptides can be identified by using the screening methods described below.

In addition, as gangliosides may promote formation of stable BoNT/A-SV2 complexes, the binding between BoNT/A and an SV2 protein may be reduced through reducing the binding between the gangliosides and the SV2 protein or through reducing the amount of gangliosides available for binding to the SV2 protein. In a related aspect, when a BoNT/A-binding polypeptide is used for reducing BoNT/A toxicity by forming a complex with BoNT/A, gangliosides may be included to facilitate the formation of the complex.

13

### Identifying Agents that can Block Binding Between BoNT/A and SV2

Agents that can block binding between BoNT/A and SV2 can be screened by employing BoNT/A and a polypeptide that contains a BoNT/A-binding sequence of an SV2 protein under the conditions suitable for BoNT/A to bind the polypeptide. Gangliosides are optionally included in the reaction mixture. The binding between BoNT/A and the polypeptide can be measured in the presence of a test agent and compared to that of a control that is not exposed to the test agent. A lower than control binding in the test group indicates that the agent can block binding between BoNT/A and the SV2 protein. Other BoNT/A-binding polypeptides that can be employed in the method include those of the present invention as described above in the section of "polypeptides, poly-nucleotides, vectors, and host cells."

There are many systems with which a skilled artisan is familiar for assaying the binding between BoNT/A and a BoNT/A-binding polypeptide. Any of these systems can be used in the screening method. Detailed experimental conditions can be readily determined by a skilled artisan. For example, the binding between BoNT/A and the polypeptide described above can be measured *in vitro* (cell free system). A cell culture system in which an SV2 protein is expressed and translocated onto the cellular membrane can also be used. For the cell culture system, in addition to the binding between BoNT/A and the SV2 protein, the cellular entry of BoNT/A and a number of other parameters can also be used as an indicator of binding between BoNT/A and SV2.

Any method known to one of ordinary skill in the art for measuring protein-protein interaction can be used to measure the binding between BoNT/A and a BoNT/A-binding polypeptide. Immunoprecipitation and affinity column isolation are two commonly used methods.

Surface plasmon resonance (SPR) is another commonly used method. SPR uses changes in refractive index to quantify binding and dissociation of macromolecules to ligands covalently linked onto a thin gold chip within a micro flow cell. This technique has been used to study protein-protein interactions in many systems, including the interactions of PA63 with EF and LF (Elliott, J. L. et al., *Biochemistry* 39:6706-6713, 2000). It provides high sensitivity and accuracy and the ability to observe binding and release in real time. Besides the equilibrium dissociation constant ( $K_d$ ), on- and off-rate constants ( $k_a$  and  $k_d$ ) may also be obtained. Typically, a protein to be studied is covalently tethered to a carboxymethyl dextran matrix bonded to the gold chip. Binding of a proteinaceous ligand to the immobilized protein results in a change in refractive index of the dextran/protein layer, and this is quantified by SPR. A BIACore 2000 instrument (Pharmacia Biotech) can be used for these measurements.

For the cell culture system, the binding of BoNT/A to a BoNT/A-binding polypeptide can be assayed by staining the cells, the examples of which are described in the example section below.

### Identifying Agents That Can Bind to a BoNT/A-Binding Sequence of SV2

Agents that can bind to a BoNT/A-binding sequence of an SV2 protein can be used to block the binding between BoNT/A and the SV2 protein. Such agents can be identified by providing a polypeptide that contains a BoNT/A-binding sequence of an SV2 protein to a test agent, and determining whether the agent binds to the BoNT/A-binding sequence. Other BoNT/A-binding polypeptides that can be employed in the method include those of the present invention as described above in the section of "polypeptides, poly-nucleotides, vec-

14

tors, and host cells." Any agent identified by the method can be further tested for the ability to block BoNT/A entry into cells or to neutralize BoNT/A toxicity. A skilled artisan is familiar with the suitable systems that can be used for the further testing. Examples of such systems are provided in the example section below.

The skilled artisan is familiar with many systems in the art for assaying the binding between a polypeptide and an agent. Any of these systems can be used in the method of the present invention. Detailed experimental conditions can be readily determined by a skilled artisan. For example, a polypeptide that contains a BoNT/A-binding sequence of an SV2 protein can be provided on a suitable substrate and exposed to a test agent. The binding of the agent to the polypeptide can be detected either by the loss of ability of the polypeptide to bind to an antibody or by the labeling of the polypeptide if the agent is radioactively, fluorescently, or otherwise labeled. In another example, a polypeptide that contains a BoNT/A-binding sequence of an SV2 protein can be expressed in a host cell, and the cell is then exposed to a test agent. Next, the polypeptide can be isolated, e.g., by immunoprecipitation or electrophoresis, and the binding between the polypeptide and the agent can be determined. As mentioned above, one way to determine the binding between the polypeptide and the agent is to label the agent so that the polypeptide that binds to the agent becomes labeled upon binding. If the test agent is a polypeptide, examples of specific techniques for assaying protein/protein binding as described above can also be used. It should be noted that when a BoNT/A-binding sequence of an SV2 protein used in the screening assay have flanking sequences, it may be necessary to confirm that an agent binds to the BoNT/A-binding sequence rather than the flanking sequences, which can be readily accomplished by a skilled artisan.

### 35 Agents That Can Be Screened

The agents screened in the above screening methods can be, for example, a high molecular weight molecule such as a polypeptide (including, e.g., a polypeptide containing a modified BoNT/A-binding sequence of an SV2 protein, or a monoclonal or polyclonal antibody against a BoNT/A-binding sequence of an SV2 protein), a polysaccharide, a lipid, a nucleic acid, a low molecular weight organic or inorganic molecule, or the like.

Batteries of agents for screening are commercially available in the form of various chemical libraries including peptide libraries. Examples of such libraries include those from ASINEX (i.e. the Combined Wisdom Library of 24,000 manually synthesized organic molecules) and CHEMBRIDGE CORPORATION (i.e. the DIVERSet<sup>TM</sup> library of 50,000 manually synthesized chemical compounds; the SCREEN-Set<sup>TM</sup> library of 24,000 manually synthesized chemical compounds; the CNS-Set<sup>TM</sup> library of 11,000 compounds; the Chemy-Pick<sup>TM</sup> library of up to 300,000 compounds) and linear library, multimeric library and cyclic library (Tecnogen (Italy)). Once an agent with desired activity is identified, a library of derivatives of that agent can be screened for better molecules. Phage display is also a suitable approach for finding novel inhibitors of the interaction between BoNT/A and SV2.

### 60 Methods of Detecting BoNT/A or *Clostridium botulinum*

In another aspect, the present invention relates to a method of detecting BoNT/A or *Clostridium botulinum*. The method involves exposing a sample suspected of containing BoNT/A to an agent that contains a polypeptide having a BoNT/A-binding sequence of an SV2 protein, and detecting binding of the polypeptide to BoNT/A. Other BoNT/A-binding polypeptides that can be employed in the method include

15

those of the present invention as described above in the section of "polypeptides, polynucleotides, vectors, and host cells."

#### Methods for Identifying Polypeptides That Can Bind to BoNT/A

In another aspect, the present invention relates to a method for identifying polypeptides that can bind to BoNT/A. The method involves providing a polypeptide that comprises a BoNT/A-binding sequence of an SV2 protein, modifying the polypeptide at the BoNT/A-binding sequence, and determining whether the modified polypeptide can bind to BoNT/A.

Kits

Any product of the invention described herein can be combined with one or more other reagent, buffer or the like in the form of a kit (e.g., a diagnosis, prevention, or treatment kit) in accord with the understanding of a skilled artisan.

The invention will be more fully understood upon consideration of the following non-limiting example.

#### EXAMPLE

In this example, we demonstrate that BoNT/A binds to all three SV2 isoforms (SV2A, SV2B, and SV2C). Particular binding fragments such as amino acids 529-562, 529-566, and 454-546 of the rat SV2C were also identified. Recombinant SV2 fragments inhibit BoNT/A binding to hippocampal neurons and motor nerve terminals. Significantly, BoNT/A binding to hippocampal neurons was abolished in SV2A/B knockout mice and this binding can be restored by transfecting neurons with SV2. Consistently, BoNT/A binding was reduced at diaphragm motor nerve terminals in SV2 knockout mice, and SV2B knockout mice displayed reduced sensitivity to BoNT/A. These data establish SV2 as the protein receptor for BoNT/A, which mediates toxin entry through synaptic vesicle recycling.

#### Materials and Methods

Materials, antibodies and SV2 knockout mouse lines: Alexa 488-conjugated  $\alpha$ -BTX was purchased from Molecular Probes, Inc. (OR). A mAb that recognizes SNAP-25 after it has been cleaved by BoNT/A (anti-SNAP-25-C) was purchased from Research & Diagnostic Antibodies, Inc. (CA). mAbs directed against SV2 (pan-SV2), Syp (Cl 7.2), Syb II (Cl 69.1) and Syt I (Syt I<sub>N</sub> Ab, Cl 604.4) were generously provided by R. Jahn (Max-Planck-Institute for Biophysical Chemistry, Gottingen, Germany). A human antibody directed against BoNT/A (RAZ-1) was generously provided by J. Marks (University of California—San Francisco, Calif.). Cy2, Cy3, Cy5, Alexa 546 and Alexa 647 conjugated secondary antibodies were purchased from Jackson Laboratories (ME) and Molecular Probes, Inc. Rabbit polyclonal anti-BoNT/A, B and E antibodies and anti-SV2A, B and C antibodies were described in Dong M et al., *J. Cell. Biol.* 162: 1293-1303, 2003; and Janz R and Sudhof T C, *Neuroscience* 94:1279-1290, 1999, both are herein incorporated by reference in their entirety. BoNT/A, B and E were purified as described in Malizio C G, Methods and Protocols, O. Hoist, ed. (Humana Press), pp. 27-39, 2000, which is incorporated by reference in its entirety. A mixture of bovine brain gangliosides was purchased from Matreya LLC (PA). The SV2 knockout mouse lines used in this study were described in Janz R et al., *Neuron* 24:1003-1016, 1999, which is incorporated by reference in its entirety. Mice were genotyped by PCR as described in Janz R et al., supra, 1999.

cDNA, constructs and transfection: Rat SV2A, B and C cDNAs were described in Bajjali S M et al. *Science* 257: 1271-3, 1992; Feany M B et al. *Cell* 70: 861-7, 1992; Bajjali S M et al. *Proc Natl Acad Sci USA* 90: 2150-4, 1993;

16

and Janz R & Sudhof T C *Neuroscience* 94: 1279-90, 1999, all of which are herein incorporated by reference in their entirety. Various SV2 luminal domain fragments were generated by PCR, subcloned into pGEX-2T and purified as GST fusion proteins (Lewis J L et al. *J Biol Chem* 276: 15458-65, 2001). GST and GST tagged SV2C-L4 proteins were also purified using magnetic GST beads according to the manufacturers protocol (Promega, WI), eluted with 40 mM Glutathione (Sigma), and subsequently dialyzed to produce high concentrations of soluble protein.

To transfect hippocampal neurons with SV2 isoforms, full length SV2A, B and C were subcloned into the Lox-Syn-Syn lentivirus vector (provided by P. Scheiffele, Columbia University, NY). This vector is a modified version of pFUGW (Lois C et al., *Science* 295:868-872, 2002) and contains separate neuronal-specific (synapsin) promoters. One promoter controls the expression of SV2 isoforms inserted between BamHI and NotI sites and the other promoter controls expression of EGFP to detect transfected cells. Transfections were performed on neurons 7-10 DIV using Lipofectamine 2000 (Invitrogen) as described in Dean C et al., *Nat. Neurosci.* 6:708-716, 2003 (incorporated by reference in its entirety) and analyzed 48 hrs later. Note: The BamHI site inside the SV2C sequence has been mutated (GGATCC to GGATAC, preserving the amino acid sequence) to simplify subcloning.

Neuronal cell cultures, BoNT uptake, immunocytochemistry: Cultures of hippocampal neurons were prepared from E18-19 rats, and SV2 knockout mouse neuron cultures were prepared from P1 mice. Neurons were plated on poly-D-lysine coated glass coverslips (12 mm) at a density of 50,000/cm<sup>2</sup> and cultured in Neurobasal medium supplemented with B-27 (2%) and Glutamax (2 mM). Experiments were carried out on neurons 10-14 days old.

To assay for BoNT/A uptake under different conditions (FIG. 1b), hippocampal neurons were incubated in one of the following assay buffers (200  $\mu$ l) containing BoNT/A (10 nM) and Syt I<sub>N</sub> Ab (604.4, 1:40) for 1 min. These buffers are: control buffer (PBS: 140 mM NaCl, 3 mM KCl, 1.5 mM KH<sub>2</sub>PO<sub>4</sub>, 8 mM Na<sub>2</sub>HPO<sub>4</sub>, 1 mM CaCl<sub>2</sub>, 0.5 mM MgCl<sub>2</sub>), high K<sup>+</sup> (same as control buffer but adjusted to 56 mM KCl and 87 mM NaCl), and high K<sup>+</sup>/No Ca<sup>2+</sup> buffer (same as high K<sup>+</sup> buffer but lacking CaCl<sub>2</sub>). Neurons were then washed in PBS (3×500  $\mu$ l) and fixed in 4% paraformaldehyde for 15 mM. After permeabilization with 0.3% Triton X-100, neurons were blocked with 10% goat serum and stained with a polyclonal anti-BoNT/A antibody (1:200) for 1 hr at room temperature. The secondary antibodies were Cy2-conjugated goat-anti-mouse and Cy3-conjugated goat-anti-rabbit. Immunofluorescence images were acquired using a confocal microscope (Olympus FV1000, 60x water-immersion objective). Identical gain and laser settings were used for images that were directly compared in the figures. For all experiments using hippocampal neurons after FIG. 1b, neurons were incubated in high K<sup>+</sup> buffer for 10 min in order to increase the amount of toxin entry.

For triple staining of BoNT/A, BoNT/B and SV2 (FIG. 4b), BoNT/B was detected with a rabbit polyclonal antibody (1:200) and a Cy2-conjugated secondary antibody; BoNT/A was detected with a human antibody (RAZ-1, 1:300) and Alexa-546 conjugated secondary antibody; and SV2 expression was detected with a mouse monoclonal antibody (pan-SV2 Ab, 1:400), and Alexa-647 conjugated secondary antibody.

To detect SNAP-25 that has been cleaved by BoNT/A (FIG. 3b), neurons were washed three times after exposure to BoNT/A, and further incubated in culture media for 6 hrs.

Cells were then fixed, permeabilized, and stained with the anti-SNAP-25-C monoclonal antibody (1:50) and the rabbit anti-BoNT/A antibody.

Image J software (NIH) was used to quantify fluorescence intensities shown in FIG. 4. Briefly, a fixed threshold was first chosen for each channel (BoNT/B and BoNT/A) to exclude background signals from regions lacking neurons, and the average intensity of the fluorescence signals from decorated neurons was measured. Neurons that were not exposed to BoNT/A and B were fixed and stained with the same antibodies in parallel. The average intensity of these images was subtracted from samples treated with the toxins. Two-tailed t tests were used to determine statistical significance.

**Co-immunoprecipitation and pull-down assays:** Rat or mice brain detergent extracts were made as described in Lewis J L et al., *J. Biol. Chem.* 276:15458-15465, 2001, which is incorporated by reference in its entirety. BoNT/A was premixed with brain extracts (400 µl, 3-6 mg/ml) for 1 hr at 4° C. before adding antibodies (5 µl), and then further incubated for 1 hr. Protein G Fast Flow beads (40 µl, Amersham Biosciences) were added and incubated for 1 hr. Beads were washed three times in TBS (20 mM Tris, 150 mM NaCl, pH 7.4) plus 0.5% Triton X-100. Bound material was subjected to SDS-PAGE and western blot analysis.

Recombinant GST fusion proteins were purified and immobilized on glutathione-Sepharose beads. Pull down assays were carried out as described in Dong M et al. (supra, 2003), using 8 µg immobilized proteins and 100 nM toxins in 100 µl TBS plus 0.5% Triton X-100. Bound material was subjected to SDS-PAGE and western blot analysis.

**Mouse hemi-diaphragm experiments:** Mouse hemi-diaphragms were kept in either control buffer (FIG. 1a, mammalian Ringer, in mM: NaCl 138.8, KCl 4, NaHCO<sub>3</sub> 12, KH<sub>2</sub>PO<sub>4</sub> 1, MgCl<sub>2</sub> 2, CaCl<sub>2</sub> 2, and glucose 11), or high K<sup>+</sup> buffer (same as control buffer but adjusted to 98 mM NaCl and 45 mM KCl), warmed to 37° C. and gassed with 95% O<sub>2</sub>/5% CO<sub>2</sub>. Hemi-diaphragms were incubated with the indicated BoNTs (25 nM) for 1 hr at room temperature (note: 10 nM BoNT/A was used and incubated for only 30 min in FIG. 3c). After incubation, diaphragms were washed and fixed with 4% paraformaldehyde for 30 min at room temperature, permeabilized and blocked in 5% goat serum plus 0.5% Triton X-100. Diaphragms were incubated with Alexa-488-conjugated α-BTX (1:250) and rabbit anti-BoNT/A or B antibodies (1:1000) at 4° C., overnight. A Cy3-conjugated anti-rabbit secondary antibody was used at a dilution of 1:800. For staining SV2A, B or C in the NMJ (FIG. 8), the hemi-diaphragms were excised and immediately fixed. A 1:1000 dilution of the specific rabbit anti-SV2A, B or C antibodies were used. All images were collected using a confocal microscope (Olympus FV1000, 60× water-immersion objective).

To quantify fluorescent signals, the α-BTX channel was pseudo-colored green and BoNT/A (or BoNT/B) channel was pseudo-colored red. Merged green and red images were imported into MetaMorph software (Improvision). The regions of interests (ROI) marking NMJs were determined by thresholding the α-BTX green channel. The same threshold values were used throughout the diaphragm experiments. The average intensity of green and red channels within ROIs were measured and the ratio between them used to determine the level of toxin binding. Two-tailed t tests were used to determine statistical significance between pairwise sets of data.

**Rapid BoNT toxicity assay in mice:** BoNT/A effective toxicity in mice was estimated using the intravenous method described in Boroff D A and Fleck U, *J. Bacteriology* 92:1580-1581, 1966 (incorporated by reference in its entirety); Dong M et al., supra, 2003; and Malizio C G, supra, 2000. Briefly,

BoNT/A (type A1) isolated from Hall strain was diluted to 10 µg/ml in 30 mM sodium phosphate buffer (pH 6.3 plus 0.2% gelatin). Each mouse was injected intravenously (lateral tail vein) with 0.1 ml of the diluted toxin and their time-to-death was recorded. The time-to-death values were converted to intraperitoneal LD<sub>50</sub>/ml using a standard curve described in Malizio C G, supra, 2000. SV2B knockout mice used in these experiments had been crossed for 6 generation against C57B16/J mice.

## 10 Results

The BoNT/A receptor resides on synaptic vesicles: The physiological target for BoNT/A is peripheral motor nerve terminals (Dolly J O et al., *Nature* 307:457-460, 1984). Stimulation of neuronal activity (i.e. neurotransmitter release) can accelerate the rate of paralysis caused by BoNT/A (Hughes R W, *J. Physiol. (Lond.)* 160:221-233, 1962). However, it is not known whether synaptic vesicle exocytosis directly increases BoNT/A binding and entry into neurons. To address this question, we visualized BoNT/A binding to motor nerve terminals in mouse diaphragm preparations. The neuromuscular junctions (NMJs) in this tissue were labeled with α-bungarotoxin (α-BTX), which binds to postsynaptic acetylcholine receptors (Astrow S H et al., *J. Neurosci.* 12:1602-1615, 1992). As shown in FIG. 1a, high K<sup>+</sup> solution (45 mM KCl), which triggers synaptic vesicle exocytosis, increased BoNT/A binding to NMJs by approximately 6-fold compared to control conditions, indicating that synaptic vesicle exocytosis exposes BoNT/A receptors.

To further analyze whether the BoNT/A receptor is on synaptic vesicles, we used cultured rat hippocampal neurons as a model system. Synaptic vesicle recycling was monitored through the uptake of an antibody that recognizes the luminal domain of synaptotagmin I (Syt I<sub>N</sub>Ab) (Dong M et al., *J. Cell. Biol.* 162:1293-1303, 2003), an abundant synaptic vesicle membrane protein. As shown in FIG. 1b, uptake of Syt I<sub>N</sub>Ab was greatly increased by a short stimulation with high K<sup>+</sup> (56 mM KCl, 1 min), and inhibited by depletion of extracellular Ca<sup>2+</sup>. Interestingly, uptake of BoNT/A to the same neurons mimicked Syt I<sub>N</sub>Ab behavior and largely co-localize with Syt I<sub>N</sub>Ab signals (FIG. 1b). To further confirm this finding, we pretreated these neurons with BoNT/B, which specifically blocks synaptic vesicle exocytosis by cleaving Syb II, a synaptic vesicle membrane protein required for exocytosis (Schiavo G et al., *Nature* 359:832-835, 1992). As shown in FIG. 1c, *BoNT/B treatment abolished uptake of BoNT/A under stimulated conditions, indicating that the BoNT/A receptor resides on vesicles containing Syb II in neurons. Together, these evidences suggest that the receptor for BoNT/A is on synaptic vesicles.*

BoNT/A binds to the luminal domain of SV2: Synaptic vesicles are well-studied organelles, and most, if not all, integral synaptic vesicle proteins have been identified (Fernandez-Chacon R and Sudhoff T C *Ann. Rev. Physiol.* 61:753-776, 1999). We screened known synaptic vesicle membrane proteins for BoNT/A interactions by using their specific antibodies to co-immunoprecipitate BoNT/A from rat brain detergent extracts. As shown in FIG. 2a, an SV2 monoclonal antibody (pan-SV2) was able to immunoprecipitate BoNT/A. This interaction is specific since an antibody against synaptophysin (Syp), another abundant vesicle protein, failed to pull down significant amounts of BoNT/A (FIG. 2a).

We next assessed whether BoNT/A-SV2 interactions are affected by gangliosides. We increased ganglioside concentration in brain detergent extracts by adding exogenous gangliosides. Immunoprecipitations were performed at various BoNT/A concentrations. As indicated in FIG. 2b, adding exogenous gangliosides increased the level of co-immuno-

precipitation of BoNT/A. This effect was not significant at high BoNT/A concentration (100 nM), but became more apparent at low toxin concentration (e.g., 20 nM), indicating gangliosides may promote formation of stable BoNT/A-SV2 complexes at low toxin concentration.

SV2 is a conserved membrane protein on synaptic vesicles and endocrine secretory vesicles in vertebrates (Buckley K and Kelly R B, *J. Cell. Biol.* 100:1284-1294, 1985; Lowe A W et al., *J. Cell. Biol.* 106:51-59, 1988). Three highly homologous isoforms have been identified, denoted as SV2A, B and C (Bajjalieh S M et al., *Proc. Natl. Acad. Sci. USA* 90:2150-2154, 1993; Bajjalieh S M et al., *Science* 257:1271-1273, 1992; Feany M B et al., *Cell* 70:861-867, 1992; Janz R and Sudhof T C, *Neuroscience* 94:1279-1290, 1999). SV2A and B are widely expressed throughout the brain, while the expression of SV2C is more restricted to evolutionarily older brain regions (Bajjalieh S M et al., *J. Neurosci.* 14:5223-5235, 1994; Janz R and Sudhof T C, supra, 1999). The antibody used in FIG. 2a recognizes all three isoforms (Lowe A W et al., supra, 1988). As depicted in FIG. 2d, SV2 isoforms share a similar topology, containing 12 putative transmembrane domains and only one relatively large luminal domain (luminal domain 4, L4) (Janz R and Sudhof T C, supra, 1999). Because the luminal domain of SV2 is the only region exposed to the outside of cells after vesicle exocytosis, we first examined whether BoNT/A binding is mediated by SV2 luminal domains. The major luminal domain (L4) of SV2A, B and C were purified as GST fusion proteins, immobilized on beads and tested for their ability to pull down BoNT/A, B and E from solution. As shown in FIG. 2c, we observed direct binding of BoNT/A, but not BoNT/B or E, to all SV2 isoforms. SV2C showed the most robust binding, and SV2B pulled down the least amount of BoNT/A.

To determine the critical BoNT/A binding region, we made a series of truncation mutants within the SV2C-L4 region. As shown in FIG. 2e, a short fragment (amino acids 529-566) was able to pull down similar levels of BoNT/A to the full L4 region. Sequence alignment showed that this region, indicated in FIG. 2d by arrows, is relatively conserved among SV2 isoforms and includes two putative N-glycosylation sites. It was further observed that a shorter fragment, amino acids 529-562, was also able to pull down BoNT/A, although not as effectively as the 529-566 fragment. In addition, various fragments containing amino acids 454-546 were also able to pull down BoNT/A.

SV2C luminal fragments inhibit BoNT/A binding to neurons: Among the three SV2 isoforms, hippocampal neurons were found to express SV2A and B, but not SV2C (Bajjalieh S M et al., supra, 1994; Janz R and Sudhof T C, supra, 1999). To determine whether SV2 mediates BoNT/A binding in these neurons, we used soluble recombinant SV2C-L4 fragments, which showed the highest apparent affinity for BoNT/A, to inhibit BoNT/A binding to neurons by competing with endogenous SV2A/B. Neurons were exposed to BoNT/A and Syt I<sub>N</sub> Ab for 10 min in the presence of an excess amount of either control protein (GST) or GST-tagged SV2C-L4 fragment. As shown in FIG. 3a, SV2C-L4 reduced BoNT/A binding to neurons compared to GST. Neurons in both conditions showed similar level of Syt I<sub>N</sub> Ab uptake, indicating that the reduction in BoNT/A binding is not due to nonspecific changes in synaptic vesicle recycling.

To further demonstrate the specificity of this inhibition, we tested in parallel another BoNT, BoNT/B, which has been shown to use the synaptic vesicle protein synaptotagmin I/II to enter cells (Dong M et al., supra, 2003; Nishiki T et al., *J. Biol. Chem.* 269:10498-10503, 1994; Nishiki T et al., *Biochim. Biophys. Acta* 1158:333-338, 1993). BoNT/B is an

ideal control since it has similar structure and size to BoNT/A and uses the same entry pathway. As shown in FIG. 3a (right panel), SV2C-L4 did not affect BoNT/B binding to neurons. Furthermore, binding of BoNT/B can be inhibited by adding a peptide (P21) derived from its receptor, synaptotagmin II (Syt II) (Dong M et al., supra, 2003), and addition of this peptide did not affect BoNT/A binding (FIGS. 7a and b). Interestingly, SV2C-L4 also did not affect the binding of BoNT/E, another major BoNT, suggesting BoNT/E does not use SV2 to enter neurons (FIG. 7c).

We further assessed whether the reduction in BoNT/A binding by addition of SV2C-L4 correlates with the protection of endogenous SNAP-25. Taking advantage of a specialized antibody, anti-SNAP-25-C, which only recognizes SNAP-25 fragments cleaved by BoNT/A (FIG. 3b), we monitored the level of cleaved fragments by immunostaining. Neurons were first treated with BoNT/A for 10 min in the presence of either GST or SV2C-L4. These neurons were washed and further incubated for 6 hrs, fixed and immunostained for cleaved SNAP-25 fragments. As shown in FIG. 3b, reduced BoNT/A binding by addition of SV2C-L4 resulted in decreased levels of SNAP-25 cleavage, indicating that SV2C-L4 prevented the functional entry of BoNT/A into neurons.

We extended this study to peripheral motor nerve terminals, the physiological target of BoNT/A in vivo. Using SV2 isoform specific antibodies, we found that motor nerve terminals at NMJs in the diaphragm express all three SV2 isoforms (FIG. 8). Pre-incubation of BoNT/A with a high concentration of SV2C-L4 fragments (30  $\mu$ M) significantly reduced BoNT/A binding to NMJs (65% reduction compared to control, P<0.0001, t-test) (FIGS. 3c and d). This decrease is specific to BoNT/A since SV2C-L4 did not affect BoNT/B binding (FIGS. 3c and d). These data suggest that binding of BoNT/A to motor nerve terminals is mediated by direct interactions with SV2 luminal domains.

BoNT/A binding is abolished in SV2A/B knockout neurons: To determine definitively whether SV2 is the receptor for BoNT/A, we turned to available SV2A and B single knockout and SV2A/B double knockout mice (Janz R et al., *Ann. NY Acad. Sci.* 733:345-255, 1999). Mice lacking SV2A (SV2A single knockout and SV2A/B double knockout) display severe seizures and die within 2-3 weeks of birth, while SV2B single knockout mice are normal. These phenotypes may be because SV2A has wider distribution than SV2B and these two isoforms are functionally redundant (Janz R et al., supra, 1999). Cultured hippocampal neurons from SV2A/B knockout mice develop normal synaptic structures and are capable of releasing neurotransmitter (Janz R et al., supra, 1999). Because these neurons only express SV2A and B, neurons from SV2A/B double knockout mice become an ideal loss-of-function model to study the role of SV2 for BoNT/A binding.

We first tested the function of SV2B by comparing BoNT/A binding to neurons from SV2B knockout (SV2B (-/-)) mice and wild-type littermate controls (WT). Neurons were exposed to BoNT/A and B simultaneously for 10 min in High K<sup>+</sup> buffer, washed and fixed. Binding of BoNT/A and B to neurons was quantified by measuring immunofluorescence intensity (see Methods for details). Normalized average intensities (% WT) are shown in FIG. 4a. SV2B knockout neurons showed significantly reduced BoNT/A binding (28% reduction compared to WT, P<0.0001, t-test), while BoNT/B binding remained the same. These data suggest that lack of SV2B does not affect the toxin entry pathway—synaptic vesicle recycling—in general, but rather specifically reduced BoNT/A binding surface binding sites.

Because SV2B(−/−) neurons still express SV2A, we asked whether remaining binding of BoNT/A is mediated by SV2A. By breeding SV2A(+−)SV2B(−/−) mice, we generated littermates that have no SV2B but wild-type levels of SV2A (SV2A(+/+)SV2B(−/−)), no SV2B and half the levels of SV2A (SV2A(+−)SV2B(−/−)), and SV2A/B double knockouts (SV2A(−/−)SV2B(−/−)) (FIG. 4b). Neurons cultured from these littermates were exposed to BoNT/A and B, washed and fixed. Triple immunostaining of BoNT/A, BoNT/B and SV2 were performed and representative images from each genotype are shown in FIG. 4b. Quantification of immunofluorescence intensity showed that BoNT/A binding to SV2A(+−)SV2B(−/−) neurons is only 47% of SV2A(+/+)SV2B(−/−) neurons (FIG. 4c). Interestingly, the majority of BoNT/A binding in SV2A(+−)SV2B(−/−) neurons colocalized with SV2A expression (FIG. 4b middle frames). Strikingly, there is virtually no binding of BoNT/A to SV2A/B double knockout neurons (FIGS. 4b and c). These changes in binding are specific to BoNT/A, since BoNT/B binding to each genotype remained the same (FIGS. 4b and c). This indicates that SVA/B knockouts specifically abolished BoNT/A recognition sites instead of causing other entry pathway defects. Together with the fact that SV2C luminal fragments were able to inhibit BoNT/A binding, we have established that BoNT/A binding to hippocampal neurons is mediated by direct interactions with SV2A and B.

Expression of SV2 restores BoNT/A binding to SV2A/B knockout neurons: Using hippocampal neurons from SV2A/B double knockout mice, we carried out rescue studies to determine whether expression of SV2A, B or C can restore BoNT/A binding. Rat SV2A, B or C were transfected into these neurons, with a lentiviral vector that can express SV2 and GFP simultaneously under separated neuronal specific promoters (synapsin promoter, details described in Methods). Forty eight hrs post-transfection, neurons were exposed to BoNT/A for 10 min, washed, and binding of BoNT/A assessed by immunostaining. Transfected neurons were identified by GFP fluorescence signals and expression of SV2 in these neurons were confirmed by immunostaining. As shown in FIG. 5, BoNT/A binding was only observed on neurons transfected with SV2A, B or C, while other neurons in the same field showed no binding. Enlarged overlay images between SV2 and BoNT/A signals showed a high degree of colocalization at synapses (FIG. 5, overlay). The high level of SV2 expression in the cell soma is likely due to over-expression of exogenous proteins since it is not found in immunostaining of endogenous SV2 in wild-type neurons. Overexpression of another synaptic vesicle protein, synaptotagmin I, using the same viral vector did not result in detectable BoNT/A fluorescence signals, confirming the specificity of the rescue effect. SV2A, B or C all rescued BoNT/A binding, indicating all three isoforms can mediate BoNT/A binding to neurons once expressed.

BoNT/A binding to motor terminals is reduced in SV2A/B knockout mice: To determine whether SV2 function as a receptor for BoNT/A at its physiological target, we examined

BoNT/A binding to diaphragm nerve terminals from SV2 knockout mice. These nerves normally express all three SV2 isoforms (FIG. 8) and we expect they all contribute to BoNT/A recognition of motor terminals. Because SV2A knockout and SV2A/B double knockout mice do not survive to adulthood and SV2C knockout mice are not available, we compared diaphragm preparations from available adult knockout mice that have the least amount of SV2 expression (SV2A(+−) SV2B(−/−)), to wild-type (WT). As shown in FIGS. 6a and b, BoNT/A binding to NMJs from SV2A(+−) SV2B(−/−) mice is significantly reduced compared to WT (72% reduction, P<0.001, t-test), while the levels of BoNT/B binding are the same (P>0.05, t-test), suggesting that SV2A and B are important for BoNT/A binding to motor nerve terminals. The remaining level of BoNT/A binding in SV2A(+−)SV2B(−/−) NMJs is likely mediated by SV2C, which is not altered in these mice, and remaining reduced level of SV2A.

SV2B knockout mice have reduced sensitivity to BoNT/A: To further establish the physiological meaning of these findings, we extended our study to the whole animal. Among available SV2 knockout mice lines, SV2A knockout and SV2A/B double knockout mice both die within weeks after birth, suggesting SV2A is essential for maintaining normal synaptic transmission. In contrast, SV2B single knockout mice (SV2B(−/−)) have no apparent difference to wild-type (WT) mice. To minimize the potential defect in vivo on synaptic transmission, we chose to compare BoNT/A sensitivity of SV2B knockout mice and WT littermates. Sensitivity to BoNT/A was assessed with an established rapid assay, in which large amount of toxins are injected intravenously and the survival time (Time-to-death) after the injection were recorded (Boroff DA and Fleck U, *J. Bacteriology* 92:1580-1581, 1966; Dong M et al., *supra*, 2003; Malizio C G, *Methods and Protocols* O. Hoist, ed. (Humana Press), pp. 27-39, 2000). This survival time can be converted to apparent toxicity from a previously established standard curve (Malizio C G, *supra*, 2000).

Identical amounts of BoNT/A ( $10^4$ - $10^6$  LD<sub>50</sub>/ml) were injected into SV2B(−/−) and WT mice and their survival time is shown in FIG. 6c. SV2B knockout mice survived significantly longer than wild-type littermates ( $43.7 \pm 1.9$  min versus  $32.6 \pm 4.6$  min). The effective toxin concentration estimated from the survival time of WT mice is about 2.5-fold more than SV2B(−/−) mice ( $8.4 \pm 2.9 \times 10^5$  LD<sub>50</sub>/ml versus  $3.4 \pm 0.5 \times 10^5$  LD<sub>50</sub>/ml, FIG. 6c). The difference in effective toxicity reflects the shift of LD<sub>50</sub> value in SV2B knockout mice, i.e., these mice require approximately 2.5 fold more BoNT/A for a lethal dose than their WT littermates. The remaining toxicity in SV2B(−/−) mice is likely mediated by SV2A and C in their motor nerve terminals. These results provided functional evidence that SV2 is the physiological receptor for BoNT/A in vivo.

The present invention is not intended to be limited to the foregoing example, but rather to encompass all such variations and modifications as come within the scope of the appended claims.

---

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 23

<210> SEQ ID NO 1  
<211> LENGTH: 2229  
<212> TYPE: DNA

-continued

&lt;213&gt; ORGANISM: Rattus norvegicus

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: CDS

&lt;222&gt; LOCATION: (1)..(2229)

&lt;400&gt; SEQUENCE: 1

atg gaa gaa ggc ttt cga gac cga gca gcg ttc atc cgt	48
Met Glu Glu Gly Phe Arg Asp Arg Ala Ala Phe Ile Arg	
5 10 15	
Gly Ala Lys	
gac att gcc aag gaa gtt aag aag cac gcg gcc aag aag	96
Asp Ile Ala Lys Glu Val Lys Lys His Ala Ala Lys Lys	
20 25 30	
Val Val Lys	
ggt ctc gac aga gtc cag gat gaa tat tcc cga agg tcc tac	144
tcc cgc Gly Leu Asp Arg Val Gln Asp Glu Tyr Ser Arg	
35 40 45	
Arg Ser Tyr Ser Arg	
ttt gag gag gag gat gat gat gac ttc cct gcc cct gct	192
gac ggc Phe Glu Glu Glu Asp Asp Asp Phe Pro Ala Pro	
50 55 60	
Ala Asp Gly	
tat tac cgc gga gaa ggg gcc cag gat gag gag gaa ggt	240
ggt ggc Tyr Tyr Arg Gly Glu Gly Ala Gln Asp Glu Glu	
65 70 75 80	
Gly Gly Ala Ser	
agt gat gcc act gag ggc cac gat gag gat gat gag atc	288
tac gag Ser Asp Ala Thr Glu Gly His Asp Glu Asp Asp	
85 90 95	
Glu Ile Tyr Glu Gly	
gaa tat cag ggc atc ccc cgg gca gag tct ggg ggc aaa	336
ggc gaa cgg Glu Tyr Gln Gly Ile Pro Arg Ala Glu Ser	
100 105 110	
Gly Gly Lys Gly Glu Arg	
atg gca gat ggg gca ccc ctg gct gga gtg aga ggg ggc	384
tta agt gat Met Ala Asp Gly Ala Pro Leu Ala Gly Val	
115 120 125	
Arg Gly Leu Ser Asp	
ggg gag ggt ccc cct ggg ggt cgc ggg gag gcg cag	432
cgg cgt aaa gat Gly Glu Gly Pro Pro Gly Gly Arg Gly	
130 135 140	
Gly Ala Gln Arg Arg Lys Asp	
cgg gaa gaa ttg gct cag cag tat gag acc atc ctc cgg	480
gag tgc Arg Glu Glu Leu Ala Gln Gln Tyr Glu Thr	
145 150 155 160	
Ile Leu Arg Glu Cys Gly	
cat ggt cgc ttc cag tgg aca ctc tac ttc gtg ctg ggt	528
ctg gcg His Gly Arg Phe Gln Trp Thr Leu Tyr Phe Val	
165 170 175	
Leu Gly Leu Ala Leu	
atg gcc gat ggt gta gag gtc ttt gtg gtg ggc ttt gtg	576
ctg ccc agt Met Ala Asp Gly Val Glu Val Phe Val Val	
180 185 190	
Gly Phe Val Leu Pro Ser	
gct gag aaa gat atg tgc ctg tcg gac tcc aac aaa ggc	624
atg cta ggc Ala Glu Lys Asp Met Cys Leu Ser Asp Ser	
195 200 205	
Asn Asn Lys Gly Met Leu Gly	
ctc att gtg tac ctg ggc atg atg gtg ggg gcc ttc ctc	672
tgg gga ggc Leu Ile Val Tyr Leu Gly Met Met Val Gly	
210 215 220	
Ala Phe Leu Trp Gly Gly	
ctg gct gat cgg ctg ggt cgg aga cag tgt ctg ctc atc	720
tcg ctc tca Leu Ala Asp Arg Leu Gly Arg Arg Gln Cys	
225 230 235 240	
Leu Ile Ser Leu Ser	
gtc aac agc gtc ttc gct ttc tca tcc ttc gtc cag ggt	768
tat ggc Val Asn Ser Val Phe Ala Phe Phe Ser Ser Phe	
245 250 255	
Val Gln Gly Tyr Gly	
acc ttc ctt ttc tgc cgc ctc ctt tct ggg gtt ggg att	816
ggt ggt tcc Thr Phe Leu Phe Cys Arg Leu Leu Ser Gly	
260 265 270	
Val Gly Ile Gly Gly Ser	
atc ccc att gtc ttc tcc tat ttt tcg gag ttt ctg gcc	864
cag gag aaa Ile Pro Ile Val Phe Ser Tyr Phe Ser Glu	
275 280 285	
Phe Leu Ala Gln Glu Lys	
cgt ggg gag cat ttg agc tgg ctc tgt atg ttc tgg atg	912
att ggt ggc	

## US 7,985,554 B2

25

-continued

26

Arg Gly Glu His Leu Ser Trp Leu Cys Met Phe Trp Met Ile Gly Gly		
290	295	300
gtg tat gca gct gca atg gcc tgg gcc atc atc ccc cac tat ggg tgg		960
Val Tyr Ala Ala Ala Met Ala Trp Ala Ile Ile Pro His Tyr Gly Trp		
305	310	315
320		
agt ttc cag atg ggc tct gct tac cag ttc cac agc tgg agg gtc ttt		1008
Ser Phe Gln Met Gly Ser Ala Tyr Gln Phe His Ser Trp Arg Val Phe		
325	330	335
gtc ctc gtc ttt gcc ttt ccc tct gtc ttt gcc atc ggg gct ctg act		1056
Val Leu Val Phe Ala Phe Pro Ser Val Phe Ala Ile Gly Ala Leu Thr		
340	345	350
acg cag ccg gag agt ccc cgc ttc tta gag aat ggg aag cac gat		1104
Thr Gln Pro Glu Ser Pro Arg Phe Phe Leu Glu Asn Gly Lys His Asp		
355	360	365
gag gcc tgg atg gtc ctg aag cag gtt cat gac acc aac atg cga gcc		1152
Glu Ala Trp Met Val Leu Lys Gln Val His Asp Thr Asn Met Arg Ala		
370	375	380
aag ggc cat cct gag cga gtc ttc tca gta acc cac att aaa acg att		1200
Lys Gly His Pro Glu Arg Val Phe Ser Val Thr His Ile Lys Thr Ile		
385	390	395
400		
cat cag gag gat gaa ttg att gag atc cag tca gac aca gga acc tgg		1248
His Gln Glu Asp Glu Leu Ile Glu Ile Gln Ser Asp Thr Gly Thr Trp		
405	410	415
tac cag cgc tgg gga gtg cgg gct ttg agc ctg ggg ggt cag gtt tgg		1296
Tyr Gln Arg Trp Gly Val Arg Ala Leu Ser Leu Gly Gly Gln Val Trp		
420	425	430
ggg aac ttc ctc tcc tgc ttc agt cca gag tac cgg cgc atc act ctg		1344
Gly Asn Phe Leu Ser Cys Phe Ser Pro Glu Tyr Arg Arg Ile Thr Leu		
435	440	445
atg atg atg ggg gta tgg ttc acc atg tcc ttc agc tac tac tac ggt ttg		1392
Met Met Met Gly Val Trp Phe Thr Met Ser Phe Ser Tyr Tyr Gly Leu		
450	455	460
act gtc tgg ttt ccc gac atg atc cgc cat ctc cag gct gtc gac tat		1440
Thr Val Trp Phe Pro Asp Met Ile Arg His Leu Gln Ala Val Asp Tyr		
465	470	475
480		
gca gcc cga acc aaa gtg ttc cca ggg gag cgc gtg gag cac gtg aca		1488
Ala Ala Arg Thr Lys Val Phe Pro Gly Glu Arg Val Glu His Val Thr		
485	490	495
ttt aac ttc aca ctg gag aat cag atc cac cga ggg gga cag tac ttc		1536
Phe Asn Phe Thr Leu Glu Asn Gln Ile His Arg Gly Gly Gln Tyr Phe		
500	505	510
aat gac aag ttc atc ggg ctg cgt ctg aag tca gtg tcc ttt gag gat		1584
Asn Asp Lys Phe Ile Gly Leu Arg Leu Lys Ser Val Ser Phe Glu Asp		
515	520	525
tcc ctg ttt gag gaa tgt tac ttt gaa gat gtc aca tcc agc aac aca		1632
Ser Leu Phe Glu Glu Cys Tyr Phe Glu Asp Val Thr Ser Ser Asn Thr		
530	535	540
ttc ttc cgc aac tgc aca ttc atc aac acc gtc ttc tac aac acg gac		1680
Phe Phe Arg Asn Cys Thr Phe Ile Asn Thr Val Phe Tyr Asn Thr Asp		
545	550	555
560		
ctg ttt gag tac aag ttc gtg aac agc cgc ctg gtg aac agc aca ttc		1728
Leu Phe Glu Tyr Lys Phe Val Asn Ser Arg Leu Val Asn Ser Thr Phe		
565	570	575
ctg cac aat aag gaa ggt tgc cca cta gat gtg aca ggg acg ggc gaa		1776
Leu His Asn Lys Glu Gly Cys Pro Leu Asp Val Thr Gly Thr Gly Glu		
580	585	590
ggt gcc tac atg gtg tac ttt gtc agc ttc ttg ggg aca ctg gct gtg		1824
Gly Ala Tyr Met Val Tyr Phe Val Ser Phe Leu Gly Thr Leu Ala Val		
595	600	605
ctc cct gga aat att gtg tct gct ctg ctc atg gac aag att ggc agg		1872

## US 7,985,554 B2

27

-continued

28

Leu Pro Gly Asn Ile Val Ser Ala Leu Leu Met Asp Lys Ile Gly Arg		
610	615	620
ctc aga atg ctt gct ggt tcc agt gtg ttg tcc tgt gtt tcc tgc ttc		1920
Leu Arg Met Leu Ala Gly Ser Ser Val Leu Ser Cys Val Ser Cys Phe		
625	630	635
640		
ttc ctg tct ttt ggg aac agt gag tca gcc atg atc gct ctg ctc tgc		1968
Phe Leu Ser Phe Gly Asn Ser Glu Ser Ala Met Ile Ala Leu Leu Cys		
645	650	655
ttt ttt ggg gga gtc agt att gca tcc tgg aac gcg ctg gac gtg ctg		2016
Leu Phe Gly Val Ser Ile Ala Ser Trp Asn Ala Leu Asp Val Leu		
660	665	670
act gtt gaa ctc tac cct tcc gac aag agg acg acg gcc ttc ggc ttc		2064
Thr Val Glu Leu Tyr Pro Ser Asp Lys Arg Thr Thr Ala Phe Gly Phe		
675	680	685
ctg aat gcc ctg tgt aag ctg gca gct gta ctg ggc atc agc atc ttc		2112
Leu Asn Ala Leu Cys Lys Leu Ala Ala Val Leu Gly Ile Ser Ile Phe		
690	695	700
acg tcc ttt gtg gga atc acc aag gcc gct ccc atc ctc ttc gcc tca		2160
Thr Ser Phe Val Gly Ile Thr Lys Ala Ala Pro Ile Leu Phe Ala Ser		
705	710	715
720		
gct gcg ctt gcc ctt ggt agc tct ctg gct ctg aag ctg cct gag acc		2208
Ala Ala Leu Ala Leu Gly Ser Ser Leu Ala Leu Lys Leu Pro Glu Thr		
725	730	735
cgg gga cag gtg ctg cag tga		2229
Arg Gly Gln Val Leu Gln		
740		

&lt;210&gt; SEQ ID NO 2

&lt;211&gt; LENGTH: 742

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Rattus norvegicus

&lt;400&gt; SEQUENCE: 2

Met Glu Glu Gly Phe Arg Asp Arg Ala Ala Phe Ile Arg Gly Ala Lys		
1	5	10
15		
Asp Ile Ala Lys Glu Val Lys Lys His Ala Ala Lys Lys Val Val Lys		
20	25	30
Gly Leu Asp Arg Val Gln Asp Glu Tyr Ser Arg Arg Ser Tyr Ser Arg		
35	40	45
Phe Glu Glu Glu Asp Asp Asp Phe Pro Ala Pro Ala Asp Gly		
50	55	60
Tyr Tyr Arg Gly Glu Gly Ala Gln Asp Glu Glu Glu Gly Ala Ser		
65	70	75
80		
Ser Asp Ala Thr Glu Gly His Asp Glu Asp Asp Glu Ile Tyr Glu Gly		
85	90	95
Glu Tyr Gln Gly Ile Pro Arg Ala Glu Ser Gly Gly Lys Gly Glu Arg		
100	105	110
Met Ala Asp Gly Ala Pro Leu Ala Gly Val Arg Gly Gly Leu Ser Asp		
115	120	125
Gly Glu Gly Pro Pro Gly Gly Arg Gly Glu Ala Gln Arg Arg Lys Asp		
130	135	140
Arg Glu Glu Leu Ala Gln Gln Tyr Glu Thr Ile Leu Arg Glu Cys Gly		
145	150	155
160		
His Gly Arg Phe Gln Trp Thr Leu Tyr Phe Val Leu Gly Leu Ala Leu		
165	170	175
Met Ala Asp Gly Val Glu Val Phe Val Val Gly Phe Val Leu Pro Ser		
180	185	190
Ala Glu Lys Asp Met Cys Leu Ser Asp Ser Asn Lys Gly Met Leu Gly		

## US 7,985,554 B2

**29****30**

-continued

195

200

205

Leu Ile Val Tyr Leu Gly Met Met Val Gly Ala Phe Leu Trp Gly Gly  
 210 215 220

Leu Ala Asp Arg Leu Gly Arg Arg Gln Cys Leu Leu Ile Ser Leu Ser  
 225 230 235 240

Val Asn Ser Val Phe Ala Phe Phe Ser Ser Phe Val Gln Gly Tyr Gly  
 245 250 255

Thr Phe Leu Phe Cys Arg Leu Leu Ser Gly Val Gly Ile Gly Gly Ser  
 260 265 270

Ile Pro Ile Val Phe Ser Tyr Phe Ser Glu Phe Leu Ala Gln Glu Lys  
 275 280 285

Arg Gly Glu His Leu Ser Trp Leu Cys Met Phe Trp Met Ile Gly Gly  
 290 295 300

Val Tyr Ala Ala Ala Met Ala Trp Ala Ile Ile Pro His Tyr Gly Trp  
 305 310 315 320

Ser Phe Gln Met Gly Ser Ala Tyr Gln Phe His Ser Trp Arg Val Phe  
 325 330 335

Val Leu Val Phe Ala Phe Pro Ser Val Phe Ala Ile Gly Ala Leu Thr  
 340 345 350

Thr Gln Pro Glu Ser Pro Arg Phe Phe Leu Glu Asn Gly Lys His Asp  
 355 360 365

Glu Ala Trp Met Val Leu Lys Gln Val His Asp Thr Asn Met Arg Ala  
 370 375 380

Lys Gly His Pro Glu Arg Val Phe Ser Val Thr His Ile Lys Thr Ile  
 385 390 395 400

His Gln Glu Asp Glu Leu Ile Glu Ile Gln Ser Asp Thr Gly Thr Trp  
 405 410 415

Tyr Gln Arg Trp Gly Val Arg Ala Leu Ser Leu Gly Gly Gln Val Trp  
 420 425 430

Gly Asn Phe Leu Ser Cys Phe Ser Pro Glu Tyr Arg Arg Ile Thr Leu  
 435 440 445

Met Met Met Gly Val Trp Phe Thr Met Ser Phe Ser Tyr Tyr Gly Leu  
 450 455 460

Thr Val Trp Phe Pro Asp Met Ile Arg His Leu Gln Ala Val Asp Tyr  
 465 470 475 480

Ala Ala Arg Thr Lys Val Phe Pro Gly Glu Arg Val Glu His Val Thr  
 485 490 495

Phe Asn Phe Thr Leu Glu Asn Gln Ile His Arg Gly Gly Gln Tyr Phe  
 500 505 510

Asn Asp Lys Phe Ile Gly Leu Arg Leu Lys Ser Val Ser Phe Glu Asp  
 515 520 525

Ser Leu Phe Glu Glu Cys Tyr Phe Glu Asp Val Thr Ser Ser Asn Thr  
 530 535 540

Phe Phe Arg Asn Cys Thr Phe Ile Asn Thr Val Phe Tyr Asn Thr Asp  
 545 550 555 560

Leu Phe Glu Tyr Lys Phe Val Asn Ser Arg Leu Val Asn Ser Thr Phe  
 565 570 575

Leu His Asn Lys Glu Gly Cys Pro Leu Asp Val Thr Gly Thr Gly Glu  
 580 585 590

Gly Ala Tyr Met Val Tyr Phe Val Ser Phe Leu Gly Thr Leu Ala Val  
 595 600 605

Leu Pro Gly Asn Ile Val Ser Ala Leu Leu Met Asp Lys Ile Gly Arg  
 610 615 620

## US 7,985,554 B2

31

32

-continued

---

Leu Arg Met Leu Ala Gly Ser Ser Val Leu Ser Cys Val Ser Cys Phe  
 625                   630                   635                   640  
  
 Phe Leu Ser Phe Gly Asn Ser Glu Ser Ala Met Ile Ala Leu Leu Cys  
 645                   650                   655  
  
 Leu Phe Gly Gly Val Ser Ile Ala Ser Trp Asn Ala Leu Asp Val Leu  
 660                   665                   670  
  
 Thr Val Glu Leu Tyr Pro Ser Asp Lys Arg Thr Thr Ala Phe Gly Phe  
 675                   680                   685  
  
 Leu Asn Ala Leu Cys Lys Leu Ala Ala Val Leu Gly Ile Ser Ile Phe  
 690                   695                   700  
  
 Thr Ser Phe Val Gly Ile Thr Lys Ala Ala Pro Ile Leu Phe Ala Ser  
 705                   710                   715                   720  
  
 Ala Ala Leu Ala Leu Gly Ser Ser Leu Ala Leu Lys Leu Pro Glu Thr  
 725                   730                   735  
  
 Arg Gly Gln Val Leu Gln  
 740

<210> SEQ ID NO 3  
 <211> LENGTH: 2052  
 <212> TYPE: DNA  
 <213> ORGANISM: Rattus norvegicus  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(2052)

&lt;400&gt; SEQUENCE: 3

atg gat gac tac agg tat cgg gac aac tat gag ggc tat gcc cct aat	48
Met Asp Asp Tyr Arg Tyr Arg Asp Asn Tyr Glu Gly Tyr Ala Pro Asn	
1                   5                   10                   15	
gat ggc tac tac cgg ggc aat gag cag aac ccg gaa gaa gat gca cag	96
Asp Gly Tyr Tyr Arg Gly Asn Glu Gln Asn Pro Glu Glu Asp Ala Gln	
20                   25                   30	
agc gat gtt aca gaa ggc cac gat gaa gag gat gac tat gag ggc	144
Ser Asp Val Thr Glu Gly His Asp Glu Glu Asp Glu Ile Tyr Glu Gly	
35                   40                   45	
gag tac caa ggc atc cct cat cca gat gat gtc aag tct aag cag act	192
Glu Tyr Gln Gly Ile Pro His Pro Asp Asp Val Lys Ser Lys Gln Thr	
50                   55                   60	
aag atg gca ccg tcc aga gca gat ggc ctt cgg ggc cag gca gac ctg	240
Lys Met Ala Pro Ser Arg Ala Asp Gly Leu Arg Gly Gln Ala Asp Leu	
65                   70                   75                   80	
atg gct gag aga atg gaa gat gag gag cag ctc gct cac cag tac gag	288
Met Ala Glu Arg Met Glu Asp Glu Glu Gln Leu Ala His Gln Tyr Glu	
85                   90                   95	
acc atc att gat gag tgt ggc cat ggg cgc ttc cag tgg acc ctc ttt	336
Thr Ile Ile Asp Glu Cys Gly His Gly Arg Phe Gln Trp Thr Leu Phe	
100                   105                   110	
ttc gtc ttg gtc ttg gcc ttg atg gct gac gga gtg gaa gtg ttt gtg	384
Phe Val Leu Val Leu Ala Leu Met Ala Asp Gly Val Glu Val Phe Val	
115                   120                   125	
gtg agc ttt gct ctg cca agt gca gag aaa gat atg tgt ctg tca agt	432
Val Ser Phe Ala Leu Pro Ser Ala Glu Lys Asp Met Cys Leu Ser Ser	
130                   135                   140	
tcc aag aaa gga atg ctc ggg ctg att gtc tac cta gga atg atg gca	480
Ser Lys Lys Gly Met Leu Gly Leu Ile Val Tyr Leu Gly Met Met Ala	
145                   150                   155                   160	
gga gcc ttc atc ctg ggg ggc ctg gct gat aaa ctg gga agg aag aag	528
Gly Ala Phe Ile Leu Gly Gly Leu Ala Asp Lys Leu Gly Arg Lys Lys	
165                   170                   175	
gtc ctc agc atg tcc ttg gct atc aat gct tcc ttt gcc tcc ctc tcc	576

-continued

Val Leu Ser Met Ser Leu Ala Ile Asn Ala Ser Phe Ala Ser Leu Ser		
180	185	190
tcc ttc gtg cag gga tat gga gct ttc ctc ttc tgc aga ctc atc tca		624
Ser Phe Val Gln Gly Tyr Gly Ala Phe Leu Phe Cys Arg Leu Ile Ser		
195	200	205
ggc ata ggt att ggg ggc tcc ctg cca att gtt ttt gcc tac ttt tct		672
Gly Ile Gly Ile Gly Gly Ser Leu Pro Ile Val Phe Ala Tyr Phe Ser		
210	215	220
gag ttc tta tca cgg gag aaa cgc ggt gag cat ctc agc tgg ctg ggt		720
Glu Phe Leu Ser Arg Glu Lys Arg Gly Glu His Leu Ser Trp Leu Gly		
225	230	235
atc ttc tgg atg act ggg ggc atc tac gca tct gcc atg gcc tgg agc		768
Ile Phe Trp Met Thr Gly Gly Ile Tyr Ala Ser Ala Met Ala Trp Ser		
245	250	255
atc att cca cac tat ggc tgg ggc ttc agc atg gga acc aat tat cac		816
Ile Ile Pro His Tyr Gly Trp Gly Phe Ser Met Gly Thr Asn Tyr His		
260	265	270
ttc cac agc tgg aga gtg ttt gtc atc gtc tgt gct cct gcc act		864
Phe His Ser Trp Arg Val Phe Val Ile Val Cys Ala Leu Pro Ala Thr		
275	280	285
gtg tcc atg gtg gcc ctg aag ttc atg cca gaa agc ccc agg ttc ctg		912
Val Ser Met Val Ala Leu Lys Phe Met Pro Glu Ser Pro Arg Phe Leu		
290	295	300
ctg gag atg ggc aag cat gat gaa gcc tgg atg att ctc aag caa gtc		960
Leu Glu Met Gly Lys His Asp Glu Ala Trp Met Ile Leu Lys Gln Val		
305	310	315
cat gac acc aac atg aga gct aag ggg acc cct gag aag gtg ttc acg		1008
His Asp Thr Asn Met Arg Ala Lys Gly Thr Pro Glu Lys Val Phe Thr		
325	330	335
gtt tcc cac atc aaa act ccc aag caa atg gat gaa ttc att gag atc		1056
Val Ser His Ile Lys Thr Pro Lys Gln Met Asp Glu Phe Ile Glu Ile		
340	345	350
cag agt tca aca ggg act tgg tac cag cgc tgg ttg gtc agg ttc atg		1104
Gln Ser Ser Thr Gly Thr Trp Tyr Gln Arg Trp Leu Val Arg Phe Met		
355	360	365
acc att ttc aaa cag gtg tgg gat aac gcc ttg tac tgt gtg atg gga		1152
Thr Ile Phe Lys Gln Val Trp Asp Asn Ala Leu Tyr Cys Val Met Gly		
370	375	380
ccc tac aga atg aac acc ctg att ctg gct gtg gtc tgg ttc acc atg		1200
Pro Tyr Arg Met Asn Thr Leu Ile Leu Ala Val Val Trp Phe Thr Met		
385	390	395
400		
gcc tta agt tac tat ggc ctg aca gtg tgg ttc ccc gac atg atc cgg		1248
Ala Leu Ser Tyr Tyr Gly Leu Thr Val Trp Phe Pro Asp Met Ile Arg		
405	410	415
tat ttc cag gat gaa gaa tat aag tct aaa atg aag gtg ttt ttt ggt		1296
Tyr Phe Gln Asp Glu Glu Tyr Lys Ser Lys Met Lys Val Phe Phe Gly		
420	425	430
gag cac gtg cat ggc gcc aca atc aac ttc acc atg gaa aac cag atc		1344
Glu His Val His Gly Ala Thr Ile Asn Phe Thr Met Glu Asn Gln Ile		
435	440	445
cac caa cat ggg aag ctt gtg aac gat aag ttc ata aag atg tac ttt		1392
His Gln His Gly Lys Leu Val Asn Asp Lys Phe Ile Lys Met Tyr Phe		
450	455	460
aag cat gtc ctc ttt gag gac aca ttc ttt gac aaa tgc tat ttt gaa		1440
Lys His Val Leu Phe Glu Asp Thr Phe Phe Asp Lys Cys Tyr Phe Glu		
465	470	475
480		
gat gtg aca tcc aca gat act tat ttc aag aac tgc acc att gaa tgc		1488
Asp Val Thr Ser Thr Asp Thr Tyr Phe Lys Asn Cys Thr Ile Glu Ser		
485	490	495
act acc ttc tac aac aca gac ctc tac aaa cac aag ttc att gac tgt		1536

## US 7,985,554 B2

35

36

-continued

Thr Thr Phe Tyr Asn Thr Asp Leu Tyr Lys His Lys Phe Ile Asp Cys		
500	505	510
cgg ttt atc aat tcc acc ttt ctg gag cag aag gag ggc tgc cac atg		1584
Arg Phe Ile Asn Ser Thr Phe Leu Glu Gln Lys Glu Gly Cys His Met		
515	520	525
gac ttt gaa gag gac aat gat ttt ctg att tac ctc gtc agc ttc ctc		1632
Asp Phe Glu Glu Asp Asn Asp Phe Leu Ile Tyr Leu Val Ser Phe Leu		
530	535	540
ggc agc ctg tct gtc ttg cct ggg aac ata att tct gcc ctg ctc atg		1680
Gly Ser Leu Ser Val Leu Pro Gly Asn Ile Ile Ser Ala Leu Leu Met		
545	550	555
gac aga atc gga aga ctt aag atg att ggt ggc tcc atg ctc atc tct		1728
Asp Arg Ile Gly Arg Leu Lys Met Ile Gly Gly Ser Met Leu Ile Ser		
565	570	575
gca gtc tgc tgc ttc ttc ctg ttt ttt ggc aac agc gag tct tgc atg		1776
Ala Val Cys Cys Phe Phe Leu Phe Gly Asn Ser Glu Ser Ala Met		
580	585	590
atc ggc tgg caa tgc ctg ttc tgt ggg acc agc att gca gcc tgg aat		1824
Ile Gly Trp Gln Cys Leu Phe Cys Gly Thr Ser Ile Ala Ala Trp Asn		
595	600	605
gct ctg gat gtg atc aca gta gag ctg tat ccc acc aac cag agg gcc		1872
Ala Leu Asp Val Ile Thr Val Glu Leu Tyr Pro Thr Asn Gln Arg Ala		
610	615	620
act gcc ttc ggc atc ctc aat gga ctg tgc aaa ctt ggt gcc atc ctg		1920
Thr Ala Phe Gly Ile Leu Asn Gly Leu Cys Lys Leu Gly Ala Ile Leu		
625	630	635
gga aac act atc ttt gct tct ttt gtt ggg atc acc aaa gtg gtc ccc		1968
Gly Asn Thr Ile Phe Ala Ser Phe Val Gly Ile Thr Lys Val Val Pro		
645	650	655
atc ctt ctg gct gct tct ctg gtt gga ggt ggc ttg gtt gcc ctt		2016
Ile Leu Leu Ala Ala Ala Ser Leu Val Gly Gly Leu Val Ala Leu		
660	665	670
cga ctg cca gag act cga gag cag gtc ctg atg tga		2052
Arg Leu Pro Glu Thr Arg Glu Gln Val Leu Met		
675	680	

&lt;210&gt; SEQ ID NO 4

&lt;211&gt; LENGTH: 683

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Rattus norvegicus

&lt;400&gt; SEQUENCE: 4

Met Asp Asp Tyr Arg Tyr Asp Asn Tyr Glu Gly Tyr Ala Pro Asn  
 1 5 10 15

Asp Gly Tyr Tyr Arg Gly Asn Glu Gln Asn Pro Glu Glu Asp Ala Gln  
 20 25 30

Ser Asp Val Thr Glu Gly His Asp Glu Glu Asp Glu Ile Tyr Glu Gly  
 35 40 45

Glu Tyr Gln Gly Ile Pro His Pro Asp Asp Val Lys Ser Lys Gln Thr  
 50 55 60

Lys Met Ala Pro Ser Arg Ala Asp Gly Leu Arg Gly Gln Ala Asp Leu  
 65 70 75 80

Met Ala Glu Arg Met Glu Asp Glu Glu Gln Leu Ala His Gln Tyr Glu  
 85 90 95

Thr Ile Ile Asp Glu Cys Gly His Gly Arg Phe Gln Trp Thr Leu Phe  
 100 105 110

Phe Val Leu Val Leu Ala Leu Met Ala Asp Gly Val Glu Val Phe Val  
 115 120 125

Val Ser Phe Ala Leu Pro Ser Ala Glu Lys Asp Met Cys Leu Ser Ser

## US 7,985,554 B2

**37**

-continued

130	135	140
Ser Lys Lys Gly Met Leu Gly Leu Ile Val Tyr Leu Gly Met Met Ala		
145	150	155
160		
Gly Ala Phe Ile Leu Gly Gly Leu Ala Asp Lys Leu Gly Arg Lys Lys		
165	170	175
Val Leu Ser Met Ser Leu Ala Ile Asn Ala Ser Phe Ala Ser Leu Ser		
180	185	190
Ser Phe Val Gln Gly Tyr Gly Ala Phe Leu Phe Cys Arg Leu Ile Ser		
195	200	205
Gly Ile Gly Ile Gly Gly Ser Leu Pro Ile Val Phe Ala Tyr Phe Ser		
210	215	220
Glu Phe Leu Ser Arg Glu Lys Arg Gly Glu His Leu Ser Trp Leu Gly		
225	230	235
240		
Ile Phe Trp Met Thr Gly Gly Ile Tyr Ala Ser Ala Met Ala Trp Ser		
245	250	255
Ile Ile Pro His Tyr Gly Trp Gly Phe Ser Met Gly Thr Asn Tyr His		
260	265	270
Phe His Ser Trp Arg Val Phe Val Ile Val Cys Ala Leu Pro Ala Thr		
275	280	285
Val Ser Met Val Ala Leu Lys Phe Met Pro Glu Ser Pro Arg Phe Leu		
290	295	300
Leu Glu Met Gly Lys His Asp Glu Ala Trp Met Ile Leu Lys Gln Val		
305	310	315
320		
His Asp Thr Asn Met Arg Ala Lys Gly Thr Pro Glu Lys Val Phe Thr		
325	330	335
Val Ser His Ile Lys Thr Pro Lys Gln Met Asp Glu Phe Ile Glu Ile		
340	345	350
Gln Ser Ser Thr Gly Thr Trp Tyr Gln Arg Trp Leu Val Arg Phe Met		
355	360	365
Thr Ile Phe Lys Gln Val Trp Asp Asn Ala Leu Tyr Cys Val Met Gly		
370	375	380
Pro Tyr Arg Met Asn Thr Leu Ile Leu Ala Val Val Trp Phe Thr Met		
385	390	395
400		
Ala Leu Ser Tyr Tyr Gly Leu Thr Val Trp Phe Pro Asp Met Ile Arg		
405	410	415
Tyr Phe Gln Asp Glu Glu Tyr Lys Ser Lys Met Lys Val Phe Phe Gly		
420	425	430
Glu His Val His Gly Ala Thr Ile Asn Phe Thr Met Glu Asn Gln Ile		
435	440	445
His Gln His Gly Lys Leu Val Asn Asp Lys Phe Ile Lys Met Tyr Phe		
450	455	460
Lys His Val Leu Phe Glu Asp Thr Phe Phe Asp Lys Cys Tyr Phe Glu		
465	470	475
480		
Asp Val Thr Ser Thr Asp Thr Tyr Phe Lys Asn Cys Thr Ile Glu Ser		
485	490	495
Thr Thr Phe Tyr Asn Thr Asp Leu Tyr Lys His Lys Phe Ile Asp Cys		
500	505	510
Arg Phe Ile Asn Ser Thr Phe Leu Glu Gln Lys Glu Gly Cys His Met		
515	520	525
Asp Phe Glu Glu Asp Asn Asp Phe Leu Ile Tyr Leu Val Ser Phe Leu		
530	535	540
Gly Ser Leu Ser Val Leu Pro Gly Asn Ile Ile Ser Ala Leu Leu Met		
545	550	555
560		

**38**

## US 7,985,554 B2

39

40

-continued

Asp Arg Ile Gly Arg Leu Lys Met Ile Gly Gly Ser Met Leu Ile Ser			
565	570	575	
Ala Val Cys Cys Phe Phe Leu Phe Phe Gly Asn Ser Glu Ser Ala Met			
580	585	590	
Ile Gly Trp Gln Cys Leu Phe Cys Gly Thr Ser Ile Ala Ala Trp Asn			
595	600	605	
Ala Leu Asp Val Ile Thr Val Glu Leu Tyr Pro Thr Asn Gln Arg Ala			
610	615	620	
Thr Ala Phe Gly Ile Leu Asn Gly Leu Cys Lys Leu Gly Ala Ile Leu			
625	630	635	640
Gly Asn Thr Ile Phe Ala Ser Phe Val Gly Ile Thr Lys Val Val Pro			
645	650	655	
Ile Leu Leu Ala Ala Ala Ser Leu Val Gly Gly Leu Val Ala Leu			
660	665	670	
Arg Leu Pro Glu Thr Arg Glu Gln Val Leu Met			
675	680		

<210> SEQ ID NO 5  
<211> LENGTH: 2184  
<212> TYPE: DNA  
<213> ORGANISM: Rattus norvegicus  
<220> FEATURE:  
<221> NAME/KEY: CDS  
<222> LOCATION: (1)..(2184)

&lt;400&gt; SEQUENCE: 5

atg gaa gac tcc tac aag gat agg act tca ctg atg aag ggc gcc aag	48		
Met Glu Asp Ser Tyr Lys Asp Arg Thr Ser Leu Met Lys Gly Ala Lys			
1	5	10	15
gac att gcc aaa gag gtg aag aag caa aca gtg aag aag gtg aac cag	96		
Asp Ile Ala Lys Glu Val Lys Lys Gln Thr Val Lys Lys Val Asn Gln			
20	25	30	
gca gtg gac cgg gcc cag gat gaa tac acc cag cgg tcc tac agt cga	144		
Ala Val Asp Arg Ala Gln Asp Glu Tyr Thr Gln Arg Ser Tyr Ser Arg			
35	40	45	
ttc cag gat gaa gat gat gat gac tac tac cca cct gga gaa acc	192		
Phe Gln Asp Glu Asp Asp Asp Asp Tyr Tyr Pro Pro Gly Glu Thr			
50	55	60	
tac agt ggg gag gcc aat gat gat gaa ggc tca agt gaa gcc act gag	240		
Tyr Ser Gly Glu Ala Asn Asp Asp Glu Gly Ser Ser Glu Ala Thr Glu			
65	70	75	80
ggt cac gat gaa gac gag atc tat gaa ggg gaa tac cag ggc atc	288		
Gly His Asp Glu Glu Asp Glu Ile Tyr Glu Gly Glu Tyr Gln Gly Ile			
85	90	95	
ccc agc acg aac caa ggg aag gac agc ata gtg tct gta gga caa ccc	336		
Pro Ser Thr Asn Gln Gly Lys Asp Ser Ile Val Ser Val Gly Gln Pro			
100	105	110	
aaa gga gat gag tac aag gac cgc aga gag ctg gag tca gag agg agg	384		
Lys Gly Asp Glu Tyr Lys Asp Arg Arg Glu Leu Glu Ser Glu Arg Arg			
115	120	125	
gct gat gag gag ctc gcc cag cag tat gag ctg ata atc caa gag	432		
Ala Asp Glu Glu Leu Ala Gln Gln Tyr Glu Leu Ile Ile Gln Glu			
130	135	140	
tgt ggc cat ggc cgt ttc cag tgg gcc ctt ttc gtc ctg ggc atg	480		
Cys Gly His Gly Arg Phe Gln Trp Ala Leu Phe Phe Val Leu Gly Met			
145	150	155	160
gct ctc atg gca gac ggc gtg gag gtg ttt gtg gtg ggc ttt gtg tta	528		
Ala Leu Met Ala Asp Gly Val Glu Val Phe Val Val Gly Phe Val Leu			
165	170	175	
ccc agt gca gag aca gac cta tgc ata ccg aat tca gga tct gga tgg	576		

## US 7,985,554 B2

**41****42**

-continued

---

Pro Ser Ala Glu Thr Asp Leu Cys Ile Pro Asn Ser Gly Ser Gly Trp		
180	185	190
cta ggc agc ata gtg tac ctc ggg atg atg gtg ggg ggc ttc ttc tgg		624
Leu Gly Ser Ile Val Tyr Leu Gly Met Met Val Gly Ala Phe Phe Trp		
195	200	205
gga gga ctg gca gac aaa gtg gga agg aag cag tct ctt ctg att tgc		672
Gly Gly Leu Ala Asp Lys Val Gly Arg Lys Gln Ser Leu Leu Ile Cys		
210	215	220
atg tcc gtc aac gga ttc ttt gcc ttc ctt tct tca ttt gtc caa ggt		720
Met Ser Val Asn Gly Phe Phe Ala Phe Leu Ser Ser Phe Val Gln Gly		
225	230	235
240		
tac ggc ttc ttt ctc ctc tgt cgt ttg ctt tca gga ttc ggg att gga		768
Tyr Gly Phe Phe Leu Leu Cys Arg Leu Leu Ser Gly Phe Gly Ile Gly		
245	250	255
ggc gcc att ccc act gtg ttc tcc tac ttt gct gaa gtc ctg gcc cg		816
Gly Ala Ile Pro Thr Val Phe Ser Tyr Phe Ala Glu Val Leu Ala Arg		
260	265	270
gag aag cgc ggt gag cac ctc agt tgg ctc tgc atg ttc tgg atg att		864
Glu Lys Arg Gly Glu His Leu Ser Trp Leu Cys Met Phe Trp Met Ile		
275	280	285
ggc ggt atc tat gct tca gcc atg gcc tgg gcc atc atc ccc cac tat		912
Gly Gly Ile Tyr Ala Ser Ala Met Ala Trp Ala Ile Ile Pro His Tyr		
290	295	300
ggg tgg agc ttc agc atg ggc tca gcc tac cag ttc cac agc tgg cgc		960
Gly Trp Ser Phe Ser Met Gly Ser Ala Tyr Gln Phe His Ser Trp Arg		
305	310	315
320		
gtc ttc gtc atc gtc tgt gcc ctc ccg tgc gtc tcc tcg gtg gtg gcc		1008
Val Phe Val Ile Val Cys Ala Leu Pro Cys Val Ser Ser Val Val Ala		
325	330	335
ctc acc ttc atg ccc gaa agc cct ccg ttc ttg ctg gag gta gga aaa		1056
Leu Thr Phe Met Pro Glu Ser Pro Arg Phe Leu Leu Glu Val Gly Lys		
340	345	350
cat gat gaa gcc tgg atg att ctg aag cta att cat gat acc aac atg		1104
His Asp Glu Ala Trp Met Ile Leu Lys Leu Ile His Asp Thr Asn Met		
355	360	365
aga gcc cgg ggc cag cca gag aag gtc ttc acg gta aat aaa atc aag		1152
Arg Ala Arg Gly Gln Pro Glu Lys Val Phe Thr Val Asn Lys Ile Lys		
370	375	380
act ccc aag caa ata gat gag ctg att gag att gag agc gac aca gga		1200
Thr Pro Lys Gln Ile Asp Glu Leu Ile Glu Ile Glu Ser Asp Thr Gly		
385	390	395
400		
acc tgg tac ccg agg tgt ttt gtt ccg atc cgc aca gaa ctg tac gga		1248
Thr Trp Tyr Arg Arg Cys Phe Val Arg Ile Arg Thr Glu Leu Tyr GLY		
405	410	415
att tgg ttg act ttt atg aga tgc ttc aac tac ccg gtc agg gaa aac		1296
Ile Trp Leu Thr Phe Met Arg Cys Phe Asn Tyr Pro Val Arg Glu Asn		
420	425	430
acc ata aag ctt acg att gtt tgg ttc acc ctg tcc ttt ggg tac tat		1344
Thr Ile Lys Leu Thr Ile Val Trp Phe Thr Leu Ser Phe Gly Tyr Tyr		
435	440	445
gga ctg tcc gtt tgg ttc cca gat gtc att aaa cac ctc cag tct gac		1392
Gly Leu Ser Val Trp Phe Pro Asp Val Ile Lys His Leu Gln Ser Asp		
450	455	460
gag tac gcc ctg ctg act ccg aat gtg cag aag gat aaa tat gca aac		1440
Glu Tyr Ala Leu Leu Thr Arg Asn Val Gln Lys Asp Lys Tyr Ala Asn		
465	470	475
480		
ttt agc att aac ttc acc atg gaa aac cag gtc cac acc gga atg gaa		1488
Phe Ser Ile Asn Phe Thr Met Glu Asn Gln Val His Thr Gly Met Glu		
485	490	495
tat gac aat ggc agg ttc ctc gga gtc aaa ttc aaa tcg gta acc ttc		1536

## US 7,985,554 B2

43

44

-continued

---

Tyr Asp Asn Gly Arg Phe Leu Gly Val Lys Phe Lys Ser Val Thr Phe		
500	505	510
aag gat tca gtg ttt aag tcc tgc acc ttt gac gat gtg acc tca gtc	1584	
Lys Asp Ser Val Phe Lys Ser Cys Thr Phe Asp Asp Val Thr Ser Val		
515	520	525
aac acc tac ttc aag aac tgc acg ttt att gat acc ctt ttt gag aac	1632	
Asn Thr Tyr Phe Lys Asn Cys Thr Phe Ile Asp Thr Leu Phe Glu Asn		
530	535	540
aca gat ttt gag ccc tat aaa ttc ata gac agc gag ttt caa aac tgc	1680	
Thr Asp Phe Glu Pro Tyr Lys Phe Ile Asp Ser Glu Phe Gln Asn Cys		
545	550	555
560		
tcg ttt ctt cac aat aag acg gga tgt cag att act ttt gac gac gac	1728	
Ser Phe Leu His Asn Lys Thr Gly Cys Gln Ile Thr Phe Asp Asp Asp		
565	570	575
tac agt gcc tac tgg att tac ttt gtc aac ttt ctc ggg aca ttg gca	1776	
Tyr Ser Ala Tyr Trp Ile Tyr Phe Val Asn Phe Leu Gly Thr Leu Ala		
580	585	590
gtg tta cca gga aat atc gtg tct gct ctc ctg atg gac agg atc ggg	1824	
Val Leu Pro Gly Asn Ile Val Ser Ala Leu Leu Met Asp Arg Ile Gly		
595	600	605
cgc tta acg atg cta ggt ggc tcc atg gtg ctc tcg ggg atc agc tgc	1872	
Arg Leu Thr Met Leu Gly Gly Ser Met Val Leu Ser Gly Ile Ser Cys		
610	615	620
ttc ttc ctg tgg ttt ggc acc agc gaa tcc atg atg ata ggc atg ctg	1920	
Phe Phe Leu Trp Phe Gly Thr Ser Glu Ser Met Met Ile Gly Met Leu		
625	630	635
640		
tgc ttg tac aac gga ctg acc atc tca gcg tgg aac tct ctt gat gta	1968	
Cys Leu Tyr Asn Gly Leu Thr Ile Ser Ala Trp Asn Ser Leu Asp Val		
645	650	655
gtc acg gtg gaa cta tac ccc aca gac cgg aga gca acg ggc ttt ggc	2016	
Val Thr Val Glu Leu Tyr Pro Thr Asp Arg Arg Ala Thr Gly Phe Gly		
660	665	670
ttc ttg aac gca ctc tgt aaa gca gcg gcc gtc ctg gga aac tta ata	2064	
Phe Leu Asn Ala Leu Cys Lys Ala Ala Ala Val Leu Gly Asn Leu Ile		
675	680	685
ttc ggc tcc ttg gtc agc atc acc aaa gca atc cct atc ctg ctg gct	2112	
Phe Gly Ser Leu Val Ser Ile Thr Lys Ala Ile Pro Ile Leu Leu Ala		
690	695	700
tcc acc gtg ctc gtg tgt gga gga ctc gtg ggg ctg cgc ctg ccc gac	2160	
Ser Thr Val Leu Val Cys Gly Gly Leu Val Gly Leu Arg Leu Pro Asp		
705	710	715
720		
aca aga acc cag gtt ctg atg tga	2184	
Thr Arg Thr Gln Val Leu Met		
725		

&lt;210&gt; SEQ ID NO 6

&lt;211&gt; LENGTH: 727

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Rattus norvegicus

&lt;400&gt; SEQUENCE: 6

Met Glu Asp Ser Tyr Lys Asp Arg Thr Ser Leu Met Lys Gly Ala Lys		
1	5	10
15		

Asp Ile Ala Lys Glu Val Lys Lys Gln Thr Val Lys Lys Val Asn Gln		
20	25	30

Ala Val Asp Arg Ala Gln Asp Glu Tyr Thr Gln Arg Ser Tyr Ser Arg		
35	40	45

Phe Gln Asp Glu Asp Asp Asp Asp Tyr Tyr Pro Pro Gly Glu Thr		
50	55	60

Tyr Ser Gly Glu Ala Asn Asp Asp Glu Gly Ser Ser Glu Ala Thr Glu

## US 7,985,554 B2

**45****46**

-continued

65	70	75	80
Gly His Asp Glu Glu Asp Glu Ile Tyr Glu Gly Glu Tyr Gln Gly Ile			
85	90	95	
Pro Ser Thr Asn Gln Gly Lys Asp Ser Ile Val Ser Val Gly Gln Pro			
100	105	110	
Lys Gly Asp Glu Tyr Lys Asp Arg Arg Glu Leu Glu Ser Glu Arg Arg			
115	120	125	
Ala Asp Glu Glu Glu Leu Ala Gln Gln Tyr Glu Leu Ile Ile Gln Glu			
130	135	140	
Cys Gly His Gly Arg Phe Gln Trp Ala Leu Phe Phe Val Leu Gly Met			
145	150	155	160
Ala Leu Met Ala Asp Gly Val Glu Val Phe Val Val Gly Phe Val Leu			
165	170	175	
Pro Ser Ala Glu Thr Asp Leu Cys Ile Pro Asn Ser Gly Ser Gly Trp			
180	185	190	
Leu Gly Ser Ile Val Tyr Leu Gly Met Met Val Gly Ala Phe Phe Trp			
195	200	205	
Gly Gly Leu Ala Asp Lys Val Gly Arg Lys Gln Ser Leu Leu Ile Cys			
210	215	220	
Met Ser Val Asn Gly Phe Phe Ala Phe Leu Ser Ser Phe Val Gln Gly			
225	230	235	240
Tyr Gly Phe Phe Leu Leu Cys Arg Leu Leu Ser Gly Phe Gly Ile Gly			
245	250	255	
Gly Ala Ile Pro Thr Val Phe Ser Tyr Phe Ala Glu Val Leu Ala Arg			
260	265	270	
Glu Lys Arg Gly Glu His Leu Ser Trp Leu Cys Met Phe Trp Met Ile			
275	280	285	
Gly Gly Ile Tyr Ala Ser Ala Met Ala Trp Ala Ile Ile Pro His Tyr			
290	295	300	
Gly Trp Ser Phe Ser Met Gly Ser Ala Tyr Gln Phe His Ser Trp Arg			
305	310	315	320
Val Phe Val Ile Val Cys Ala Leu Pro Cys Val Ser Ser Val Val Ala			
325	330	335	
Leu Thr Phe Met Pro Glu Ser Pro Arg Phe Leu Leu Glu Val Gly Lys			
340	345	350	
His Asp Glu Ala Trp Met Ile Leu Lys Leu Ile His Asp Thr Asn Met			
355	360	365	
Arg Ala Arg Gly Gln Pro Glu Lys Val Phe Thr Val Asn Lys Ile Lys			
370	375	380	
Thr Pro Lys Gln Ile Asp Glu Leu Ile Glu Ile Glu Ser Asp Thr Gly			
385	390	395	400
Thr Trp Tyr Arg Arg Cys Phe Val Arg Ile Arg Thr Glu Leu Tyr Gly			
405	410	415	
Ile Trp Leu Thr Phe Met Arg Cys Phe Asn Tyr Pro Val Arg Glu Asn			
420	425	430	
Thr Ile Lys Leu Thr Ile Val Trp Phe Thr Leu Ser Phe Gly Tyr Tyr			
435	440	445	
Gly Leu Ser Val Trp Phe Pro Asp Val Ile Lys His Leu Gln Ser Asp			
450	455	460	
Glu Tyr Ala Leu Leu Thr Arg Asn Val Gln Lys Asp Lys Tyr Ala Asn			
465	470	475	480
Phe Ser Ile Asn Phe Thr Met Glu Asn Gln Val His Thr Gly Met Glu			
485	490	495	

## US 7,985,554 B2

47

-continued

Tyr Asp Asn Gly Arg Phe Leu Gly Val Lys Phe Lys Ser Val Thr Phe  
500 505 510

Lys Asp Ser Val Phe Lys Ser Cys Thr Phe Asp Asp Val Thr Ser Val  
515 520 525

Asn Thr Tyr Phe Lys Asn Cys Thr Phe Ile Asp Thr Leu Phe Glu Asn  
530 535 540

Thr Asp Phe Glu Pro Tyr Lys Phe Ile Asp Ser Glu Phe Gln Asn Cys  
545 550 555 560

Ser Phe Leu His Asn Lys Thr Gly Cys Gln Ile Thr Phe Asp Asp Asp  
565 570 575

Tyr Ser Ala Tyr Trp Ile Tyr Phe Val Asn Phe Leu Gly Thr Leu Ala  
580 585 590

Val Leu Pro Gly Asn Ile Val Ser Ala Leu Leu Met Asp Arg Ile Gly  
595 600 605

Arg Leu Thr Met Leu Gly Gly Ser Met Val Leu Ser Gly Ile Ser Cys  
610 615 620

Phe Phe Leu Trp Phe Gly Thr Ser Glu Ser Met Met Ile Gly Met Leu  
625 630 635 640

Cys Leu Tyr Asn Gly Leu Thr Ile Ser Ala Trp Asn Ser Leu Asp Val  
645 650 655

Val Thr Val Glu Leu Tyr Pro Thr Asp Arg Arg Ala Thr Gly Phe Gly  
660 665 670

Phe Leu Asn Ala Leu Cys Lys Ala Ala Ala Val Leu Gly Asn Leu Ile  
675 680 685

Phe Gly Ser Leu Val Ser Ile Thr Lys Ala Ile Pro Ile Leu Leu Ala  
690 695 700

Ser Thr Val Leu Val Cys Gly Gly Leu Val Gly Leu Arg Leu Pro Asp  
705 710 715 720

Thr Arg Thr Gln Val Leu Met  
725

<210> SEQ ID NO 7  
<211> LENGTH: 2229  
<212> TYPE: DNA  
<213> ORGANISM: Mus musculus  
<220> FEATURE:  
<221> NAME/KEY: CDS  
<222> LOCATION: (1)..(2229)

&lt;400&gt; SEQUENCE: 7

atg gaa gaa ggc ttt cga gac cga gca gcg ttc atc cgt ggg gcc aaa Met Glu Glu Gly Phe Arg Asp Arg Ala Ala Phe Ile Arg Gly Ala Lys 1 5 10 15	48
gac att gcc aag gaa gtg aag aag cat gcg gcc aag aag gtg gtg aag Asp Ile Ala Lys Glu Val Lys Lys His Ala Ala Lys Lys Val Val Lys 20 25 30	96
ggc ctt gac aga gtc cag gat gag tat tcc cga agg tcc tac tcc cgc Gly Leu Asp Arg Val Gln Asp Glu Tyr Ser Arg Arg Ser Tyr Ser Arg 35 40 45	144
ttt gag gag gag gac gac gat gac ttc cct gcc cct gcg gac ggc Phe Glu Glu Asp Asp Asp Asp Phe Pro Ala Pro Ala Asp GLY 50 55 60	192
tat tac cgc gga gaa ggg gcc cag gat gag gag gaa ggt ggc gct tct Tyr Tyr Arg Gly Glu Gly Ala Gln Asp Glu Glu Glu Gly Gly Ala Ser 65 70 75 80	240
agt gat gcc acc gag ggc cac gat gaa gat gat gag atc tat gag gga Ser Asp Ala Thr Glu Gly His Asp Glu Asp Asp Glu Ile Tyr Glu GLY 85 90 95	288

48

## US 7,985,554 B2

49

-continued

50

gaa tat cag ggc atc ccc cg <sup>g</sup> gca gag tct ggg ggc aaa ggc gaa cgc Glu Tyr Gln Gly Ile Pro Arg Ala Glu Ser Gly Gly Lys Gly Glu Arg 100 105 110	336
atg gca gat ggg gca ccc ctg gct gga gtg aga ggg ggc ttg agt gat Met Ala Asp Gly Ala Pro Leu Ala Gly Val Arg Gly Gly Leu Ser Asp 115 120 125	384
ggg gag ggt ccc cct ggg ggt cgg ggg gag ggc cag cgg cgt aaa gat Gly Glu Gly Pro Pro Gly Gly Arg Gly Glu Ala Gln Arg Arg Lys Asp 130 135 140	432
cgg gaa ttg got cag cag tat gaa acc atc ctc cgg gag tgg tgc Arg Glu Glu Leu Ala Gln Gln Tyr Glu Thr Ile Leu Arg Glu Cys Gly 145 150 155 160	480
cat ggc cgc ttc cag tgg aca ctc tac ttc gtg ctg ggt ctg gcg ctg His Gly Arg Phe Gln Trp Thr Leu Tyr Phe Val Leu Gly Leu Ala Leu 165 170 175	528
atg gca gat ggt gta gag gtc ttt gtg gtg ggc ttt gtg ctg ccc agt Met Ala Asp Gly Val Glu Val Phe Val Val Gly Phe Val Leu Pro Ser 180 185 190	576
gct gag aaa gac atg tgc ctg tcg gac tcc aac aaa ggc atg cta ggc Ala Glu Lys Asp Met Cys Leu Ser Asp Ser Asn Lys Gly Met Leu Gly 195 200 205	624
ctc att gtg tac ctg ggc atg atg gtg ggg gcc ttc ctc tgg gga ggc Leu Ile Val Tyr Leu Gly Met Met Val Gly Ala Phe Leu Trp Gly Gly 210 215 220	672
ctg gct gat cgg ctg ggt cgg aga cag tgt ctg ctc atc tca ctc tca Leu Ala Asp Arg Leu Gly Arg Arg Gln Cys Leu Leu Ile Ser Leu Ser 225 230 235 240	720
gtc aac agc gtc ttc gcc ttc tcg tcc ttc gtc cag ggt tat gga Val Asn Ser Val Phe Phe Ser Ser Phe Val Gln Gly Tyr Gly 245 250 255	768
acc ttt ctc ttc tgc cgc ctc ctt tcc ggg gtc ggg att ggc ggt tcc Thr Phe Leu Phe Cys Arg Leu Leu Ser Gly Val Gly Ile Gly Gly Ser 260 265 270	816
atc ccc ata gtc ttc tcc tat ttt tcg gag ttt ctg gcg cag gag aaa Ile Pro Ile Val Phe Ser Tyr Phe Ser Glu Phe Leu Ala Gln Glu Lys 275 280 285	864
cgt ggg gag cat ttg agc tgg ctc tgt atg ttc tgg atc ggt gga Arg Gly Glu His Leu Ser Trp Leu Cys Met Phe Trp Met Ile Gly Gly 290 295 300	912
gtg tat gca gct gca atg gcc tgg atc atc cct cac tat ggg tgg Val Tyr Ala Ala Ala Met Ala Trp Ala Ile Ile Pro His Tyr Gly Trp 305 310 315 320	960
agt ttc cag atg ggc ttc gct tac cag ttc cac agc tgg agg gtg ttt Ser Phe Gln Met Gly Ser Ala Tyr Gln Phe His Ser Trp Arg Val Phe 325 330 335	1008
gtc ctc gtg tgt gcc ttt ccc tct gtg ttt gcc atc ggg gct ctg act Val Leu Val Cys Ala Phe Pro Ser Val Phe Ala Ile Gly Ala Leu Thr 340 345 350	1056
acg cag cca gag agt ccc cgc ttc cta gag aat ggg aag cat gag Thr Gln Pro Glu Ser Pro Arg Phe Phe Leu Glu Asn Gly Lys His Asp 355 360 365	1104
gaa gcc tgg atg gta ctg aag cag gtt cac gac acc aac atg cga gcc Glu Ala Trp Met Val Leu Lys Gln Val His Asp Thr Asn Met Arg Ala 370 375 380	1152
aag ggc cac cct gag cgc gtc ttc tca gtg acc cac att aaa acg att Lys Gly His Pro Glu Arg Val Phe Ser Val Thr His Ile Lys Thr Ile 385 390 395 400	1200
cat caa gag gat gaa ttg att gag atc cag tct gac aca gga acc tgg His Gln Glu Asp Glu Leu Ile Glu Ile Gln Ser Asp Thr Gly Thr Trp 405 410 415	1248

-continued

---

tac cag cgc tgg gga gta cgg gct ttg agc ctt ggg ggt cag gtt tgg Tyr Gln Arg Trp Gly Val Arg Ala Leu Ser Leu Gly Gln Val Trp 420 425 430	1296
ggg aat ttc ctc tcc tgc ttc agt cca gag tat cgg cgc atc acg ctg Gly Asn Phe Leu Ser Cys Phe Ser Pro Glu Tyr Arg Arg Ile Thr Leu 435 440 445	1344
atg atg atg ggt gtg tgg ttc acc atg tct ttc agc tac tat ggt ttg Met Met Met Gly Val Trp Phe Thr Met Ser Phe Ser Tyr Tyr Gly Leu 450 455 460	1392
act gtc tgg ttt ccc gac atg atc cgc cat ctc cag gct gtg gac tat Thr Val Trp Phe Pro Asp Met Ile Arg His Leu Gln Ala Val Asp Tyr 465 470 475 480	1440
gca gcc cga acc aaa gtg ttc cca ggg gag cgc gtg gag cat gtg acg Ala Ala Arg Thr Lys Val Phe Pro Gly Glu Arg Val Glu His Val Thr 485 490 495	1488
ttt aac ttc aca ctg gag aat cag atc cac cga ggg gga cag tac ttc Phe Asn Phe Thr Leu Glu Asn Gln Ile His Arg Gly Gly Gln Tyr Phe 500 505 510	1536
aat gac aag ttc atc ggg ctg cgt ctg aag tca gtg tcc ttt gag gat Asn Asp Lys Phe Ile Gly Leu Arg Leu Lys Ser Val Phe Glu Asp 515 520 525	1584
tcc ctg ttt gag gag tgt tac ttt gaa gat gtt aca tcc agc aac aca Ser Leu Phe Glu Glu Cys Tyr Phe Glu Asp Val Thr Ser Ser Asn Thr 530 535 540	1632
ttc ttc cgc aac tgc acg ttc atc aac act gtg ttc tat aac act gac Phe Phe Arg Asn Cys Thr Phe Ile Asn Thr Val Phe Tyr Asn Thr Asp 545 550 555 560	1680
cta ttt gag tac aag ttc gtg aac agc cgg ctg gtg aac agc acg ttc Leu Phe Glu Tyr Lys Phe Val Asn Ser Arg Leu Val Asn Ser Thr Phe 565 570 575	1728
ctg cac aat aag gaa ggc tgc cgg cta gac gtg acg ggg aca ggc gaa Leu His Asn Lys Glu Gly Cys Pro Leu Asp Val Thr Gly Thr Gly Glu 580 585 590	1776
ggt gcc tac atg gtg tac ttt gtc agc ttc ttg ggg aca ctg gct gtg Gly Ala Tyr Met Val Tyr Phe Val Ser Phe Leu Gly Thr Leu Ala Val 595 600 605	1824
ctt cct gga aac att gtg tct gtc atg gac aag att ggc agg Leu Pro Gly Asn Ile Val Ser Ala Leu Leu Met Asp Lys Ile Gly Arg 610 615 620	1872
ctc aga atg ctt gct ggt tcc agt gtg ttg tcc tgt gtg tcc tgc ttc Leu Arg Met Leu Ala Gly Ser Ser Val Leu Ser Cys Val Ser Cys Phe 625 630 635 640	1920
ttc ctg tct ttt ggg aac agc gag tca gcc atg atc gct ctg ctc tgc Phe Leu Ser Phe Gly Asn Ser Glu Ser Ala Met Ile Ala Leu Leu Cys 645 650 655	1968
ctt ttt ggg gga gtt agc atc gca tcc tgg aac gcg ctg gac gtg ctg Leu Phe Gly Val Ser Ile Ala Ser Trp Asn Ala Leu Asp Val Leu 660 665 670	2016
acc gtt gag ctc tac cct tcc gac aag agg act act gcc ttt ggc ttc Thr Val Glu Leu Tyr Pro Ser Asp Lys Arg Thr Thr Ala Phe Gly Phe 675 680 685	2064
ctg aat gcc ctg tgt aag ctg gca gct gtg ctg ggg atc agc atc ttc Leu Asn Ala Leu Cys Lys Leu Ala Ala Val Leu Gly Ile Ser Ile Phe 690 695 700	2112
aca tcc ttt gtg ggc atc acc aag gct gct ccc att ctc ttt gcc tcc Thr Ser Phe Val Gly Ile Thr Lys Ala Ala Pro Ile Leu Phe Ala Ser 705 710 715 720	2160
gct gct ctt gcc ctt ggt agc tct ctg gct ctg aag ctg cct gag acc Ala Ala Leu Ala Leu Gly Ser Ser Leu Ala Leu Lys Leu Pro Glu Thr 725 730 735	2208

## US 7,985,554 B2

**53**

-continued

cgg gga cag gtg ctg cag tga  
 Arg Gly Gln Val Leu Gln  
 740

2229

**54**

<210> SEQ ID NO 8  
 <211> LENGTH: 742  
 <212> TYPE: PRT  
 <213> ORGANISM: Mus musculus  
 <400> SEQUENCE: 8

Met Glu Glu Gly Phe Arg Asp Arg Ala Ala Phe Ile Arg Gly Ala Lys  
 1 5 10 15

Asp Ile Ala Lys Glu Val Lys Lys His Ala Ala Lys Lys Val Val Lys  
 20 25 30

Gly Leu Asp Arg Val Gln Asp Glu Tyr Ser Arg Arg Ser Tyr Ser Arg  
 35 40 45

Phe Glu Glu Glu Asp Asp Asp Asp Phe Pro Ala Pro Ala Asp Gly  
 50 55 60

Tyr Tyr Arg Gly Glu Gly Ala Gln Asp Glu Glu Gly Gly Ala Ser  
 65 70 75 80

Ser Asp Ala Thr Glu Gly His Asp Glu Asp Asp Glu Ile Tyr Glu Gly  
 85 90 95

Glu Tyr Gln Gly Ile Pro Arg Ala Glu Ser Gly Gly Lys Gly Glu Arg  
 100 105 110

Met Ala Asp Gly Ala Pro Leu Ala Gly Val Arg Gly Gly Leu Ser Asp  
 115 120 125

Gly Glu Gly Pro Pro Gly Gly Arg Gly Glu Ala Gln Arg Arg Lys Asp  
 130 135 140

Arg Glu Glu Leu Ala Gln Gln Tyr Glu Thr Ile Leu Arg Glu Cys Gly  
 145 150 155 160

His Gly Arg Phe Gln Trp Thr Leu Tyr Phe Val Leu Gly Leu Ala Leu  
 165 170 175

Met Ala Asp Gly Val Glu Val Phe Val Val Gly Phe Val Leu Pro Ser  
 180 185 190

Ala Glu Lys Asp Met Cys Leu Ser Asp Ser Asn Lys Gly Met Leu Gly  
 195 200 205

Leu Ile Val Tyr Leu Gly Met Met Val Gly Ala Phe Leu Trp Gly Gly  
 210 215 220

Leu Ala Asp Arg Leu Gly Arg Arg Gln Cys Leu Leu Ile Ser Leu Ser  
 225 230 235 240

Val Asn Ser Val Phe Ala Phe Phe Ser Ser Phe Val Gln Gly Tyr Gly  
 245 250 255

Thr Phe Leu Phe Cys Arg Leu Leu Ser Gly Val Gly Ile Gly Gly Ser  
 260 265 270

Ile Pro Ile Val Phe Ser Tyr Phe Ser Glu Phe Leu Ala Gln Glu Lys  
 275 280 285

Arg Gly Glu His Leu Ser Trp Leu Cys Met Phe Trp Met Ile Gly Gly  
 290 295 300

Val Tyr Ala Ala Ala Met Ala Trp Ala Ile Ile Pro His Tyr Gly Trp  
 305 310 315 320

Ser Phe Gln Met Gly Ser Ala Tyr Gln Phe His Ser Trp Arg Val Phe  
 325 330 335

Val Leu Val Cys Ala Phe Pro Ser Val Phe Ala Ile Gly Ala Leu Thr  
 340 345 350

Thr Gln Pro Glu Ser Pro Arg Phe Phe Leu Glu Asn Gly Lys His Asp  
 355 360 365

-continued

Glu Ala Trp Met Val Leu Lys Gln Val His Asp Thr Asn Met Arg Ala  
 370 375 380  
 Lys Gly His Pro Glu Arg Val Phe Ser Val Thr His Ile Lys Thr Ile  
 385 390 395 400  
 His Gln Glu Asp Glu Leu Ile Glu Ile Gln Ser Asp Thr Gly Thr Trp  
 405 410 415  
 Tyr Gln Arg Trp Gly Val Arg Ala Leu Ser Leu Gly Gly Gln Val Trp  
 420 425 430  
 Gly Asn Phe Leu Ser Cys Phe Ser Pro Glu Tyr Arg Arg Ile Thr Leu  
 435 440 445  
 Met Met Met Gly Val Trp Phe Thr Met Ser Phe Ser Tyr Tyr Gly Leu  
 450 455 460  
 Thr Val Trp Phe Pro Asp Met Ile Arg His Leu Gln Ala Val Asp Tyr  
 465 470 475 480  
 Ala Ala Arg Thr Lys Val Phe Pro Gly Glu Arg Val Glu His Val Thr  
 485 490 495  
 Phe Asn Phe Thr Leu Glu Asn Gln Ile His Arg Gly Gly Gln Tyr Phe  
 500 505 510  
 Asn Asp Lys Phe Ile Gly Leu Arg Leu Lys Ser Val Ser Phe Glu Asp  
 515 520 525  
 Ser Leu Phe Glu Glu Cys Tyr Phe Glu Asp Val Thr Ser Ser Asn Thr  
 530 535 540  
 Phe Phe Arg Asn Cys Thr Phe Ile Asn Thr Val Phe Tyr Asn Thr Asp  
 545 550 555 560  
 Leu Phe Glu Tyr Lys Phe Val Asn Ser Arg Leu Val Asn Ser Thr Phe  
 565 570 575  
 Leu His Asn Lys Glu Gly Cys Pro Leu Asp Val Thr Gly Thr Gly Glu  
 580 585 590  
 Gly Ala Tyr Met Val Tyr Phe Val Ser Phe Leu Gly Thr Leu Ala Val  
 595 600 605  
 Leu Pro Gly Asn Ile Val Ser Ala Leu Leu Met Asp Lys Ile Gly Arg  
 610 615 620  
 Leu Arg Met Leu Ala Gly Ser Ser Val Leu Ser Cys Val Ser Cys Phe  
 625 630 635 640  
 Phe Leu Ser Phe Gly Asn Ser Glu Ser Ala Met Ile Ala Leu Leu Cys  
 645 650 655  
 Leu Phe Gly Gly Val Ser Ile Ala Ser Trp Asn Ala Leu Asp Val Leu  
 660 665 670  
 Thr Val Glu Leu Tyr Pro Ser Asp Lys Arg Thr Thr Ala Phe Gly Phe  
 675 680 685  
 Leu Asn Ala Leu Cys Lys Leu Ala Ala Val Leu Gly Ile Ser Ile Phe  
 690 695 700  
 Thr Ser Phe Val Gly Ile Thr Lys Ala Ala Pro Ile Leu Phe Ala Ser  
 705 710 715 720  
 Ala Ala Leu Ala Leu Gly Ser Ser Leu Ala Leu Lys Leu Pro Glu Thr  
 725 730 735  
 Arg Gly Gln Val Leu Gln  
 740

<210> SEQ ID NO 9  
 <211> LENGTH: 2052  
 <212> TYPE: DNA  
 <213> ORGANISM: Mus musculus  
 <220> FEATURE:  
 <221> NAME/KEY: CDS

## US 7,985,554 B2

**57**

-continued

**58**

&lt;222&gt; LOCATION: (1)..(2052)

&lt;400&gt; SEQUENCE: 9

atg gat gac tac agg tat cgg gac aac tat gag ggc tat gcc cct agt	48
Met Asp Asp Tyr Arg Tyr Arg Asp Asn Tyr Glu Gly Tyr Ala Pro Ser	
1 5 10 15	
gat ggc tac tac cgt agc aat gag cag aat cag gaa gaa gat gca cag	96
Asp Gly Tyr Tyr Arg Ser Asn Glu Gln Asn Gln Glu Glu Asp Ala Gln	
20 25 30	
agc gat gtt aca gaa ggc cat gac gag gaa gat gag atc tat gaa ggc	144
Ser Asp Val Thr Glu Gly His Asp Glu Glu Asp Glu Ile Tyr Glu GLY	
35 40 45	
gag tac caa ggc atc cct cat cca gat gat gtc aag tct aag cag acc	192
Glu Tyr Gln Gly Ile Pro His Pro Asp Asp Val Lys Ser Lys Gln Thr	
50 55 60	
aag atg gcg ccc tcc aga gca gat ggt ctt ggg ggc cag gca gac ttg	240
Lys Met Ala Pro Ser Arg Ala Asp Gly Leu Gly Gln Ala Asp Leu	
65 70 75 80	
atg gct gag agg atg gaa gat gag gag ctg gct cac caa tat gag	288
Met Ala Glu Arg Met Glu Asp Glu Glu Leu Ala His Gln Tyr Glu	
85 90 95	
acc atc att gat gag tgt ggc cat ggg cgc ttc cag tgg acc ctc ttc	336
Thr Ile Ile Asp Glu Cys Gly His Gly Arg Phe Gln Trp Thr Leu Phe	
100 105 110	
ttc gtc ttg ggt ttg gcc ttg atg gct gat gga gtg gaa ata ttt gta	384
Phe Val Leu Gly Leu Ala Leu Met Ala Asp Gly Val Glu Ile Phe Val	
115 120 125	
gtg agc ttt gct ctg cca agt gca gag aaa gac atg tgt ctg tcc agt	432
Val Ser Phe Ala Leu Pro Ser Ala Glu Lys Asp Met Cys Leu Ser Ser	
130 135 140	
tcc aag aaa gga atg ctt ggg ctg ata gtc tac cta gga atg atg gca	480
Ser Lys Lys Gly Met Leu Gly Leu Ile Val Tyr Leu Gly Met Met Ala	
145 150 155 160	
ggg gcc ttc atc ttg ggc ggc ctg gct gat aaa ctg gga agg aag aag	528
Gly Ala Phe Ile Leu Gly Leu Ala Asp Lys Leu Gly Arg Lys Lys	
165 170 175	
gtc ctc agc atg tca ctg gcc atc aat gcc tcc ttt gct tca ctc tcc	576
Val Leu Ser Met Ser Leu Ala Ile Asn Ala Ser Phe Ala Ser Leu Ser	
180 185 190	
tcc ttc gtg cag gga tat gga gcc ttc ctc ttc tgc aga ctc atc tca	624
Ser Phe Val Gln Gly Tyr Gly Ala Phe Leu Phe Cys Arg Leu Ile Ser	
195 200 205	
ggc ata ggg att ggg ggc tcc ctg cca att gtt ttt gcc tac ttt tct	672
Gly Ile Gly Ile Gly Gly Ser Leu Pro Ile Val Phe Ala Tyr Phe Ser	
210 215 220	
gag ttc tta tca cga gag aaa cgc ggt gag cat ctt agc tgg ctg ggc	720
Glu Phe Leu Ser Arg Glu Lys Arg Gly Glu His Leu Ser Trp Leu Gly	
225 230 235 240	
atc ttc tgg atg act gga ggc atc tat gca tct gcc atg gcc tgg agc	768
Ile Phe Trp Met Thr Gly Gly Ile Tyr Ala Ser Ala Met Ala Trp Ser	
245 250 255	
atc att cca cac tat ggc tgg ggc ttc agc atg ggg act aat tac cac	816
Ile Ile Pro His Tyr Gly Trp Gly Phe Ser Met Gly Thr Asn Tyr His	
260 265 270	
ttc cac agc tgg aga gtg ttt gtc atc gtc tgt gct ctg ccc gcc act	864
Phe His Ser Trp Arg Val Phe Val Ile Val Cys Ala Leu Pro Ala Thr	
275 280 285	
gtg tcc atg gtg gct ctg aag ttc atg cca gaa agc ccc agg ttc ctg	912
Val Ser Met Val Ala Leu Lys Phe Met Pro Glu Ser Pro Arg Phe Leu	
290 295 300	

-continued

ctg gag atg ggc aaa cat gat gaa gcc tgg atg att ctc aaa caa gtc Leu Glu Met Gly Lys His Asp Glu Ala Trp Met Ile Leu Lys Gln Val 305 310 315 320	960
cat gat aca aac atg aga gct aag ggg acc ccg gaa aag gtg ttc acg His Asp Thr Asn Met Arg Ala Lys Gly Thr Pro Glu Lys Val Phe Thr 325 330 335	1008
gtt tcc cac atc aaa act ccc aag caa atg gat gaa ttc att gag ata Val Ser His Ile Lys Thr Pro Lys Gln Met Asp Glu Phe Ile Glu Ile 340 345 350	1056
cag agc tca acc gga act tgg tac cag cgc tgg ctg gtc agg ttc atg Gln Ser Ser Thr Gly Thr Trp Tyr Gln Arg Trp Leu Val Arg Phe Met 355 360 365	1104
acc att ttc aaa cag gtc tgg gat aac gcc ttt tac tgt gtg atg ggg Thr Ile Phe Lys Gln Val Trp Asp Asn Ala Leu Tyr Cys Val Met Gly 370 375 380	1152
ccc tac aga atg aac acc ctg att ctg gct gtg gtc tgg ttc acc atg Pro Tyr Arg Met Asn Thr Leu Ile Leu Ala Val Val Trp Phe Thr Met 385 390 395 400	1200
gcc tta agt tac tac ggc ctg acg gtg tgg ttc ccc gac atg atc cgc Ala Leu Ser Tyr Tyr Gly Leu Thr Val Trp Phe Pro Asp Met Ile Arg 405 410 415	1248
tat ttc cag gat gaa gaa tat aag tct aaa atg aag gtg ttt ttt ggt Tyr Phe Gln Asp Glu Glu Tyr Lys Ser Lys Met Lys Val Phe Phe Gly 420 425 430	1296
gag cac gtg cat ggc gcc acg atc aac ttt acc atg gaa aac cag atc Glu His Val His Gly Ala Thr Ile Asn Phe Thr Met Glu Asn Gln Ile 435 440 445	1344
cac caa cat ggg aag ctt gtg aac gat aag ttc ata aag atg tat ttt His Gln His Gly Leu Val Asn Asp Lys Phe Ile Lys Met Tyr Phe 450 455 460	1392
aaa cat gtc ctc ttt gag gac aca ttc ttt gac aaa tgc tat ttt gaa Lys His Val Leu Phe Glu Asp Thr Phe Phe Asp Lys Cys Tyr Phe Glu 465 470 475 480	1440
gat gtg aca tcc aca gat acg tat ttc aag aac tgc acc atc gaa tcg Asp Val Thr Ser Thr Asp Thr Tyr Phe Lys Asn Cys Thr Ile Glu Ser 485 490 495	1488
acc acc ttc tac aac aca gac ctc tac aaa cac aag ttc atc aac tgt Thr Thr Phe Tyr Asn Thr Asp Leu Tyr Lys His Lys Phe Ile Asn Cys 500 505 510	1536
cgg ttt atc aat tcc acc ttt ctg gag cag aag gag ggc tgc cac atg Arg Phe Ile Asn Ser Thr Phe Leu Glu Gln Lys Glu Gly Cys His Met 515 520 525	1584
gac ttt gaa gag gac aat gat ttt ctg att tac ctc gtc agc ttc ctc Asp Phe Glu Glu Asp Asn Asp Phe Leu Ile Tyr Leu Val Ser Phe Leu 530 535 540	1632
ggc agc ctc tct gtc ttg cct ggg aac ata att tct gcc ctc atg Gly Ser Leu Ser Val Leu Pro Gly Asn Ile Ile Ser Ala Leu Leu Met 545 550 555 560	1680
gac aga att gga aga ctc aag atg att ggc ggc tcc atg ctc atc tct Asp Arg Ile Gly Arg Leu Lys Met Ile Gly Gly Ser Met Leu Ile Ser 565 570 575	1728
gca gtc tgc tgc ttc ttc ctg ttt ttt ggc aac agc gag tct gcg atg Ala Val Cys Cys Phe Phe Leu Phe Phe Gly Asn Ser Glu Ser Ala Met 580 585 590	1776
atc ggc tgg caa tgc ctg ttc tgt ggg acc agc att gca gcc tgg aat Ile Gly Trp Gln Cys Leu Phe Cys Gly Thr Ser Ile Ala Ala Trp Asn 595 600 605	1824
gct ctg gat gtg atc aca gtt gag ctg tat ccc acc aac cag agg gcc Ala Leu Asp Val Ile Thr Val Glu Leu Tyr Pro Thr Asn Gln Arg Ala 610 615 620	1872

## US 7,985,554 B2

**61****62**

-continued

acg gcc ttc ggc atc ctc aac gga ctg tgc aag ttt ggg gcc atc ctg	1920
Thr Ala Phe Gly Ile Leu Asn Gly Leu Cys Lys Phe Gly Ala Ile Leu	
625 630 635 640	
gga aac act atc ttt gct tct ttt gtt ggg ata acc aaa gtg gtc ccc	1968
Gly Asn Thr Ile Phe Ala Ser Phe Val Gly Ile Thr Lys Val Val Pro	
645 650 655	
atc ctt ctg gct gct get tct ctg gtt gga ggt ggc ctg att gcc ctt	2016
Ile Leu Leu Ala Ala Ser Leu Val Gly Gly Leu Ile Ala Leu	
660 665 670	
cga ttg cca gag act cga gag caa gtc ctg atg tga	2052
Arg Leu Pro Glu Thr Arg Glu Gln Val Leu Met	
675 680	

<210> SEQ ID NO 10  
<211> LENGTH: 683  
<212> TYPE: PRT  
<213> ORGANISM: Mus musculus

&lt;400&gt; SEQUENCE: 10

Met Asp Asp Tyr Arg Tyr Arg Asp Asn Tyr Glu Gly Tyr Ala Pro Ser	
1 5 10 15	
Asp Gly Tyr Tyr Arg Ser Asn Glu Gln Asn Gln Glu Glu Asp Ala Gln	
20 25 30	
Ser Asp Val Thr Glu Gly His Asp Glu Glu Asp Glu Ile Tyr Glu Gly	
35 40 45	
Glu Tyr Gln Gly Ile Pro His Pro Asp Asp Val Lys Ser Lys Gln Thr	
50 55 60	
Lys Met Ala Pro Ser Arg Ala Asp Gly Leu Gly Gln Ala Asp Leu	
65 70 75 80	
Met Ala Glu Arg Met Glu Asp Glu Glu Leu Ala His Gln Tyr Glu	
85 90 95	
Thr Ile Ile Asp Glu Cys Gly His Gly Arg Phe Gln Trp Thr Leu Phe	
100 105 110	
Phe Val Leu Gly Leu Ala Leu Met Ala Asp Gly Val Glu Ile Phe Val	
115 120 125	
Val Ser Phe Ala Leu Pro Ser Ala Glu Lys Asp Met Cys Leu Ser Ser	
130 135 140	
Ser Lys Lys Gly Met Leu Gly Leu Ile Val Tyr Leu Gly Met Met Ala	
145 150 155 160	
Gly Ala Phe Ile Leu Gly Leu Ala Asp Lys Leu Gly Arg Lys Lys	
165 170 175	
Val Leu Ser Met Ser Leu Ala Ile Asn Ala Ser Phe Ala Ser Leu Ser	
180 185 190	
Ser Phe Val Gln Gly Tyr Gly Ala Phe Leu Phe Cys Arg Leu Ile Ser	
195 200 205	
Gly Ile Gly Ile Gly Gly Ser Leu Pro Ile Val Phe Ala Tyr Phe Ser	
210 215 220	
Glu Phe Leu Ser Arg Glu Lys Arg Gly Glu His Leu Ser Trp Leu Gly	
225 230 235 240	
Ile Phe Trp Met Thr Gly Gly Ile Tyr Ala Ser Ala Met Ala Trp Ser	
245 250 255	
Ile Ile Pro His Tyr Gly Trp Gly Phe Ser Met Gly Thr Asn Tyr His	
260 265 270	
Phe His Ser Trp Arg Val Phe Val Ile Val Cys Ala Leu Pro Ala Thr	
275 280 285	
Val Ser Met Val Ala Leu Lys Phe Met Pro Glu Ser Pro Arg Phe Leu	
290 295 300	

-continued

Leu Glu Met Gly Lys His Asp Glu Ala Trp Met Ile Leu Lys Gln Val  
 305 310 315 320  
 His Asp Thr Asn Met Arg Ala Lys Gly Thr Pro Glu Lys Val Phe Thr  
 325 330 335  
 Val Ser His Ile Lys Thr Pro Lys Gln Met Asp Glu Phe Ile Glu Ile  
 340 345 350  
 Gln Ser Ser Thr Gly Thr Trp Tyr Gln Arg Trp Leu Val Arg Phe Met  
 355 360 365  
 Thr Ile Phe Lys Gln Val Trp Asp Asn Ala Leu Tyr Cys Val Met Gly  
 370 375 380  
 Pro Tyr Arg Met Asn Thr Leu Ile Leu Ala Val Val Trp Phe Thr Met  
 385 390 395 400  
 Ala Leu Ser Tyr Tyr Gly Leu Thr Val Trp Phe Pro Asp Met Ile Arg  
 405 410 415  
 Tyr Phe Gln Asp Glu Glu Tyr Lys Ser Lys Met Lys Val Phe Phe Gly  
 420 425 430  
 Glu His Val His Gly Ala Thr Ile Asn Phe Thr Met Glu Asn Gln Ile  
 435 440 445  
 His Gln His Gly Lys Leu Val Asn Asp Lys Phe Ile Lys Met Tyr Phe  
 450 455 460  
 Lys His Val Leu Phe Glu Asp Thr Phe Asp Lys Cys Tyr Phe Glu  
 465 470 475 480  
 Asp Val Thr Ser Thr Asp Thr Tyr Phe Lys Asn Cys Thr Ile Glu Ser  
 485 490 495  
 Thr Thr Phe Tyr Asn Thr Asp Leu Tyr Lys His Lys Phe Ile Asn Cys  
 500 505 510  
 Arg Phe Ile Asn Ser Thr Phe Leu Glu Gln Lys Glu Gly Cys His Met  
 515 520 525  
 Asp Phe Glu Glu Asp Asn Asp Phe Leu Ile Tyr Leu Val Ser Phe Leu  
 530 535 540  
 Gly Ser Leu Ser Val Leu Pro Gly Asn Ile Ile Ser Ala Leu Leu Met  
 545 550 555 560  
 Asp Arg Ile Gly Arg Leu Lys Met Ile Gly Gly Ser Met Leu Ile Ser  
 565 570 575  
 Ala Val Cys Cys Phe Phe Leu Phe Gly Asn Ser Glu Ser Ala Met  
 580 585 590  
 Ile Gly Trp Gln Cys Leu Phe Cys Gly Thr Ser Ile Ala Ala Trp Asn  
 595 600 605  
 Ala Leu Asp Val Ile Thr Val Glu Leu Tyr Pro Thr Asn Gln Arg Ala  
 610 615 620  
 Thr Ala Phe Gly Ile Leu Asn Gly Leu Cys Lys Phe Gly Ala Ile Leu  
 625 630 635 640  
 Gly Asn Thr Ile Phe Ala Ser Phe Val Gly Ile Thr Lys Val Val Pro  
 645 650 655  
 Ile Leu Leu Ala Ala Ala Ser Leu Val Gly Gly Leu Ile Ala Leu  
 660 665 670  
 Arg Leu Pro Glu Thr Arg Glu Gln Val Leu Met  
 675 680

```

<210> SEQ ID NO 11
<211> LENGTH: 2184
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<220> FEATURE:
<221> NAME/KEY: CDS
  
```

## US 7,985,554 B2

**65****66**

-continued

&lt;222&gt; LOCATION: (1)..(2181)

&lt;400&gt; SEQUENCE: 11

atg gaa gac tcc tac aag gat agg act tca ctg atg aag ggt gcc aag Met Glu Asp Ser Tyr Lys Asp Arg Thr Ser Leu Met Lys Gly Ala Lys 1 5 10 15	48
gac att gcc aaa gag gtg aag aag cag acg gtg aag aag gtg aac cag Asp Ile Ala Lys Glu Val Lys Lys Gln Thr Val Lys Lys Val Asn Gln 20 25 30	96
gca gtg gat cgg gcc cag gat gaa tat acc cag cgg tcc tac agt cgg Ala Val Asp Arg Ala Gln Asp Glu Tyr Thr Gln Arg Ser Tyr Ser Arg 35 40 45	144
ttc cag gat gaa gag gac gat gac tac tac cca cct ggc gaa acc Phe Gln Asp Glu Glu Asp Asp Asp Tyr Tyr Pro Pro Gly Glu Thr 50 55 60	192
tac agt ggg gag gtc aat gat gat gaa ggc tca agt gag gcc act gag Tyr Ser Gly Glu Val Asn Asp Asp Glu Gly Ser Ser Glu Ala Thr Glu 65 70 75 80	240
ggt cac gac gag gag gat gag atc tat gaa ggg gag tac cag ggc atc Gly His Asp Glu Asp Glu Ile Tyr Glu Gly Glu Tyr Gln Gly Ile 85 90 95	288
ccc agc acg aac cag ggg aaa gac agc atc gtg tct gta gga cag ccc Pro Ser Thr Asn Gln Gly Lys Asp Ser Ile Val Ser Val Gly Gln Pro 100 105 110	336
aaa ggt gat gag tac aag gac cgc aga gag cta gag tca gag agg agg Lys Gly Asp Glu Tyr Lys Asp Arg Arg Glu Leu Glu Ser Glu Arg Arg 115 120 125	384
gct gat gag gaa gag ctc gcc cag cag tat gag ctg ata atc caa gag Ala Asp Glu Glu Leu Ala Gln Gln Tyr Glu Leu Ile Ile Gln Glu 130 135 140	432
tgt ggc cac ggc cgt ttc cag tgg gcc ctt ttc gtc ctg ggc atg Cys Gly His Gly Arg Phe Gln Trp Ala Leu Phe Phe Val Leu Gly Met 145 150 155 160	480
gct ctc atg gcc gat ggc gtg gag gtg ttt gtg gtg ggc ttc gtg cta Ala Leu Met Ala Asp Gly Val Val Phe Val Val Gly Phe Val Leu 165 170 175	528
ccc agt gca gag aca gac cta tgc ata cca aat tcg gga tct gga tgg Pro Ser Ala Glu Thr Asp Leu Cys Ile Pro Asn Ser Gly Ser Gly Trp 180 185 190	576
cta ggt agc ata gtg tac ctc ggg atg atg gtg ggg gcg ttc ttc tgg Leu Gly Ser Ile Val Tyr Leu Gly Met Met Val Gly Ala Phe Phe Trp 195 200 205	624
gga gga ctg gca gac aaa gta gga agg aag cag tct ctt ctg att tgc Gly Gly Leu Ala Asp Lys Val Gly Arg Lys Gln Ser Leu Leu Ile Cys 210 215 220	672
atg tct gtc aac gga ttc ttt gcc ttc ctc tcc tca ttt gtc caa ggt Met Ser Val Asn Gly Phe Phe Ala Phe Leu Ser Ser Phe Val Gln Gly 225 230 235 240	720
tac ggc ttc ttt ctc gtc tgt cgg ttg ctt tct gga ttc ggg att gga Tyr Gly Phe Phe Val Cys Arg Leu Leu Ser Gly Phe Gly Ile GLY 245 250 255	768
ggc gcc att ccc act gtg ttc tcc tac ttc gct gaa gtc ctg gcc cgg Gly Ala Ile Pro Thr Val Phe Ser Tyr Phe Ala Glu Val Leu Ala Arg 260 265 270	816
gag aag cgg ggt gag cac ctc agt tgg ctc tgc atg ttc tgg atg att Glu Lys Arg Gly Glu His Leu Ser Trp Leu Cys Met Phe Trp Met Ile 275 280 285	864
ggc ggc atc tac gcc tcc gcc atg gcc tgg gcc att ccc cac tac Gly Gly Ile Tyr Ala Ser Ala Met Ala Trp Ala Ile Ile Pro His Tyr 290 295 300	912

## US 7,985,554 B2

**67****68**

-continued

---

ggg tgg agc ttc agc atg ggt tca gcc tac cag ttc cac agc tgg cgc Gly Trp Ser Phe Ser Met Gly Ser Ala Tyr Gln Phe His Ser Trp Arg 305 310 315 320	960
gtc ttc gtc atc gtc tgt gcg ctc ccg tgc gtc tcc tct gtg gtg gct Val Phe Val Ile Val Cys Ala Leu Pro Cys Val Ser Ser Val Val Ala 325 330 335	1008
ctc acc ttc atg cca gaa agc cct cgg ttc ttg ctg gag gtg gga aaa Leu Thr Phe Met Pro Glu Ser Pro Arg Phe Leu Leu Glu Val Gly Lys 340 345 350	1056
cat gat gaa gcc tgg atg att ctg aag tta att cat gac acc aac atg His Asp Glu Ala Trp Met Ile Leu Lys Leu Ile His Asp Thr Asn Met 355 360 365	1104
aga gcc cgg ggc cag cca gag aag gtc ttc acg gta aat aaa atc aag Arg Ala Arg Gly Gln Pro Glu Lys Val Phe Thr Val Asn Lys Ile Lys 370 375 380	1152
act ccc aaa caa ata gat gag ctg atc gaa att gag agc gac acg gga Thr Pro Lys Gln Ile Asp Glu Leu Ile Glu Ile Ser Asp Thr Gly 385 390 395 400	1200
acc tgg tac agg agg tgt ttc gtt cgg atc cgc acc gaa ctg tac gga Thr Trp Tyr Arg Arg Cys Phe Val Arg Thr Glu Leu Tyr Gly 405 410 415	1248
att tgg ctg aca ttc atg aga tgc ttc aac tac cca gtc agg gaa aac Ile Trp Leu Thr Phe Met Arg Cys Phe Asn Tyr Pro Val Arg Glu Asn 420 425 430	1296
acc atc aag ctt acg att gtc tgg ttc acc ctg tcc ttc ggg tac tat Thr Ile Lys Leu Thr Ile Val Trp Phe Thr Leu Ser Phe Gly Tyr Tyr 435 440 445	1344
ggg ttg tcc gtt tgg ttc cct gat gtc att aaa cat ctc cag tct gat Gly Leu Ser Val Trp Phe Pro Asp Val Ile Lys His Leu Gln Ser Asp 450 455 460	1392
gag tat gca ctg cta act agg aat gtgcaa aag gat aaa tat gca aac Glu Tyr Ala Leu Leu Thr Arg Asn Val Gln Lys Asp Lys Tyr Ala Asn 465 470 475 480	1440
tcc agc att aac ttt acc atg gag aac cag atc cac act gga atg gaa Phe Ser Ile Asn Phe Thr Met Glu Asn Gln Ile His Thr Gly Met Glu 485 490 495	1488
tac gag aac ggc aga ttc ctc gga gtc aag ttc aaa tcg gta acc ttc Tyr Glu Asn Gly Arg Phe Leu Gly Val Lys Phe Lys Ser Val Thr Phe 500 505 510	1536
aaa gat tca gtg ttt aag tcc tgc acc ttt gac gac gtg acc tca gtc Lys Asp Ser Val Phe Lys Ser Cys Thr Phe Asp Asp Val Thr Ser Val 515 520 525	1584
aac acc tac ttc aag aac tgc acg ttt att gat acc ctt ttt gat aac Asn Thr Tyr Phe Lys Asn Cys Thr Phe Ile Asp Thr Leu Phe Asp Asn 530 535 540	1632
aca gat ttt gag ccc tat aaa ttc ata gac agt gaa ttt cag aac tgc Thr Asp Phe Glu Pro Tyr Lys Phe Ile Asp Ser Glu Phe Gln Asn Cys 545 550 555 560	1680
tca ttt ctt cac aat aag acg ggg tgc cag att act ttt gat gac gac Ser Phe Leu His Asn Lys Thr Gly Cys Gln Ile Thr Phe Asp Asp Asp 565 570 575	1728
tat agt gcc tac tgg att tac ttt gtc aac ttt ctt ggg aca ttg gca Tyr Ser Ala Tyr Trp Ile Tyr Phe Val Asn Phe Leu Gly Thr Leu Ala 580 585 590	1776
gtg ttg cca gga aat atc gtg tct gct ctc ctg atg gac agg atc ggg Val Leu Pro Gly Asn Ile Val Ser Ala Leu Leu Met Asp Arg Ile Gly 595 600 605	1824
cgt tta acg atg cta gga ggc tcc atg gtg ctc tcc ggg atc agt tgc Arg Leu Thr Met Leu Gly Gly Ser Met Val Leu Ser Gly Ile Ser Cys 610 615 620	1872

## US 7,985,554 B2

**69****70**

-continued

---

ttc ttc ctg tgg ttt ggc acc aac gaa tcc atg atg ata ggc atg ctg Phe Phe Leu Trp Phe Gly Thr Ser Glu Ser Met Met Ile Gly Met Leu 625 630 635 640	1920
tgc ttg tat aat ggg ctg acc atc tca gcg tgg aat tct ctc gat gtc Cys Leu Tyr Asn Gly Leu Thr Ile Ser Ala Trp Asn Ser Leu Asp Val 645 650 655	1968
gtc acg gtg gaa ctg tat ccc aca gac cgg aga gca acg ggc ttc ggc Val Thr Val Glu Leu Tyr Pro Thr Asp Arg Arg Ala Thr Gly Phe Gly 660 665 670	2016
ttc ttg aac gcc ctc tgt aaa gcg gcg gcc gtc ctg gga aac tta atc Phe Leu Asn Ala Leu Cys Lys Ala Ala Val Leu Gly Asn Leu Ile 675 680 685	2064
ttc ggc tcc ttg gtc aac atc acc aaa gcc atc ccc atc ctg ctg gct Phe Gly Ser Leu Val Ser Ile Thr Lys Ala Ile Pro Ile Leu Leu Ala 690 695 700	2112
tcc act gtg ctc gtg tgt gga gga ctc gtg ggg ctg cgc ctg ccc gac Ser Thr Val Leu Val Cys Gly Gly Leu Val Gly Leu Arg Leu Pro Asp 705 710 715 720	2160
aca cga acc cag gtt ctg atg tga Thr Arg Thr Gln Val Leu Met 725	2184
<210> SEQ ID NO 12 <211> LENGTH: 727 <212> TYPE: PRT <213> ORGANISM: Mus musculus	
<400> SEQUENCE: 12	
Met Glu Asp Ser Tyr Lys Asp Arg Thr Ser Leu Met Lys Gly Ala Lys 1 5 10 15	
Asp Ile Ala Lys Glu Val Lys Lys Gln Thr Val Lys Lys Val Asn Gln 20 25 30	
Ala Val Asp Arg Ala Gln Asp Glu Tyr Thr Gln Arg Ser Tyr Ser Arg 35 40 45	
Phe Gln Asp Glu Glu Asp Asp Asp Tyr Tyr Pro Pro Gly Glu Thr 50 55 60	
Tyr Ser Gly Glu Val Asn Asp Asp Glu Gly Ser Ser Glu Ala Thr Glu 65 70 75 80	
Gly His Asp Glu Glu Asp Glu Ile Tyr Glu Gly Glu Tyr Gln Gly Ile 85 90 95	
Pro Ser Thr Asn Gln Gly Lys Asp Ser Ile Val Ser Val Gly Gln Pro 100 105 110	
Lys Gly Asp Glu Tyr Lys Asp Arg Arg Glu Leu Glu Ser Glu Arg Arg 115 120 125	
Ala Asp Glu Glu Glu Leu Ala Gln Gln Tyr Glu Leu Ile Ile Gln Glu 130 135 140	
Cys Gly His Gly Arg Phe Gln Trp Ala Leu Phe Phe Val Leu Gly Met 145 150 155 160	
Ala Leu Met Ala Asp Gly Val Glu Val Phe Val Val Gly Phe Val Leu 165 170 175	
Pro Ser Ala Glu Thr Asp Leu Cys Ile Pro Asn Ser Gly Ser Gly Trp 180 185 190	
Leu Gly Ser Ile Val Tyr Leu Gly Met Met Val Gly Ala Phe Phe Trp 195 200 205	
Gly Gly Leu Ala Asp Lys Val Gly Arg Lys Gln Ser Leu Leu Ile Cys 210 215 220	
Met Ser Val Asn Gly Phe Phe Ala Phe Leu Ser Ser Phe Val Gln Gly 225 230 235 240	

-continued

Tyr Gly Phe Phe Leu Val Cys Arg Leu Leu Ser Gly Phe Gly Ile Gly  
 245 250 255

Gly Ala Ile Pro Thr Val Phe Ser Tyr Phe Ala Glu Val Leu Ala Arg  
 260 265 270

Glu Lys Arg Gly Glu His Leu Ser Trp Leu Cys Met Phe Trp Met Ile  
 275 280 285

Gly Gly Ile Tyr Ala Ser Ala Met Ala Trp Ala Ile Ile Pro His Tyr  
 290 295 300

Gly Trp Ser Phe Ser Met Gly Ser Ala Tyr Gln Phe His Ser Trp Arg  
 305 310 315 320

Val Phe Val Ile Val Cys Ala Leu Pro Cys Val Ser Ser Val Val Ala  
 325 330 335

Leu Thr Phe Met Pro Glu Ser Pro Arg Phe Leu Leu Glu Val Gly Lys  
 340 345 350

His Asp Glu Ala Trp Met Ile Leu Lys Leu Ile His Asp Thr Asn Met  
 355 360 365

Arg Ala Arg Gly Gln Pro Glu Lys Val Phe Thr Val Asn Lys Ile Lys  
 370 375 380

Thr Pro Lys Gln Ile Asp Glu Leu Ile Glu Ile Glu Ser Asp Thr Gly  
 385 390 395 400

Thr Trp Tyr Arg Arg Cys Phe Val Arg Ile Arg Thr Glu Leu Tyr Gly  
 405 410 415

Ile Trp Leu Thr Phe Met Arg Cys Phe Asn Tyr Pro Val Arg Glu Asn  
 420 425 430

Thr Ile Lys Leu Thr Ile Val Trp Phe Thr Leu Ser Phe Gly Tyr Tyr  
 435 440 445

Gly Leu Ser Val Trp Phe Pro Asp Val Ile Lys His Leu Gln Ser Asp  
 450 455 460

Glu Tyr Ala Leu Leu Thr Arg Asn Val Gln Lys Asp Lys Tyr Ala Asn  
 465 470 475 480

Phe Ser Ile Asn Phe Thr Met Glu Asn Gln Ile His Thr Gly Met Glu  
 485 490 495

Tyr Glu Asn Gly Arg Phe Leu Gly Val Lys Phe Lys Ser Val Thr Phe  
 500 505 510

Lys Asp Ser Val Phe Lys Ser Cys Thr Phe Asp Asp Val Thr Ser Val  
 515 520 525

Asn Thr Tyr Phe Lys Asn Cys Thr Phe Ile Asp Thr Leu Phe Asp Asn  
 530 535 540

Thr Asp Phe Glu Pro Tyr Lys Phe Ile Asp Ser Glu Phe Gln Asn Cys  
 545 550 555 560

Ser Phe Leu His Asn Lys Thr Gly Cys Gln Ile Thr Phe Asp Asp Asp  
 565 570 575

Tyr Ser Ala Tyr Trp Ile Tyr Phe Val Asn Phe Leu Gly Thr Leu Ala  
 580 585 590

Val Leu Pro Gly Asn Ile Val Ser Ala Leu Leu Met Asp Arg Ile Gly  
 595 600 605

Arg Leu Thr Met Leu Gly Gly Ser Met Val Leu Ser Gly Ile Ser Cys  
 610 615 620

Phe Phe Leu Trp Phe Gly Thr Ser Glu Ser Met Met Ile Gly Met Leu  
 625 630 635 640

Cys Leu Tyr Asn Gly Leu Thr Ile Ser Ala Trp Asn Ser Leu Asp Val  
 645 650 655

Val Thr Val Glu Leu Tyr Pro Thr Asp Arg Arg Ala Thr Gly Phe Gly

-continued

660	665	670
Phe Leu Asn Ala Leu Cys Lys Ala Ala Ala Val	Gly Asn Leu Ile	
675	680	685
Phe Gly Ser Leu Val Ser Ile Thr Lys Ala Ile Pro	Ile Leu Leu Ala	
690	695	700
Ser Thr Val Leu Val Cys Gly Gly Leu Val Gly	Leu Arg Leu Pro Asp	
705	710	715
720		
Thr Arg Thr Gln Val Leu Met		
	725	

<210> SEQ ID NO 13  
<211> LENGTH: 2229  
<212> TYPE: DNA  
<213> ORGANISM: Homo sapiens  
<220> FEATURE:  
<221> NAME/KEY: CDS  
<222> LOCATION: (1)..(2229)

&lt;400&gt; SEQUENCE: 13

atg gaa gag ggc ttc cga gac cgg gca gct ttc atc cgt	48
Met Glu Gly Phe Arg Asp Arg Ala Ala Phe Ile Arg Gly	
1 5 10 15	
Met Glu Gly Phe Arg Asp Arg Ala Ala Phe Ile Arg Gly	
Asp Ile Ala Lys Glu Val Lys Lys His Ala Ala Lys Lys	96
20 25 30	
Asp Ile Ala Lys Glu Val Lys Lys His Ala Ala Lys Lys	
Arg Val Gln Asp Glu Tyr Ser Arg Arg Ser Tyr Ser Arg	144
35 40 45	
Arg Val Gln Asp Glu Tyr Ser Arg Arg Ser Tyr Ser Arg	
ttt gag gag gag tat tat gac ttc cct gct ccc agt	192
Phe Glu Glu Asp Asp Asp Asp Phe Pro Ala Pro Ser Asp	
50 55 60	
Tyr Arg Gly Glu Thr Gln Asp Glu Glu Gly Ala Ser	240
65 70 75 80	
Tyr Arg Gly Glu Thr Gln Asp Glu Glu Gly Ala Ser	
agt gat gct act gag ggc cat gac gag gat gat gag atc	288
Ser Asp Ala Thr Glu Gly His Asp Glu Asp Asp Glu Ile	
85 90 95	
Tyr Glu Gly His Asp Glu Asp Asp Glu Ile Tyr Glu Gly	
gaa tat cag gac att ccc cgg gca gag tct ggg ggc	336
Glu Tyr Gln Asp Ile Pro Arg Ala Glu Ser Gly Gly	
100 105 110	
Glu Tyr Gln Asp Ile Pro Arg Ala Glu Ser Gly Gly	
atg gca gat ggg gcg ccc ctg gct gga gta agg ggg ggc	384
Met Ala Asp Gly Ala Pro Leu Ala Gly Val Arg Gly	
115 120 125	
Met Ala Asp Gly Ala Pro Leu Ala Gly Val Arg Gly	
ggg gag ggt ccc cct ggg ggc cgg ggg gag gca caa cga	432
Gly Glu Gly Pro Pro Gly Gly Arg Gly Glu Ala Gln Arg	
130 135 140	
Gly Glu Gly Pro Pro Gly Gly Arg Gly Glu Ala Gln Arg	
cga gaa gaa ctg goc caa cag tat gaa gcc atc cta cgg	480
Arg Glu Glu Leu Ala Gln Gln Tyr Glu Ala Ile Leu Arg	
145 150 155 160	
Arg Glu Glu Leu Ala Gln Gln Tyr Glu Ala Ile Leu Arg	
cac ggc cgc ttc cag tgg aca ctg tat ttt gtg ctt ggt	528
His Gly Arg Phe Gln Trp Thr Leu Tyr Phe Val Leu Gly	
165 170 175	
His Gly Arg Phe Gln Trp Thr Leu Tyr Phe Val Leu Gly	
atg gct gac ggt gtg gag gtc ttt gtg gtg ggc ttc	576
Met Ala Asp Gly Val Glu Val Phe Val Val Gly Phe Val	
180 185 190	
Met Ala Asp Gly Val Glu Val Phe Val Val Gly Phe Val	
gct gag aaa gac atg tgc ctg tcc gac tcc aac aaa ggc	624
Ala Glu Lys Asp Met Cys Leu Ser Asp Ser Asn Lys Gly	
195 200 205	
Ala Glu Lys Asp Met Cys Leu Ser Asp Ser Asn Lys Gly	
ctc atc gtc tac ctg ggc atg atg gtg gga gcc ttc ctc	672
Tgg gga ggt Leu Ile Val Tyr Leu Gly Met Met Val Gly	
210 215 220	
Tgg gga ggt Leu Ile Val Tyr Leu Gly Met Met Val Gly	

-continued

ctg gct gac cgg ctg ggt cgg agg cag tgt ctg ctc atc tcg ctc tca Leu Ala Asp Arg Leu Gly Arg Arg Gln Cys Leu Leu Ile Ser Leu Ser 225 230 235 240	720
gtc aac agc gtc ttc gcc ttc ttc tca tct ttt gtc cag ggt tac ggc Val Asn Ser Val Phe Ala Phe Phe Ser Ser Phe Val Gln Gly Tyr Gly 245 250 255	768
act ttc ctc ttc tgc cgc cta ctt tct ggg gtt ggg att gga ggg tcc Thr Phe Leu Phe Cys Arg Leu Leu Ser Gly Val Gly Ile Gly Gly Ser 260 265 270	816
atc ccc att gtc ttc tcc tat ttc tcc gag ttt ctg gcc cag gag aaa Ile Pro Ile Val Phe Ser Tyr Phe Ser Glu Phe Leu Ala Gln Glu Lys 275 280 285	864
cga ggg gag cat ttg agc tgg ctc tgc atg ttt tgg atg att ggt ggc Arg Gly Glu His Leu Ser Trp Leu Cys Met Phe Trp Met Ile Gly Gly 290 295 300	912
gtg tac gca gct gct atg gcc tgg gcc atc atc ccc cac tat ggg tgg Val Tyr Ala Ala Ala Met Ala Trp Ala Ile Ile Pro His Tyr Gly Trp 305 310 315 320	960
agt ttt cag atg ggt tct gcc tac cag ttc cac agc tgg agg gtc ttc Ser Phe Gln Met Gly Ser Ala Tyr Gln Phe His Ser Trp Arg Val Phe 325 330 335	1008
gtc ctc gtc tgc gcc ttt cct tct gtg ttt gcc att ggg gct ctg acc Val Leu Val Cys Ala Phe Pro Ser Val Phe Ala Ile Gly Ala Leu Thr 340 345 350	1056
acg cag cct gag agc ccc cgt ttc ttc cta gag aat gga aag cat gat Thr Gln Pro Glu Ser Pro Arg Phe Phe Leu Glu Asn Gly Lys His Asp 355 360 365	1104
gag gcc tgg atg gtg ctg aag cag gtc cat gat acc aac atg cga gcc Glu Ala Trp Met Val Leu Lys Gln Val His Asp Thr Asn Met Arg Ala 370 375 380	1152
aaa gga cat cct gag cga gtg ttc tca gta acc cac att aag acg att Lys Gly His Pro Glu Arg Val Phe Ser Val Thr His Ile Lys Thr Ile 385 390 395 400	1200
cat cag gag gat gaa ttg att gag atc cag tgg gac aca ggg acc tgg His Gln Glu Asp Glu Leu Ile Glu Ile Gln Ser Asp Thr Gly Thr Trp 405 410 415	1248
tac cag cgc tgg ggg gtc cgg gcc ttg agc cta ggg ggg cag gtt tgg Tyr Gln Arg Trp Gly Val Arg Ala Leu Ser Leu Gly Gly Gln Val Trp 420 425 430	1296
ggg aat ttt ctc tcc tgt ttt ggt ccc gaa tat cgg cgc atc act ctg Gly Asn Phe Leu Ser Cys Phe Gly Pro Glu Tyr Arg Arg Ile Thr Leu 435 440 445	1344
atg atg atg ggt gtg tgg ttc acc atg tca ttc agc tac tat ggc ctg Met Met Met Gly Val Trp Phe Thr Met Ser Phe Ser Tyr Tyr Gly Leu 450 455 460	1392
acc gtc tgg ttt cct gag atg atc cgc cat ctc cag gca gtg gac tat Thr Val Trp Phe Pro Asp Met Ile Arg His Leu Gln Ala Val Asp Tyr 465 470 475 480	1440
gca tcc cgc acc aaa gtg ttc ccc ggg gag cgc gta ggg cat gta act Ala Ser Arg Thr Lys Val Phe Pro Gly Glu Arg Val Gly His Val Thr 485 490 495	1488
ttt aac ttc acg ttg gag aat cag atc cac cga ggc ggg cag tac ttc Phe Asn Phe Thr Leu Glu Asn Gln Ile His Arg Gly Gly Gln Tyr Phe 500 505 510	1536
aat gac aag ttc att ggg ctg cgg ctc aag tca gtg tcc ttt gag gat Asn Asp Lys Phe Ile Gly Leu Arg Leu Lys Ser Val Phe Glu Asp 515 520 525	1584
tcc ctg ttt gaa gag tgg tat ttt gag gat gtc aca tcc agc aac acg Ser Leu Phe Glu Glu Cys Tyr Phe Glu Asp Val Thr Ser Ser Asn Thr 530 535 540	1632

## US 7,985,554 B2

77

-continued

78

ttt ttc cgc aac tgc aca ttc atc aac act gtg ttc tat aac act gac Phe Phe Arg Asn Cys Thr Phe Ile Asn Thr Val Phe Tyr Asn Thr Asp 545 550 555 560	1680
ctg ttc gag tac aag ttt gtg aac agc cgt ctg ata aac agt aca ttc Leu Phe Glu Tyr Lys Phe Val Asn Ser Arg Leu Ile Asn Ser Thr Phe 565 570 575	1728
ctg cac aac aag gag ggc tgc ccc cta gac gtg aca ggg acg ggc gaa Leu His Asn Lys Glu Gly Cys Pro Leu Asp Val Thr Gly Thr Gly Glu 580 585 590	1776
ggt gcc tac atg gta tac ttt gtg agc ttc ctg ggg aca ctg gca gtg Gly Ala Tyr Met Val Tyr Phe Val Ser Phe Leu Gly Thr Leu Ala Val 595 600 605	1824
ctt cct ggg aat atc gtg tct gcc ctg ctc atg gac aag atc ggc agg Leu Pro Gly Asn Ile Val Ser Ala Leu Leu Met Asp Lys Ile Gly Arg 610 615 620	1872
ctc aga atg ctt gct ggc tcc agc gtg atg tcc tgt gtc tcc tgc ttc Leu Arg Met Leu Ala Gly Ser Ser Val Met Ser Cys Val Ser Cys Phe 625 630 635 640	1920
ttc ctg tct ttt ggg aac agt gag tcg gcc atg atc gct ctg ctc tgc Phe Leu Ser Phe Gly Asn Ser Glu Ser Ala Met Ile Ala Leu Leu Cys 645 650 655	1968
ctt ttt ggc ggg gtc agc att gca tcc tgg aat gcg ctg gac gtg ttg Leu Phe Gly Val Ser Ile Ala Ser Trp Asn Ala Leu Asp Val Leu 660 665 670	2016
act gtt gaa ctc tac ccc tca gac aag agg acc aca gct ttt ggc ttc Thr Val Glu Leu Tyr Pro Ser Asp Lys Arg Thr Thr Ala Phe Gly Phe 675 680 685	2064
ctg aat gcc ctg tgt aag ctg gca gct gtg ctg ggg atc agc atc ttc Leu Asn Ala Leu Cys Lys Leu Ala Ala Val Leu Gly Ile Ser Ile Phe 690 695 700	2112
aca tcc ttc gtg gga atc acc aag gct gca ccc atc ctc ttt gcc tca Thr Ser Phe Val Gly Ile Thr Lys Ala Ala Pro Ile Leu Phe Ala Ser 705 710 715 720	2160
gct gcc ctt gcc ctt ggc agc tct ctg gcc ctg aag ctg cct gag acc Ala Ala Leu Ala Leu Gly Ser Ser Leu Ala Leu Lys Leu Pro Glu Thr 725 730 735	2208
cgg ggg cag gtg ctg cag tga Arg Gly Gln Val Leu Gln 740	2229

&lt;210&gt; SEQ ID NO 14

&lt;211&gt; LENGTH: 742

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 14

Met Glu Glu Gly Phe Arg Asp Arg Ala Ala Phe Ile Arg Gly Ala Lys 1 5 10 15
Asp Ile Ala Lys Glu Val Lys Lys His Ala Ala Lys Lys Val Val Lys 20 25 30
Gly Leu Asp Arg Val Gln Asp Glu Tyr Ser Arg Arg Ser Tyr Ser Arg 35 40 45
Phe Glu Glu Asp Asp Asp Asp Phe Pro Ala Pro Ser Asp Gly 50 55 60
Tyr Tyr Arg Gly Glu Gly Thr Gln Asp Glu Glu Gly Gly Ala Ser 65 70 75 80
Ser Asp Ala Thr Glu Gly His Asp Glu Asp Asp Glu Ile Tyr Glu Gly 85 90 95
Glu Tyr Gln Asp Ile Pro Arg Ala Glu Ser Gly Gly Lys Gly Glu Arg

## US 7,985,554 B2

79

80

-continued

100	105	110	
Met Ala Asp Gly Ala Pro Leu Ala Gly Val Arg Gly	Gly Leu Ser Asp		
115	120	125	
Gly Glu Gly Pro Pro Gly Gly Arg Gly	Glu Ala Gln Arg Arg Lys	Glu	
130	135	140	
Arg Glu Glu Leu Ala Gln Gln Tyr	Glu Ala Ile Leu Arg	Glu Cys Gly	
145	150	155	160
His Gly Arg Phe Gln Trp Thr Leu Tyr	Phe Val Leu Gly	Leu Ala Leu	
165	170	175	
Met Ala Asp Gly Val Glu Val Phe	Val Val Gly Phe Val	Leu Pro Ser	
180	185	190	
Ala Glu Lys Asp Met Cys Leu Ser Asp	Ser Asn Lys Gly	Met Leu Gly	
195	200	205	
Leu Ile Val Tyr Leu Gly Met Met Val	Gly Ala Phe Leu Trp	Gly Gly	
210	215	220	
Leu Ala Asp Arg Leu Gly Arg Arg Gln	Cys Leu Leu Ile Ser	Leu Ser	
225	230	235	240
Val Asn Ser Val Phe Ala Phe Phe Ser	Ser Phe Val Gln	Gly Tyr Gly	
245	250	255	
Thr Phe Leu Phe Cys Arg Leu Leu Ser	Gly Val Gly Ile Gly	Gly Ser	
260	265	270	
Ile Pro Ile Val Phe Ser Tyr	Phe Ser Glu Phe	Leu Ala Gln Glu Lys	
275	280	285	
Arg Gly Glu His Leu Ser Trp Leu Cys	Met Phe Trp Met Ile	Gly Gly	
290	295	300	
Val Tyr Ala Ala Ala Met Ala Trp	Ala Ile Ile Pro His	Tyr Gly Trp	
305	310	315	320
Ser Phe Gln Met Gly Ser Ala Tyr	Gln Phe His Ser	Trp Arg Val Phe	
325	330	335	
Val Leu Val Cys Ala Phe Pro Ser	Val Phe Ala Ile Gly	Ala Leu Thr	
340	345	350	
Thr Gln Pro Glu Ser Pro Arg Phe	Phe Leu Glu Asn	Gly Lys His Asp	
355	360	365	
Glu Ala Trp Met Val Leu Lys Gln	Val His Asp Thr	Asn Met Arg Ala	
370	375	380	
Lys Gly His Pro Glu Arg Val	Phe Ser Val Thr	His Ile Lys Thr Ile	
385	390	395	400
His Gln Glu Asp Glu Leu Ile	Glu Ile Gln Ser Asp	Thr Gly Thr Trp	
405	410	415	
Tyr Gln Arg Trp Gly Val Arg Ala	Leu Ser Leu Gly	Gly Gln Val Trp	
420	425	430	
Gly Asn Phe Leu Ser Cys Phe	Gly Pro Glu Tyr Arg	Arg Ile Thr Leu	
435	440	445	
Met Met Met Gly Val Trp Phe	Thr Met Ser Phe	Tyr Tyr Gly Leu	
450	455	460	
Thr Val Trp Phe Pro Asp Met Ile	Arg His Leu Gln	Ala Val Asp Tyr	
465	470	475	480
Ala Ser Arg Thr Lys Val Phe Pro	Gly Glu Arg Val	Gly His Val Thr	
485	490	495	
Phe Asn Phe Thr Leu Glu Asn Gln	Ile His Arg Gly	Gly Gln Tyr Phe	
500	505	510	
Asn Asp Lys Phe Ile Gly Leu Arg	Leu Lys Ser Val	Ser Phe Glu Asp	
515	520	525	

-continued

---

Ser Leu Phe Glu Glu Cys Tyr Phe Glu Asp Val Thr Ser Ser Asn Thr  
530 535 540

Phe Phe Arg Asn Cys Thr Phe Ile Asn Thr Val Phe Tyr Asn Thr Asp  
545 550 555 560

Leu Phe Glu Tyr Lys Phe Val Asn Ser Arg Leu Ile Asn Ser Thr Phe  
565 570 575

Leu His Asn Lys Glu Gly Cys Pro Leu Asp Val Thr Gly Thr Gly Glu  
580 585 590

Gly Ala Tyr Met Val Tyr Phe Val Ser Phe Leu Gly Thr Leu Ala Val  
595 600 605

Leu Pro Gly Asn Ile Val Ser Ala Leu Leu Met Asp Lys Ile Gly Arg  
610 615 620

Leu Arg Met Leu Ala Gly Ser Ser Val Met Ser Cys Val Ser Cys Phe  
625 630 635 640

Phe Leu Ser Phe Gly Asn Ser Glu Ser Ala Met Ile Ala Leu Leu Cys  
645 650 655

Leu Phe Gly Gly Val Ser Ile Ala Ser Trp Asn Ala Leu Asp Val Leu  
660 665 670

Thr Val Glu Leu Tyr Pro Ser Asp Lys Arg Thr Thr Ala Phe Gly Phe  
675 680 685

Leu Asn Ala Leu Cys Lys Leu Ala Ala Val Leu Gly Ile Ser Ile Phe  
690 695 700

Thr Ser Phe Val Gly Ile Thr Lys Ala Ala Pro Ile Leu Phe Ala Ser  
705 710 715 720

Ala Ala Leu Ala Leu Gly Ser Ser Leu Ala Leu Lys Leu Pro Glu Thr  
725 730 735

Arg Gly Gln Val Leu Gln  
740

<210> SEQ ID NO 15  
<211> LENGTH: 2052  
<212> TYPE: DNA  
<213> ORGANISM: Homo sapiens  
<220> FEATURE:  
<221> NAME/KEY: CDS  
<222> LOCATION: (1)..(2052)

&lt;400&gt; SEQUENCE: 15

atg gat gac tac aag tat cag gac aat tat ggg ggc tat gct ccc agt	48
Met Asp Asp Tyr Lys Tyr Gln Asp Asn Tyr Gly Gly Tyr Ala Pro Ser	
1 5 10 15	
gat ggc tat tac cgc ggc aat gag tcc aac cca gaa gaa gat gca cag	96
Asp Gly Tyr Tyr Arg Gly Asn Glu Ser Asn Pro Glu Glu Asp Ala Gln	
20 25 30	
agt gat gtc acc gaa ggc cat gat gag gaa gac gag atc tat gag ggc	144
Ser Asp Val Thr Glu Gly His Asp Glu Glu Asp Glu Ile Tyr Glu GLY	
35 40 45	
gag tac cag ggt atc cct cac cca gat gat gtc aag gcc aag cag gcc	192
Glu Tyr Gln Gly Ile Pro His Pro Asp Asp Val Lys Ala Lys Gln Ala	
50 55 60	
aag atg gcg ccc tcc aga atg gac agc ctt cgg ggc cag aca gac ctg	240
Lys Met Ala Pro Ser Arg Met Asp Ser Leu Arg Gly Gln Thr Asp Leu	
65 70 75 80	
atg gct gag agg ctg gaa gat gag gag cag ttg gcc cat cag tac gag	288
Met Ala Glu Arg Leu Glu Asp Glu Glu Gln Leu Ala His Gln Tyr Glu	
85 90 95	
acc atc atg gat gag tgt ggc cat ggc cgc ttc cag tgg atc ctc ttt	336
Thr Ile Met Asp Glu Cys Gly His Gly Arg Phe Gln Trp Ile Leu Phe	
100 105 110	

-continued

ttc gtc ttg ggt ttg gcc ctg atg gcc gat ggg gtg gaa gtg ttc gtg Phe Val Leu Gly Leu Ala Leu Met Ala Asp Gly Val Glu Val Phe Val 115 120 125	384
gtg agt ttt gcc ccc agt gca gag aag gac atg tgt ctg tcc agt Val Ser Phe Ala Leu Pro Ser Ala Glu Lys Asp Met Cys Leu Ser Ser 130 135 140	432
tcc aaa aaa gga atg cta ggg atg ata gtc tac ttg gga atg atg gcg Ser Lys Lys Gly Met Leu Gly Met Ile Val Tyr Leu Gly Met Met Ala 145 150 155 160	480
ggc gcc ttc atc ctg gga ggc ctg gct gat aag ctg gga agg aag cga Gly Ala Phe Ile Leu Gly Leu Ala Asp Lys Leu Gly Arg Lys Arg 165 170 175	528
gtc ctc agc atg tct ctg gcc gtc aat gcc tcc ttc gcc tcc ctc tct Val Leu Ser Met Ser Leu Ala Val Asn Ala Ser Phe Ala Ser Leu Ser 180 185 190	576
tcc ttc gtg cag gga tat gga gcc ttc ctc ttc tgc cga ctc atc tca Ser Phe Val Gln Gly Tyr Gly Ala Phe Leu Phe Cys Arg Leu Ile Ser 195 200 205	624
ggc atc ggt att ggg ggt gct cta ccg att gtt ttt gcc tat ttt tct Gly Ile Gly Ile Gly Gly Ala Leu Pro Ile Val Phe Ala Tyr Phe Ser 210 215 220	672
gaa ttc ttg tct cgg gag aag cga gga gaa cac ctc agt tgg ctg ggc Glu Phe Leu Ser Arg Glu Lys Arg Gly Glu His Leu Ser Trp Leu Gly 225 230 235 240	720
atc ttc tgg atg act ggg ggc ctg tac gca tct gcc atg gcc tgg agc Ile Phe Trp Met Thr Gly Gly Leu Tyr Ala Ser Ala Met Ala Trp Ser 245 250 255	768
atc atc cca cac tat ggc ttg ggc ttc agc atg ggg acc aat tac cac Ile Ile Pro His Tyr Gly Trp Gly Phe Ser Met Gly Thr Asn Tyr His 260 265 270	816
ttc cat agc tgg aga gtg ttt gtc atc gtc tgt gct ctg ccc tgc acc Phe His Ser Trp Arg Val Phe Val Ile Val Cys Ala Leu Pro Cys Thr 275 280 285	864
gtg tcc atg gtg gcc ctg aag ttc atg cca gag agc cca agg ttt ctg Val Ser Met Val Ala Leu Lys Phe Met Pro Glu Ser Pro Arg Phe Leu 290 295 300	912
cta gag atg ggc aaa cat gat gaa gcc tgg atg att ctc aag caa gtc Leu Glu Met Gly Lys His Asp Glu Ala Trp Met Ile Leu Lys Gln Val 305 310 315 320	960
cat gac acc aac atg aga gct aag ggg acc cca gag aaa gtg ttc acg His Asp Thr Asn Met Arg Ala Lys Gly Thr Pro Glu Lys Val Phe Thr 325 330 335	1008
gtt tcc aac atc aaa act ccc aag caa atg gat gaa ttc att gag atc Val Ser Asn Ile Lys Thr Pro Lys Gln Met Asp Glu Phe Ile Glu Ile 340 345 350	1056
caa agt tca aca gga acc tgg tac cag cgc tgg ctg gtc aga ttc aag Gln Ser Ser Thr Gly Thr Trp Tyr Gln Arg Trp Leu Val Arg Phe Lys 355 360 365	1104
acc att ttc aag cag gtc tgg gat aat gcc ctg tac tgt gtg atg ggg Thr Ile Phe Lys Gln Val Trp Asp Asn Ala Leu Tyr Cys Val Met Gly 370 375 380	1152
ccc tac aga atg aat aca ctg att ctg gcc gtg gtt tgg ttt gcc atg Pro Tyr Arg Met Asn Thr Leu Ile Leu Ala Val Val Trp Phe Ala Met 385 390 395 400	1200
gca ttc agt tac tat gga ctg aca gtt tgg ttt cct gat atg atc cgc Ala Phe Ser Tyr Tyr Gly Leu Thr Val Trp Phe Pro Asp Met Ile Arg 405 410 415	1248
tat ttt caa gat gaa gaa tac aag tct aaa atg aag gtg ttt ttt ggt Tyr Phe Gln Asp Glu Glu Tyr Lys Ser Lys Met Lys Val Phe Phe Gly 420 425 430	1296

gag cat gtg tac ggc gcc aca atc aac ttc acg atg gaa aat cag atc Glu His Val Tyr Gly Ala Thr Ile Asn Phe Thr Met Glu Asn Gln Ile 435 440 445	1344
cac caa cat ggg aaa ctt gtg aat gat aag ttc aca aga atg tac ttt His Gln His Gly Lys Leu Val Asn Asp Lys Phe Thr Arg Met Tyr Phe 450 455 460	1392
aaa cat gta ctc ttt gag gac aca ttc ttt gac gag tgc tat ttt gaa Lys His Val Leu Phe Glu Asp Thr Phe Phe Asp Glu Cys Tyr Phe Glu 465 470 475 480	1440
gac gta aca tca aca gat acc tac ttc aaa aat tgt acc att gaa tca Asp Val Thr Ser Thr Asp Thr Tyr Phe Lys Asn Cys Thr Ile Glu Ser 485 490 495	1488
acc atc ttt tac aac aca gac ctc tac gag cac aag ttc atc aac tgt Thr Ile Phe Tyr Asn Thr Asp Leu Tyr Glu His Lys Phe Ile Asn Cys 500 505 510	1536
cgg ttt atc aac tcc acc ttc ctg gag cag aag gag ggc tgc cac atg Arg Phe Ile Asn Ser Thr Phe Leu Glu Gln Lys Glu Gly Cys His Met 515 520 525	1584
gac ttg gag caa gat aat gac ttc ctg att tac ctc gtc agc ttc ctg Asp Leu Glu Gln Asp Asn Asp Phe Leu Ile Tyr Leu Val Ser Phe Leu 530 535 540	1632
ggc agc ctg tct gtc tta ccc ggg aac atc att tct gcc ctg ctc atg Gly Ser Leu Ser Val Leu Pro Gly Asn Ile Ile Ser Ala Leu Leu Met 545 550 555 560	1680
gat aga att gga agg ctc aag atg att ggt ggc tcc atg cta atc tct Asp Arg Ile Gly Arg Leu Lys Met Ile Gly Gly Ser Met Leu Ile Ser 565 570 575	1728
gca gtc tgc tgc ttc ttc ctg ttt ttt ggc aac agt gag tct gca atg Ala Val Cys Cys Phe Phe Leu Phe Gly Asn Ser Glu Ser Ala Met 580 585 590	1776
atc ggc tgg cag tgc ctg ttc tgt ggg aca agc att gca gcc tgg aat Ile Gly Trp Gln Cys Leu Phe Cys Gly Thr Ser Ile Ala Ala Trp Asn 595 600 605	1824
gct ctg gat gtg atc aca gtg gag ctg tat ccc acc aac cag aga gca Ala Leu Asp Val Ile Thr Val Glu Leu Tyr Pro Thr Asn Gln Arg Ala 610 615 620	1872
aca gcc ttc ggc att ctc aat gga tta tgc aaa ttt ggc gcc atc ctg Thr Ala Phe Gly Ile Leu Asn Gly Leu Cys Lys Phe Gly Ala Ile Leu 625 630 635 640	1920
gga aac acc atc ttt gct tct ttt gtt ggg ata acc aaa gtg gtc ccc Gly Asn Thr Ile Phe Ala Ser Phe Val Gly Ile Thr Lys Val Val Pro 645 650 655	1968
atc ctt ctg gct gct gct tct ctg gtt ggg ggt ggc ctg att gcc ctt Ile Leu Leu Ala Ala Ser Leu Val Gly Gly Leu Ile Ala Leu 660 665 670	2016
cga ctg cca gag act cga gaa cag gtc ctg atg tga Arg Leu Pro Glu Thr Arg Glu Gln Val Leu Met 675 680	2052

<210> SEQ ID NO 16  
<211> LENGTH: 683  
<212> TYPE: PRT  
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 16

Met Asp Asp Tyr Lys Tyr Gln Asp Asn Tyr Gly Gly Tyr Ala Pro Ser 1 5 10 15
Asp Gly Tyr Tyr Arg Gly Asn Glu Ser Asn Pro Glu Glu Asp Ala Gln 20 25 30
Ser Asp Val Thr Glu Gly His Asp Glu Glu Asp Glu Ile Tyr Glu Gly

## US 7,985,554 B2

**87****88**

-continued

35

40

45

Glu Tyr Gln Gly Ile Pro His Pro Asp Asp Val Lys Ala Lys Gln Ala  
 50 55 60

Lys Met Ala Pro Ser Arg Met Asp Ser Leu Arg Gly Gln Thr Asp Leu  
 65 70 75 80

Met Ala Glu Arg Leu Glu Asp Glu Glu Gln Leu Ala His Gln Tyr Glu  
 85 90 95

Thr Ile Met Asp Glu Cys Gly His Gly Arg Phe Gln Trp Ile Leu Phe  
 100 105 110

Phe Val Leu Gly Leu Ala Leu Met Ala Asp Gly Val Glu Val Phe Val  
 115 120 125

Val Ser Phe Ala Leu Pro Ser Ala Glu Lys Asp Met Cys Leu Ser Ser  
 130 135 140

Ser Lys Lys Gly Met Leu Gly Met Ile Val Tyr Leu Gly Met Met Ala  
 145 150 155 160

Gly Ala Phe Ile Leu Gly Gly Leu Ala Asp Lys Leu Gly Arg Lys Arg  
 165 170 175

Val Leu Ser Met Ser Leu Ala Val Asn Ala Ser Phe Ala Ser Leu Ser  
 180 185 190

Ser Phe Val Gln Gly Tyr Gly Ala Phe Leu Phe Cys Arg Leu Ile Ser  
 195 200 205

Gly Ile Gly Ile Gly Gly Ala Leu Pro Ile Val Phe Ala Tyr Phe Ser  
 210 215 220

Glu Phe Leu Ser Arg Glu Lys Arg Gly Glu His Leu Ser Trp Leu Gly  
 225 230 235 240

Ile Phe Trp Met Thr Gly Gly Leu Tyr Ala Ser Ala Met Ala Trp Ser  
 245 250 255

Ile Ile Pro His Tyr Gly Trp Gly Phe Ser Met Gly Thr Asn Tyr His  
 260 265 270

Phe His Ser Trp Arg Val Phe Val Ile Val Cys Ala Leu Pro Cys Thr  
 275 280 285

Val Ser Met Val Ala Leu Lys Phe Met Pro Glu Ser Pro Arg Phe Leu  
 290 295 300

Leu Glu Met Gly Lys His Asp Glu Ala Trp Met Ile Leu Lys Gln Val  
 305 310 315 320

His Asp Thr Asn Met Arg Ala Lys Gly Thr Pro Glu Lys Val Phe Thr  
 325 330 335

Val Ser Asn Ile Lys Thr Pro Lys Gln Met Asp Glu Phe Ile Glu Ile  
 340 345 350

Gln Ser Ser Thr Gly Thr Trp Tyr Gln Arg Trp Leu Val Arg Phe Lys  
 355 360 365

Thr Ile Phe Lys Gln Val Trp Asp Asn Ala Leu Tyr Cys Val Met Gly  
 370 375 380

Pro Tyr Arg Met Asn Thr Leu Ile Leu Ala Val Val Trp Phe Ala Met  
 385 390 395 400

Ala Phe Ser Tyr Tyr Gly Leu Thr Val Trp Phe Pro Asp Met Ile Arg  
 405 410 415

Tyr Phe Gln Asp Glu Glu Tyr Lys Ser Lys Met Lys Val Phe Phe Gly  
 420 425 430

Glu His Val Tyr Gly Ala Thr Ile Asn Phe Thr Met Glu Asn Gln Ile  
 435 440 445

His Gln His Gly Lys Leu Val Asn Asp Lys Phe Thr Arg Met Tyr Phe  
 450 455 460

## US 7,985,554 B2

89

90

-continued

Lys His Val Leu Phe Glu Asp Thr Phe Phe Asp Glu Cys Tyr Phe Glu  
 465 470 475 480

Asp Val Thr Ser Thr Asp Thr Tyr Phe Lys Asn Cys Thr Ile Glu Ser  
 485 490 495

Thr Ile Phe Tyr Asn Thr Asp Leu Tyr Glu His Lys Phe Ile Asn Cys  
 500 505 510

Arg Phe Ile Asn Ser Thr Phe Leu Glu Gln Lys Glu Gly Cys His Met  
 515 520 525

Asp Leu Glu Gln Asp Asn Asp Phe Leu Ile Tyr Leu Val Ser Phe Leu  
 530 535 540

Gly Ser Leu Ser Val Leu Pro Gly Asn Ile Ile Ser Ala Leu Leu Met  
 545 550 555 560

Asp Arg Ile Gly Arg Leu Lys Met Ile Gly Gly Ser Met Leu Ile Ser  
 565 570 575

Ala Val Cys Cys Phe Phe Leu Phe Phe Gly Asn Ser Glu Ser Ala Met  
 580 585 590

Ile Gly Trp Gln Cys Leu Phe Cys Gly Thr Ser Ile Ala Ala Trp Asn  
 595 600 605

Ala Leu Asp Val Ile Thr Val Glu Leu Tyr Pro Thr Asn Gln Arg Ala  
 610 615 620

Thr Ala Phe Gly Ile Leu Asn Gly Leu Cys Lys Phe Gly Ala Ile Leu  
 625 630 635 640

Gly Asn Thr Ile Phe Ala Ser Phe Val Gly Ile Thr Lys Val Val Pro  
 645 650 655

Ile Leu Leu Ala Ala Ala Ser Leu Val Gly Gly Leu Ile Ala Leu  
 660 665 670

Arg Leu Pro Glu Thr Arg Glu Gln Val Leu Met  
 675 680

<210> SEQ ID NO 17  
 <211> LENGTH: 2184  
 <212> TYPE: DNA  
 <213> ORGANISM: Homo sapiens  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(2184)

&lt;400&gt; SEQUENCE: 17

atg gaa gac tct tac aag gat agg act tca ctg atg aag ggt gcc aag	48
Met Glu Asp Ser Tyr Lys Asp Arg Thr Ser Leu Met Lys Gly Ala Lys	
1 5 10 15	
gac att gcc aga gag gtg aag aaa caa aca gta aag aag gtg aat caa	96
Asp Ile Ala Arg Glu Val Lys Lys Gln Thr Val Lys Lys Val Asn Gln	
20 25 30	
gct gtg gac cga gcc cag gat gaa tac acc cag agg tcc tac agt cgg	144
Ala Val Asp Arg Ala Gln Asp Glu Tyr Thr Gln Arg Ser Tyr Ser Arg	
35 40 45	
ttc caa gat gaa gaa gat gat gac tac tac ccg gct gga gaa acc	192
Phe Gln Asp Glu Glu Asp Asp Asp Tyr Tyr Pro Ala Gly Glu Thr	
50 55 60	
tat aat ggt gag gcc aac gat gac gaa ggc tca agt gaa gcc act gag	240
Tyr Asn Gly Glu Ala Asn Asp Asp Glu Gly Ser Ser Glu Ala Thr Glu	
65 70 75 80	
ggg cat gat gaa gat gat gag atc tat gag ggg gag tat cag ggc atc	288
Gly His Asp Glu Asp Asp Glu Ile Tyr Glu Gly Glu Tyr Gln Gly Ile	
85 90 95	
ccc agt atg aac caa gcg aag gac agc atc gtg tca gtg ggg cag ccc	336
Pro Ser Met Asn Gln Ala Lys Asp Ser Ile Val Ser Val Gly Gln Pro	
100 105 110	

-continued

---

aag ggc gat gag tac aag gac cga cgg gag ctg gaa tca gaa agg aga Lys Gly Asp Glu Tyr Lys Asp Arg Arg Glu Leu Glu Ser Glu Arg Arg 115 120 125	384
gct gac gag gaa gag tta gcc cag cag tat gag ctg ata atc caa gaa Ala Asp Glu Glu Leu Ala Gln Gln Tyr Glu Leu Ile Ile Gln Glu 130 135 140	432
tgc ggt cat ggt cgt ttt cag tgg gcc ctt ttc gtc ctg ggc atg Cys Gly His Gly Arg Phe Gln Trp Ala Leu Phe Phe Val Leu Gly Met 145 150 155 160	480
gct ctt atg gca gac ggt gta gag gtg ttt gtc gtt ggc ttc gtg tta Ala Leu Met Ala Asp Gly Val Glu Val Phe Val Val Gly Phe Val Leu 165 170 175	528
ccc agt gct gag aca gac ctc tgc atc cca aat tca gga tct gga tgg Pro Ser Ala Glu Thr Asp Leu Cys Ile Pro Asn Ser Gly Ser Gly Trp 180 185 190	576
cta ggc agc ata gtg tac ctc ggg atg atg gtg ggg gcg ttc ttc tgg Leu Gly Ser Ile Val Tyr Leu Gly Met Met Val Gly Ala Phe Phe Trp 195 200 205	624
gga gga ctg gca gac aaa gtg gga agg aaa cag tct ctt ctg att tgc Gly Gly Leu Ala Asp Lys Val Gly Arg Lys Gln Ser Leu Leu Ile Cys 210 215 220	672
atg tct gtc aac gga ttc ttt gcc ttc ctt tct tca ttt gtc caa ggt Met Ser Val Asn Gly Phe Phe Ala Phe Leu Ser Ser Phe Val Gln Gly 225 230 235 240	720
tat ggc ttc ttt ctc ttc tgt cgc tta ctt tct gga ttc ggg att gga Tyr Gly Phe Leu Phe Cys Arg Leu Leu Ser Gly Phe Gly Ile Gly 245 250 255	768
gga gcc ata ccc act gtg ttc tcg tac ttt gct gaa gtc ctg gcc cgg Gly Ala Ile Pro Thr Val Phe Ser Tyr Phe Ala Glu Val Leu Ala Arg 260 265 270	816
gaa aag cgg ggc gaa cac ttg agc tgg ctc tgc atg ttc tgg atg atc Glu Lys Arg Gly Glu His Leu Ser Trp Leu Cys Met Phe Trp Met Ile 275 280 285	864
ggc ggc atc tac gcc tct gcc atg gcc tgg gcc atc atc ccg cac tac Gly Gly Ile Tyr Ala Ser Ala Met Ala Trp Ala Ile Ile Pro His Tyr 290 295 300	912
ggg tgg agc ttc agc atg gga tcg gcc tac cag ttt cac agt tgg cgt Gly Trp Ser Phe Ser Met Gly Ser Ala Tyr Gln Phe His Ser Trp Arg 305 310 315 320	960
gtg ttt gtc atc gtc tgt gca ctc ccc tgt gtc tcc tcc gtg gtg gcc Val Phe Val Ile Val Cys Ala Leu Pro Cys Val Ser Ser Val Val Ala 325 330 335	1008
ctc aca ttc atg cct gaa agc cca cga ttc ttg ttg gag gtt gga aaa Leu Thr Phe Met Pro Glu Ser Pro Arg Phe Leu Leu Glu Val Gly Lys 340 345 350	1056
cat gat gaa gct tgg atg att ctg aag tta att cat gac acc aac atg His Asp Glu Ala Trp Met Ile Leu Lys Leu Ile His Asp Thr Asn Met 355 360 365	1104
aga gcc cgg ggt cag cct gag aag gtc ttc acg gta aac aaa ata aaa Arg Ala Arg Gly Gln Pro Glu Lys Val Phe Thr Val Asn Lys Ile Lys 370 375 380	1152
act cct aaa caa ata gat gag ctg att gaa att gag agt gac aca gga Thr Pro Lys Gln Ile Asp Glu Leu Ile Glu Ile Glu Ser Asp Thr Gly 385 390 395 400	1200
aca tgg tat agg agg tgt ttt gtt cgg atc cgc acc gag ctg tac gga Thr Trp Tyr Arg Arg Cys Phe Val Arg Ile Arg Thr Glu Leu Tyr Gly 405 410 415	1248
att tgg ttg act ttt atg aga tgt ttc aac tac cca gtc agg gat aat Ile Trp Leu Thr Phe Met Arg Cys Phe Asn Tyr Pro Val Arg Asp Asn 420 425 430	1296

-continued

aca ata aag ctt aca att gtt tgg ttc acc ctg tcc ttt ggg tac tat Thr Ile Lys Leu Thr Ile Val Trp Phe Thr Leu Ser Phe Gly Tyr Tyr 435 440 445	1344
gga tta tcc gtt tgg ttc cct gat gtc att aaa cct ctg cag tcc gat Gly Leu Ser Val Trp Phe Pro Asp Val Ile Lys Pro Leu Gln Ser Asp 450 455 460	1392
gaa tat gca ttg cta acc aga aat gtg gag aga gat aaa tat gca aat Glu Tyr Ala Leu Leu Thr Arg Asn Val Glu Arg Asp Lys Tyr Ala Asn 465 470 475 480	1440
ttc act att aac ttt aca atg gaa aat cag att cat act gga atg gaa Phe Thr Ile Asn Phe Thr Met Glu Asn Gln Ile His Thr Gly Met Glu 485 490 495	1488
tac gac aat ggc aga ttc ata ggg gtc aag ttc aaa tct gta act ttc Tyr Asp Asn Gly Arg Phe Ile Gly Val Lys Phe Lys Ser Val Thr Phe 500 505 510	1536
aaa gac tct gtt ttt aag tcc tgc acc ttt gag gat gta act tca gtg Lys Asp Ser Val Phe Lys Ser Cys Thr Phe Glu Asp Val Thr Ser Val 515 520 525	1584
aac acc tac ttc aag aac tgc aca ttt att gac act gtt ttt gac aac Asn Thr Tyr Phe Lys Asn Cys Thr Phe Ile Asp Thr Val Phe Asp Asn 530 535 540	1632
aca gat ttt gag cca tat aaa ttc att gac agt gaa ttt aaa aac tgc Thr Asp Phe Glu Pro Tyr Lys Phe Ile Asp Ser Glu Phe Lys Asn Cys 545 550 555 560	1680
tcg ttt ttt cac aac aag acg gga tgt cag att acc ttt gat gat gac Ser Phe Phe His Asn Lys Thr Gly Cys Gln Ile Thr Phe Asp Asp Asp 565 570 575	1728
tat agt gcc tac tgg att tat ttt gtc aac ttt ctg ggg aca ttg gca Tyr Ser Ala Tyr Trp Ile Tyr Phe Val Asn Phe Leu Gly Thr Leu Ala 580 585 590	1776
gta ttg cca ggg aac att gtg tct gct ctg ctg atg gac aga att ggg Val Leu Pro Gly Asn Ile Val Ser Ala Leu Leu Met Asp Arg Ile Gly 595 600 605	1824
cgc tta aca atg cta ggt ggc tct atg gtg ott tgg ggg atc agc tgt Arg Leu Thr Met Leu Gly Ser Met Val Leu Ser Gly Ile Ser Cys 610 615 620	1872
ttc ttc ctt tgg ttc ggc acc agt gaa tcc atg atg ata ggc atg ctg Phe Phe Leu Trp Phe Gly Thr Ser Glu Ser Met Met Ile Gly Met Leu 625 630 635 640	1920
tgt ctg tac aat gga ttg acc atc tca gcc tgg aac tct ctt gac gtg Cys Leu Tyr Asn Gly Leu Thr Ile Ser Ala Trp Asn Ser Leu Asp Val 645 650 655	1968
gtc act gtg gaa ctg tac ccc aca gac cgg agg gca aca ggc ttt ggc Val Thr Val Glu Leu Tyr Pro Thr Asp Arg Arg Ala Thr Gly Phe Gly 660 665 670	2016
ttc tta aat gcg cta tgc aag gca gca gcc gtc ctg gga aac tta ata Phe Leu Asn Ala Leu Cys Lys Ala Ala Val Leu Gly Asn Leu Ile 675 680 685	2064
ttt ggc tct ctg gtc agc atc acc aaa tca atc ccc atc ctg ctg gct Phe Gly Ser Leu Val Ser Ile Thr Lys Ser Ile Pro Ile Leu Leu Ala 690 695 700	2112
tct act gtg ctc gtg tgt gga gga ctc gtt ggg ctg tgc ctg cct gac Ser Thr Val Leu Val Cys Gly Gly Leu Val Gly Leu Cys Leu Pro Asp 705 710 715 720	2160
aca cga acc cag gtt ctg atg taa Thr Arg Thr Gln Val Leu Met 725	2184

-continued

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 18

Met Glu Asp Ser Tyr Lys Asp Arg Thr Ser Leu Met Lys Gly Ala Lys  
 1 5 10 15

Asp Ile Ala Arg Glu Val Lys Lys Gln Thr Val Lys Lys Val Asn Gln  
 20 25 30

Ala Val Asp Arg Ala Gln Asp Glu Tyr Thr Gln Arg Ser Tyr Ser Arg  
 35 40 45

Phe Gln Asp Glu Glu Asp Asp Asp Tyr Tyr Pro Ala Gly Glu Thr  
 50 55 60

Tyr Asn Gly Glu Ala Asn Asp Asp Glu Gly Ser Ser Glu Ala Thr Glu  
 65 70 75 80

Gly His Asp Glu Asp Asp Glu Ile Tyr Glu Gly Glu Tyr Gln Gly Ile  
 85 90 95

Pro Ser Met Asn Gln Ala Lys Asp Ser Ile Val Ser Val Gly Gln Pro  
 100 105 110

Lys Gly Asp Glu Tyr Lys Asp Arg Arg Glu Leu Glu Ser Glu Arg Arg  
 115 120 125

Ala Asp Glu Glu Leu Ala Gln Gln Tyr Glu Leu Ile Ile Gln Glu  
 130 135 140

Cys Gly His Gly Arg Phe Gln Trp Ala Leu Phe Phe Val Leu Gly Met  
 145 150 155 160

Ala Leu Met Ala Asp Gly Val Glu Val Phe Val Val Gly Phe Val Leu  
 165 170 175

Pro Ser Ala Glu Thr Asp Leu Cys Ile Pro Asn Ser Gly Ser Gly Trp  
 180 185 190

Leu Gly Ser Ile Val Tyr Leu Gly Met Met Val Gly Ala Phe Phe Trp  
 195 200 205

Gly Gly Leu Ala Asp Lys Val Gly Arg Lys Gln Ser Leu Leu Ile Cys  
 210 215 220

Met Ser Val Asn Gly Phe Phe Ala Phe Leu Ser Ser Phe Val Gln Gly  
 225 230 235 240

Tyr Gly Phe Phe Leu Phe Cys Arg Leu Leu Ser Gly Phe Gly Ile Gly  
 245 250 255

Gly Ala Ile Pro Thr Val Phe Ser Tyr Phe Ala Glu Val Leu Ala Arg  
 260 265 270

Glu Lys Arg Gly Glu His Leu Ser Trp Leu Cys Met Phe Trp Met Ile  
 275 280 285

Gly Gly Ile Tyr Ala Ser Ala Met Ala Trp Ala Ile Ile Pro His Tyr  
 290 295 300

Gly Trp Ser Phe Ser Met Gly Ser Ala Tyr Gln Phe His Ser Trp Arg  
 305 310 315 320

Val Phe Val Ile Val Cys Ala Leu Pro Cys Val Ser Ser Val Val Ala  
 325 330 335

Leu Thr Phe Met Pro Glu Ser Pro Arg Phe Leu Leu Glu Val Gly Lys  
 340 345 350

His Asp Glu Ala Trp Met Ile Leu Lys Leu Ile His Asp Thr Asn Met  
 355 360 365

Arg Ala Arg Gly Gln Pro Glu Lys Val Phe Thr Val Asn Lys Ile Lys  
 370 375 380

Thr Pro Lys Gln Ile Asp Glu Leu Ile Glu Ile Glu Ser Asp Thr Gly  
 385 390 395 400

## US 7,985,554 B2

97

98

-continued

Thr Trp Tyr Arg Arg Cys Phe Val Arg Ile Arg Thr Glu Leu Tyr Gly  
                   405                  410                  415  
  
 Ile Trp Leu Thr Phe Met Arg Cys Phe Asn Tyr Pro Val Arg Asp Asn  
                   420                  425                  430  
  
 Thr Ile Lys Leu Thr Ile Val Trp Phe Thr Leu Ser Phe Gly Tyr Tyr  
                   435                  440                  445  
  
 Gly Leu Ser Val Trp Phe Pro Asp Val Ile Lys Pro Leu Gln Ser Asp  
                   450                  455                  460  
  
 Glu Tyr Ala Leu Leu Thr Arg Asn Val Glu Arg Asp Lys Tyr Ala Asn  
                   465                  470                  475                  480  
  
 Phe Thr Ile Asn Phe Thr Met Glu Asn Gln Ile His Thr Gly Met Glu  
                   485                  490                  495  
  
 Tyr Asp Asn Gly Arg Phe Ile Gly Val Lys Phe Lys Ser Val Thr Phe  
                   500                  505                  510  
  
 Lys Asp Ser Val Phe Lys Ser Cys Thr Phe Glu Asp Val Thr Ser Val  
                   515                  520                  525  
  
 Asn Thr Tyr Phe Lys Asn Cys Thr Phe Ile Asp Thr Val Phe Asp Asn  
                   530                  535                  540  
  
 Thr Asp Phe Glu Pro Tyr Lys Phe Ile Asp Ser Glu Phe Lys Asn Cys  
                   545                  550                  555                  560  
  
 Ser Phe Phe His Asn Lys Thr Gly Cys Gln Ile Thr Phe Asp Asp Asp  
                   565                  570                  575  
  
 Tyr Ser Ala Tyr Trp Ile Tyr Phe Val Asn Phe Leu Gly Thr Leu Ala  
                   580                  585                  590  
  
 Val Leu Pro Gly Asn Ile Val Ser Ala Leu Leu Met Asp Arg Ile Gly  
                   595                  600                  605  
  
 Arg Leu Thr Met Leu Gly Gly Ser Met Val Leu Ser Gly Ile Ser Cys  
                   610                  615                  620  
  
 Phe Phe Leu Trp Phe Gly Thr Ser Glu Ser Met Met Ile Gly Met Leu  
                   625                  630                  635                  640  
  
 Cys Leu Tyr Asn Gly Leu Thr Ile Ser Ala Trp Asn Ser Leu Asp Val  
                   645                  650                  655  
  
 Val Thr Val Glu Leu Tyr Pro Thr Asp Arg Arg Ala Thr Gly Phe Gly  
                   660                  665                  670  
  
 Phe Leu Asn Ala Leu Cys Lys Ala Ala Ala Val Leu Gly Asn Leu Ile  
                   675                  680                  685  
  
 Phe Gly Ser Leu Val Ser Ile Thr Lys Ser Ile Pro Ile Leu Leu Ala  
                   690                  695                  700  
  
 Ser Thr Val Leu Val Cys Gly Gly Leu Val Gly Leu Cys Leu Pro Asp  
                   705                  710                  715                  720  
  
 Thr Arg Thr Gln Val Leu Met  
                   725

<210> SEQ ID NO 19  
 <211> LENGTH: 2229  
 <212> TYPE: DNA  
 <213> ORGANISM: Bos taurus  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(2229)

&lt;400&gt; SEQUENCE: 19

atg gaa gag ggc ttc aga gac cgg gca gct ttc atc cgt ggg gcc aaa  
 Met Glu Glu Gly Phe Arg Asp Arg Ala Ala Phe Ile Arg Gly Ala Lys  
 1                  5                  10                  15

48

gac att gcc aag gaa gtc aag aag cat gca acc aag aag gtg gtg aag  
 Asp Ile Ala Lys Glu Val Lys Lys His Ala Thr Lys Lys Val Val Lys

96

## US 7,985,554 B2

99

100

-continued

20	25	30	
ggc ctg gac aga gtc cag gat gaa tat tcc cgg aga tcc tac tcc cgc Gly Leu Asp Arg Val Gln Asp Glu Tyr Ser Arg Arg Ser Tyr Ser Arg	35	40	144
ttt gag gag gag gat gat gat gac ttc ccc gcc cct gct gat ggc Phe Glu Glu Glu Asp Asp Asp Asp Phe Pro Ala Pro Ala Asp Gly	50	55	192
tat tac cgc ggg gaa ggg gcc cag gat gag gag gaa ggc ggc gca tct Tyr Tyr Arg Gly Glu Gly Ala Gln Asp Glu Glu Gly Gly Ala Ser	65	70	240
agt gat gcc acc gag ggc cac gac gag gat gat gag atc tac gag ggg Ser Asp Ala Thr Glu Gly His Asp Glu Asp Asp Glu Ile Tyr Glu Gly	85	90	288
gaa tat cag ggc atc ccc cgg gca gag tct ggg ggc aaa ggc gag cgg Glu Tyr Gln Gly Ile Pro Arg Ala Glu Ser Gly Gly Lys Gly Glu Arg	100	105	336
atg gca gat ggg gca ccc ctg gct gga gtg agg ggg ggc ttg ggt gat Met Ala Asp Gly Ala Pro Leu Ala Gly Val Arg Gly Gly Leu Gly Asp	115	120	384
ggg gag ggt ccc ccc ggg ggg cgg gga gaa gcg cag cgg cgg aaa gaa Gly Glu Gly Pro Pro Gly Gly Arg Gly Glu Ala Gln Arg Arg Lys Glu	130	135	432
cgg gaa gaa cta gcc cag cag tat gaa gcc atc cta cgg gag tgc ggc Arg Glu Glu Leu Ala Gln Gln Tyr Glu Ala Ile Leu Arg Glu Cys Gly	145	150	480
cat ggc cgc ttc cag tgg aca ctc tat ttc gtg ctt ggt ctg gca ctg His Gly Arg Phe Gln Trp Thr Leu Tyr Phe Val Leu Gly Leu Ala Leu	165	170	528
atg gcc gat ggt gtt gag gtc ttc gtg gtg ggc ttc gtg ctg ccc agt Met Ala Asp Gly Val Val Phe Val Val Gly Phe Val Leu Pro Ser	180	185	576
gct gag aaa gac atg tgc ctg tct gac tcc aac aaa ggc atg ctg ggc Ala Glu Lys Asp Met Cys Leu Ser Asp Ser Asn Lys Gly Met Leu Gly	195	200	624
ctc att gtc tac ctg ggc atg atg gtg gga gcc ttc ctc tgg gga ggg Leu Ile Val Tyr Leu Gly Met Met Val Gly Ala Phe Leu Trp Gly Gly	210	215	672
ctg gct gat cgg ctg ggt cga aga cag tgt ctg ctc atc tca ctc tca Leu Ala Asp Arg Leu Gly Arg Arg Gln Cys Leu Ile Ser Leu Ser	225	230	720
gtc aac agt gtc ttc gcc ttt ttc tca tct ttc gtc cag ggt tat ggc Val Asn Ser Val Phe Ala Phe Phe Ser Ser Phe Val Gln Gly Tyr Gly	245	250	768
act ttc ctt ttc tgc cgt ctc ctt tct ggg gtt ggg atc gga ggg tcc Thr Phe Leu Phe Cys Arg Leu Leu Ser Gly Val Gly Ile Gly Gly Ser	260	265	816
atc ccc atc gtc ttc tcc tat ttc tcg gag ttt ctg gca cag gag aaa Ile Pro Ile Val Phe Ser Tyr Phe Ser Glu Phe Leu Ala Gln Glu Lys	275	280	864
cgt ggg gag cat ttg agc tgg ctc tgc atg ttt tgg atg att ggt gga Arg Gly Glu His Leu Ser Trp Leu Cys Met Phe Trp Met Ile Gly GLY	290	295	912
gtg tat gca gct gct atg gcc tgg gcc atc atc ccc cac tat ggg tgg Val Tyr Ala Ala Met Ala Trp Ala Ile Ile Pro His Tyr Gly Trp	305	310	960
agc ttt cag atg ggg tct gct tac cag ttc cac agc tgg agg gtc ttt Ser Phe Gln Met Gly Ser Ala Tyr Gln Phe His Ser Trp Arg Val Phe	325	330	1008
gtc ctc gtc tgc gct ttc cct tct gtg ttt gcc att ggg gct ctg acc Val Leu Val Cys Ala Phe Pro Ser Val Phe Ala Ile Gly Ala Leu Thr			1056

## US 7,985,554 B2

101

-continued

102

340	345	350	
aca cag cct gaa agc ccc cgt ttc ttc ctg gag aat ggg aag cat gat Thr Gln Pro Glu Ser Pro Arg Phe Phe Leu Glu Asn Gly Lys His Asp 355	360	365	1104
gag gcc tgg atg gta ctg aag cag gtc cat gag acc aac atg cgg gcc Glu Ala Trp Met Val Leu Lys Gln Val His Asp Thr Asn Met Arg Ala 370	375	380	1152
aag ggg cat cct gag cga gtc ttc tcg gta acc cac att aag aca att Lys Gly His Pro Glu Arg Val Phe Ser Val Thr His Ile Lys Thr Ile 385	390	395	400
cat cag gag gat gag ttg att gag atc cag tct gac aca ggg gcc tgg His Gln Glu Asp Glu Leu Ile Glu Ile Gln Ser Asp Thr Gly Ala Trp 405	410	415	1248
tac cag cgc tgg ggg gtc cgg gcc ttg agc ctg gga ggg cag gtc tgg Tyr Gln Arg Trp Gly Val Arg Ala Leu Ser Leu Gly Gly Gln Val Trp 420	425	430	1296
ggg aat ttc ctc tct tgt ttt ggt cca gaa tac cgc cgc atc act ctg Gly Asn Phe Leu Ser Cys Phe Gly Pro Glu Tyr Arg Arg Ile Thr Leu 435	440	445	1344
atg atg atg ggt gtg tgg ttc acc atg tca ttc agc tac tat ggc ctg Met Met Met Gly Val Trp Phe Thr Met Ser Phe Ser Tyr Tyr Gly Leu 450	455	460	1392
act gtc tgg ttt ccc gac atg atc cgc cat ctc caa gcg gtg gac tat Thr Val Trp Phe Pro Asp Met Ile Arg His Leu Gln Ala Val Asp Tyr 465	470	475	1440
gca gcc cgc acc aaa gtg ttc cct ggg gaa cgt gtg gag cac gtg act Ala Ala Arg Thr Lys Val Phe Pro Gly Glu Arg Val Glu His Val Thr 485	490	495	1488
ttt aac ttc acc ttg gag aat cag atc cac cga ggg gga cag tac ttc Phe Asn Phe Thr Leu Glu Asn Gln Ile His Arg Gly Gly Gln Tyr Phe 500	505	510	1536
aat gac aag ttc att ggg cta cgt ctg aag tca gta tcc ttt gag gac Asn Asp Lys Phe Ile Gly Leu Arg Leu Lys Ser Val Ser Phe Glu Asp 515	520	525	1584
tcc ctg ttt gag gag tgt tat ttc gag gat gtc aca tcc agc aac aca Ser Leu Phe Glu Glu Cys Tyr Phe Glu Asp Val Thr Ser Ser Asn Thr 530	535	540	1632
ttt ttc cgc aac tgc acg ttc atc aac acc gtg ttc tat aac act gac Phe Phe Arg Asn Cys Thr Phe Ile Asn Thr Val Phe Tyr Asn Thr Asp 545	550	555	1680
ctg ttt gag tac aag ttt gtg aac agc cgt ctg gtg aac agc aca ttc Leu Phe Glu Tyr Lys Phe Val Asn Ser Arg Leu Val Asn Ser Thr Phe 565	570	575	1728
ctg cac aac aag gag ggc tgc ccc ctg gac gtg acg ggg acg ggt gaa Leu His Asn Lys Glu Gly Cys Pro Leu Asp Val Thr Gly Thr Gly Glu 580	585	590	1776
ggc gcc tac atg gtg tat ttt gtc agc ttc ttg ggg acg ctg gct gtg Gly Ala Tyr Met Val Tyr Phe Val Ser Phe Leu Gly Thr Leu Ala Val 595	600	605	1824
ctt cct ggg aac att gtg tct gct ctg ctc atg gac aag att ggc agg Leu Pro Gly Asn Ile Val Ser Ala Leu Leu Met Asp Lys Ile Gly Arg 610	615	620	1872
ctc cga atg ctt gct ggc tcc agc gtg atg tcc tgt gtc tcc tgc ttc Leu Arg Met Leu Ala Gly Ser Ser Val Met Ser Cys Val Ser Cys Phe 625	630	635	1920
ttc ctg tct ttc ggg aac agt gag tcc gcc atg atc gct ctg ctc tgc Phe Leu Ser Phe Gly Asn Ser Glu Ser Ala Met Ile Ala Leu Leu Cys 645	650	655	1968
ctt ttc ggg ggg gtc agc atc gca tcc tgg aac gcg ctg gac gtg ttg Leu Phe Gly Val Ser Ile Ala Ser Trp Asn Ala Leu Asp Val Leu			2016

## US 7,985,554 B2

103

-continued

104

---

660	665	670	
act gtt gaa ctc tac ccc tcg gac aag aga acc aca gcc ttc ggc ttc			2064
Thr Val Glu Leu Tyr Pro Ser Asp Lys Arg Thr Thr Ala Phe Gly Phe			
675	680	685	
ctg aat gcc ctg tgt aag ctg gca gct gtg ctg ggg atc agc atc ttc			2112
Leu Asn Ala Leu Cys Lys Leu Ala Ala Val Leu Gly Ile Ser Ile Phe			
690	695	700	
acg tcc ttt gtg gga atc acc aag gct gcc ccc atc ctc ttt gcc tcc			2160
Thr Ser Phe Val Gly Ile Thr Lys Ala Ala Pro Ile Leu Phe Ala Ser			
705	710	715	720
gct gcc ctt gcc ctc ggg agt tct ctg gcc ctg aag ctg ccc gag acc			2208
Ala Ala Leu Ala Leu Gly Ser Ser Leu Ala Leu Lys Leu Pro Glu Thr			
725	730	735	
cgg ggg cag gtg ctg cag tga			2229
Arg Gly Gln Val Leu Gln			
740			
<210> SEQ ID NO 20			
<211> LENGTH: 742			
<212> TYPE: PRT			
<213> ORGANISM: Bos taurus			
<400> SEQUENCE: 20			
Met Glu Glu Gly Phe Arg Asp Arg Ala Ala Phe Ile Arg Gly Ala Lys			
1	5	10	15
Asp Ile Ala Lys Glu Val Lys Lys His Ala Thr Lys Lys Val Val Lys			
20	25	30	
Gly Leu Asp Arg Val Gln Asp Glu Tyr Ser Arg Arg Ser Tyr Ser Arg			
35	40	45	
Phe Glu Glu Asp Asp Asp Asp Phe Pro Ala Pro Ala Asp Gly			
50	55	60	
Tyr Tyr Arg Gly Glu Gly Ala Gln Asp Glu Glu Glu Gly Ala Ser			
65	70	75	80
Ser Asp Ala Thr Glu Gly His Asp Glu Asp Asp Glu Ile Tyr Glu Gly			
85	90	95	
Glu Tyr Gln Gly Ile Pro Arg Ala Glu Ser Gly Gly Lys Gly Glu Arg			
100	105	110	
Met Ala Asp Gly Ala Pro Leu Ala Gly Val Arg Gly Gly Leu Gly Asp			
115	120	125	
Gly Glu Gly Pro Pro Gly Gly Arg Gly Glu Ala Gln Arg Arg Lys Glu			
130	135	140	
Arg Glu Glu Leu Ala Gln Gln Tyr Glu Ala Ile Leu Arg Glu Cys Gly			
145	150	155	160
His Gly Arg Phe Gln Trp Thr Leu Tyr Phe Val Leu Gly Leu Ala Leu			
165	170	175	
Met Ala Asp Gly Val Glu Val Phe Val Val Gly Phe Val Leu Pro Ser			
180	185	190	
Ala Glu Lys Asp Met Cys Leu Ser Asp Ser Asn Lys Gly Met Leu Gly			
195	200	205	
Leu Ile Val Tyr Leu Gly Met Met Val Gly Ala Phe Leu Trp Gly Gly			
210	215	220	
Leu Ala Asp Arg Leu Gly Arg Arg Gln Cys Leu Leu Ile Ser Leu Ser			
225	230	235	240
Val Asn Ser Val Phe Ala Phe Phe Ser Ser Phe Val Glu Gln Gly Tyr Gly			
245	250	255	
Thr Phe Leu Phe Cys Arg Leu Leu Ser Gly Val Gly Ile Gly Gly Ser			
260	265	270	

## US 7,985,554 B2

**105****106**

-continued

Ile Pro Ile Val Phe Ser Tyr Phe Ser Glu Phe Leu Ala Gln Glu Lys  
275 280 285

Arg Gly Glu His Leu Ser Trp Leu Cys Met Phe Trp Met Ile Gly Gly  
290 295 300

Val Tyr Ala Ala Ala Met Ala Trp Ala Ile Ile Pro His Tyr Gly Trp  
305 310 315 320

Ser Phe Gln Met Gly Ser Ala Tyr Gln Phe His Ser Trp Arg Val Phe  
325 330 335

Val Leu Val Cys Ala Phe Pro Ser Val Phe Ala Ile Gly Ala Leu Thr  
340 345 350

Thr Gln Pro Glu Ser Pro Arg Phe Phe Leu Glu Asn Gly Lys His Asp  
355 360 365

Glu Ala Trp Met Val Leu Lys Gln Val His Asp Thr Asn Met Arg Ala  
370 375 380

Lys Gly His Pro Glu Arg Val Phe Ser Val Thr His Ile Lys Thr Ile  
385 390 395 400

His Gln Glu Asp Glu Leu Ile Glu Ile Gln Ser Asp Thr Gly Ala Trp  
405 410 415

Tyr Gln Arg Trp Gly Val Arg Ala Leu Ser Leu Gly Gly Gln Val Trp  
420 425 430

Gly Asn Phe Leu Ser Cys Phe Gly Pro Glu Tyr Arg Arg Ile Thr Leu  
435 440 445

Met Met Met Gly Val Trp Phe Thr Met Ser Phe Ser Tyr Tyr Gly Leu  
450 455 460

Thr Val Trp Phe Pro Asp Met Ile Arg His Leu Gln Ala Val Asp Tyr  
465 470 475 480

Ala Ala Arg Thr Lys Val Phe Pro Gly Glu Arg Val Glu His Val Thr  
485 490 495

Phe Asn Phe Thr Leu Glu Asn Gln Ile His Arg Gly Gly Gln Tyr Phe  
500 505 510

Asn Asp Lys Phe Ile Gly Leu Arg Leu Lys Ser Val Ser Phe Glu Asp  
515 520 525

Ser Leu Phe Glu Glu Cys Tyr Phe Glu Asp Val Thr Ser Ser Asn Thr  
530 535 540

Phe Phe Arg Asn Cys Thr Phe Ile Asn Thr Val Phe Tyr Asn Thr Asp  
545 550 555 560

Leu Phe Glu Tyr Lys Phe Val Asn Ser Arg Leu Val Asn Ser Thr Phe  
565 570 575

Leu His Asn Lys Glu Gly Cys Pro Leu Asp Val Thr Gly Glu  
580 585 590

Gly Ala Tyr Met Val Tyr Phe Val Ser Phe Leu Gly Thr Leu Ala Val  
595 600 605

Leu Pro Gly Asn Ile Val Ser Ala Leu Leu Met Asp Lys Ile Gly Arg  
610 615 620

Leu Arg Met Leu Ala Gly Ser Ser Val Met Ser Cys Val Ser Cys Phe  
625 630 635 640

Phe Leu Ser Phe Gly Asn Ser Glu Ser Ala Met Ile Ala Leu Leu Cys  
645 650 655

Leu Phe Gly Gly Val Ser Ile Ala Ser Trp Asn Ala Leu Asp Val Leu  
660 665 670

Thr Val Glu Leu Tyr Pro Ser Asp Lys Arg Thr Thr Ala Phe Gly Phe  
675 680 685

Leu Asn Ala Leu Cys Lys Leu Ala Ala Val Leu Gly Ile Ser Ile Phe

## US 7,985,554 B2

107

-continued

108

690	695	700
Thr Ser Phe Val Gly Ile Thr Lys Ala Ala Pro Ile Leu Phe Ala Ser		
705	710	715
720		
Ala Ala Leu Ala Leu Gly Ser Ser Leu Ala Leu Lys Leu Pro Glu Thr		
725	730	735
Arg Gly Gln Val Leu Gln		
740		

<210> SEQ ID NO 21  
<211> LENGTH: 2175  
<212> TYPE: DNA  
<213> ORGANISM: Discopyge ommata  
<220> FEATURE:  
<221> NAME/KEY: CDS  
<222> LOCATION: (1) .. (2175)

&lt;400&gt; SEQUENCE: 21

atg gat gac gct tac agg aac agg act acc ctg atg aag ggt gcc aaa	48		
Met Asp Asp Ala Tyr Arg Asn Arg Thr Thr Leu Met Lys Gly Ala Lys			
1	5	10	15
gac att gcc aaa gaa gtt aag aag caa aca ata aag aaa ggc act gtg	96		
Asp Ile Ala Lys Glu Val Lys Lys Gln Thr Ile Lys Lys Gly Thr Val			
20	25	30	
gga gca gag tac acg cag gac aga tac tca aag acc gct tat gcc aat	144		
Gly Ala Glu Tyr Thr Gln Asp Arg Tyr Ser Lys Thr Ala Tyr Ala Asn			
35	40	45	
ttt caa gat gat gac tgc tac aac tat agc aga ggg acc tat gga gaa	192		
Phe Gln Asp Asp Cys Tyr Asn Tyr Ser Arg Gly Thr Tyr Gly Glu			
50	55	60	
gaa caa caa gag gat gag ggt tca agt gat gcc act gaa gga cac gat	240		
Glu Gln Gln Glu Asp Glu Gly Ser Ser Asp Ala Thr Glu Gly His Asp			
65	70	75	80
gag gag gat gag att tac gaa ggg gag tat cag ggg atc cct gat atg	288		
Glu Glu Asp Glu Ile Tyr Glu Gly Glu Tyr Gln Gly Ile Pro Asp Met			
85	90	95	
agc caa aag aag gag agc cag gtt gcc att gga caa cta gtc tca gat	336		
Ser Gln Lys Lys Glu Ser Gln Val Ala Ile Gly Gln Leu Val Ser Asp			
100	105	110	
gag tac aag gag cgc gag gag ctg gat gct gag agg aga gct gat gaa	384		
Glu Tyr Lys Asp Arg Glu Glu Leu Asp Ala Glu Arg Arg Ala Asp Glu			
115	120	125	
gag gag ctg gcg cag cag tat gag ctg atc att cag gag tgc ggc cat	432		
Glu Glu Leu Ala Gln Gln Tyr Glu Leu Ile Ile Gln Glu Cys Gly His			
130	135	140	
ggg cgg ttc cag tgg gca ttg ttc ctt gtg cta gga ttg tcc ctc atg	480		
Gly Arg Phe Gln Trp Ala Leu Phe Leu Val Leu Gly Leu Ser Leu Met			
145	150	155	160
gct gat gga gtg gag gtg ttt gtg ggt ttt gtc ctg cca agt got	528		
Ala Asp Gly Val Glu Val Phe Val Val Gly Phe Val Leu Pro Ser Ala			
165	170	175	
gag acg gac atg tgt gtt gaa aat tcc aat tca gga tgg ctg ggc agc	576		
Glu Thr Asp Met Cys Val Glu Asn Ser Asn Ser Gly Trp Leu Gly Ser			
180	185	190	
ata gtc tac ctt ggg atg atg ctc ggg gcc ttt ttc tgg ggt ggt tta	624		
Ile Val Tyr Leu Gly Met Met Leu Gly Ala Phe Phe Trp Gly Gly Leu			
195	200	205	
gca gac aag atg ggc cgt cgg caa acc ctc att att tgt atg tcc atc	672		
Ala Asp Lys Met Gly Arg Arg Gln Thr Leu Ile Ile Cys Met Ser Ile			
210	215	220	
aac gga ttc ttc gcc ttt cta tca tct ttt gtc cag ggt tac agc ctc	720		
Asn Gly Phe Phe Ala Phe Leu Ser Ser Phe Val Gln Gly Tyr Ser Leu			

## US 7,985,554 B2

109

110

-continued

225	230	235	240	
ttc ctt ttc tgc cga ttc ttt gct gga ttt ggg att gga gga gca gtt Phe Leu Phe Cys Arg Phe Phe Ala Gly Phe Gly Ile Gly Gly Ala Val 245 250 255				768
cca gtt gtg ttt gcc tac ttt gcg gaa gtc ctg gcc cg <sup>g</sup> gag aag cg <sup>g</sup> Pro Val Val Phe Ala Tyr Phe Ala Glu Val Leu Ala Arg Glu Lys Arg 260 265 270				816
ggt gag cac ttg agc tgg ctc tgc atg ttc tgg atg atc gga ggg atc Gly Glu His Leu Ser Trp Leu Cys Met Phe Trp Met Ile Gly Gly Ile 275 280 285				864
tac gca tcg gcc atg gca tgg gcc atc att cct cac tat ggt tgg agt Tyr Ala Ser Ala Met Ala Trp Ala Ile Ile Pro His Tyr Gly Trp Ser 290 295 300				912
ttc agt atg ggt tct gcg tac cag ttc cac agc tgg cga gtg ttt gtc Phe Ser Met Gly Ser Ala Tyr Gln Phe His Ser Trp Arg Val Phe Val 305 310 315 320				960
gtt gtc tgt gca ctt ccc tgc atg tcc tca gtt gtg gca ctc acc ttc Val Val Cys Ala Leu Pro Cys Met Ser Ser Val Val Ala Leu Thr Phe 325 330 335				1008
atg cct gaa agt cct cga tat ctg ctg gag gta gga aaa cat gat gag Met Pro Glu Ser Pro Arg Tyr Leu Leu Glu Val Gly Lys His Asp Glu 340 345 350				1056
gcc tgg atg att ctg aag caa atc cat gac aca aac atg aga ggc cg <sup>g</sup> Ala Trp Met Ile Leu Lys Gln Ile His Asp Thr Asn Met Arg Ala Arg 355 360 365				1104
gga caa cct gag aaa gtg ttc acg gtc aat aga atc aag act ccc aag Gly Gln Pro Glu Lys Val Phe Thr Val Asn Arg Ile Lys Thr Pro Lys 370 375 380				1152
ttg att gat gaa ttg ata gag atc cag aca gac aca ggc acc tgg tat Leu Ile Asp Glu Leu Ile Glu Ile Gln Thr Asp Thr Gly Thr Trp Tyr 385 390 395 400				1200
atg agg tgg ttt gtt cga atc aaa act gaa atg tat gga att tgg ttg Met Arg Trp Phe Val Arg Ile Lys Thr Glu Met Tyr Gly Ile Trp Leu 405 410 415				1248
aca ttc atg aga tgt tta gac tat cct gtc aaa cga aac acc att ctt Thr Phe Met Arg Cys Leu Asp Tyr Pro Val Lys Arg Asn Thr Ile Leu 420 425 430				1296
ctg att ata gtt tgg aca acc tta tca ttt ggt tac tat ggt ctc tct Leu Ile Ile Val Trp Thr Thr Leu Ser Phe Gly Tyr Tyr Gly Leu Ser 435 440 445				1344
gtc tgg ttc cct gat gtt atc aaa cac ctt cag gct gat gag tat gca Val Trp Phe Pro Asp Val Ile Lys His Leu Gln Ala Asp Glu Tyr Ala 450 455 460				1392
tcc cgg gtg aaa agg ttt tat gga gaa aaa gtt gaa gat ttt gtg ttc Ser Arg Val Lys Arg Phe Tyr Gly Glu Lys Val Glu Asp Phe Val Phe 465 470 475 480				1440
aac ttt acg ctg gaa aac cag atc cac act aat gga gag tac atc aga Asn Phe Thr Leu Glu Asn Gln Ile His Thr Asn Gly Glu Tyr Ile Arg 485 490 495				1488
gac agg ttc acc atc atg aag ttt aaa gca gta aca ttc gag gat tcc Asp Arg Phe Thr Ile Met Lys Phe Lys Ala Val Thr Phe Glu Asp Ser 500 505 510				1536
ctc ttt aag aac tgt tat ttt gaa gat atc aca tcg ttg tct act tat Leu Phe Lys Asn Cys Tyr Phe Glu Asp Ile Thr Ser Leu Ser Thr Tyr 515 520 525				1584
ttt aag aac tgc aca ttt aca gaa acc ctt ttc tat aat aca gat ctc Phe Lys Asn Cys Thr Phe Thr Glu Thr Leu Phe Tyr Asn Thr Asp Leu 530 535 540				1632
gaa gag ttt aaa ttc att gat tgt caa ttt atc aat tcc aca ttt ctg Glu Glu Phe Lys Phe Ile Asp Cys Gln Phe Ile Asn Ser Thr Phe Leu				1680

## US 7,985,554 B2

111

112

-continued

545	550	555	560	
cac aat aag aaa ggc tgt cag att aac ttt gac gaa gac tac agt gcc His Asn Lys Lys Gly Cys Gln Ile Asn Phe Asp Glu Asp Tyr Ser Ala 565 570 575				1728
tac tgg att tat ttt gtc aac ttc cta gga aca ctg gca gtg ttg cca Tyr Trp Ile Tyr Phe Val Asn Phe Leu Gly Thr Leu Ala Val Leu Pro 580 585 590				1776
ggc aac att gta tct gca ttg ctc atg gac agg att gga cgc ctg aca Gly Asn Ile Val Ser Ala Leu Leu Met Asp Arg Ile Gly Arg Leu Thr 595 600 605				1824
atg tta ggt ggc tcc atg gtt ctg tct ggg atc agc tgc ttc ttg ctg Met Leu Gly Gly Ser Met Val Leu Ser Gly Ile Ser Cys Phe Phe Leu 610 615 620				1872
tgg ttt ggg aca agt gaa gcc atg atg att gga atg ttg tgc ctg tac Trp Phe Gly Thr Ser Glu Ala Met Met Ile Gly Met Leu Cys Leu Tyr 625 630 635 640				1920
aat gga ctg act att tca gcg tgg aac tcc ctt gac gtg atc act gtg Asn Gly Leu Thr Ile Ser Ala Trp Asn Ser Leu Asp Val Ile Thr Val 645 650 655				1968
gaa ctt ctg cca act gac aga aga gca act gga ttt gga ttt ttg aat Glu Leu Leu Pro Thr Asp Arg Arg Ala Thr Gly Phe Gly Phe Leu Asn 660 665 670				2016
gcc ctg tgc aaa gct gcg act gta ctt gga aat ctc att ttt ggt tct Ala Leu Cys Lys Ala Ala Thr Val Leu Gly Asn Leu Ile Phe Gly Ser 675 680 685				2064
ttg gtc ggt ata acc aaa tcg atc ccg att atg tta gca tcc act gtc Leu Val Gly Ile Thr Lys Ser Ile Pro Ile Met Leu Ala Ser Thr Val 690 695 700				2112
cta gtc tgc gga ggc ctc gtg gga ctc cga ctt cct gac aca agg aac Leu Val Cys Gly Gly Leu Val Gly Leu Arg Leu Pro Asp Thr Arg Asn 705 710 715 720				2160
cag gtg ctc atg tga Gln Val Leu Met				2175

&lt;210&gt; SEQ ID NO 22

&lt;211&gt; LENGTH: 724

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Discopyge ommata

&lt;400&gt; SEQUENCE: 22

Met Asp Asp Ala Tyr Arg Asn Arg Thr Thr Leu Met Lys Gly Ala Lys  
1 5 10 15

Asp Ile Ala Lys Glu Val Lys Lys Gln Thr Ile Lys Lys Gly Thr Val  
20 25 30

Gly Ala Glu Tyr Thr Gln Asp Arg Tyr Ser Lys Thr Ala Tyr Ala Asn  
35 40 45

Phe Gln Asp Asp Cys Tyr Asn Tyr Ser Arg Gly Thr Tyr Gly Glu  
50 55 60

Glu Gln Gln Glu Asp Glu Gly Ser Ser Asp Ala Thr Glu Gly His Asp  
65 70 75 80

Glu Glu Asp Glu Ile Tyr Glu Gly Glu Tyr Gln Gly Ile Pro Asp Met  
85 90 95

Ser Gln Lys Lys Glu Ser Gln Val Ala Ile Gly Gln Leu Val Ser Asp  
100 105 110

Glu Tyr Lys Asp Arg Glu Glu Leu Asp Ala Glu Arg Arg Ala Asp Glu  
115 120 125

Glu Glu Leu Ala Gln Gln Tyr Glu Leu Ile Ile Gln Glu Cys Gly His  
130 135 140

-continued

---

Gly Arg Phe Gln Trp Ala Leu Phe Leu Val Leu Gly Leu Ser Leu Met  
145 150 155 160

Ala Asp Gly Val Glu Val Phe Val Val Gly Phe Val Leu Pro Ser Ala  
165 170 175

Glu Thr Asp Met Cys Val Glu Asn Ser Asn Ser Gly Trp Leu Gly Ser  
180 185 190

Ile Val Tyr Leu Gly Met Met Leu Gly Ala Phe Phe Trp Gly Gly Leu  
195 200 205

Ala Asp Lys Met Gly Arg Arg Gln Thr Leu Ile Ile Cys Met Ser Ile  
210 215 220

Asn Gly Phe Phe Ala Phe Leu Ser Ser Phe Val Gln Gly Tyr Ser Leu  
225 230 235 240

Phe Leu Phe Cys Arg Phe Phe Ala Gly Phe Gly Ile Gly Ala Val  
245 250 255

Pro Val Val Phe Ala Tyr Phe Ala Glu Val Leu Ala Arg Glu Lys Arg  
260 265 270

Gly Glu His Leu Ser Trp Leu Cys Met Phe Trp Met Ile Gly Gly Ile  
275 280 285

Tyr Ala Ser Ala Met Ala Trp Ala Ile Ile Pro His Tyr Gly Trp Ser  
290 295 300

Phe Ser Met Gly Ser Ala Tyr Gln Phe His Ser Trp Arg Val Phe Val  
305 310 315 320

Val Val Cys Ala Leu Pro Cys Met Ser Ser Val Val Ala Leu Thr Phe  
325 330 335

Met Pro Glu Ser Pro Arg Tyr Leu Leu Glu Val Gly Lys His Asp Glu  
340 345 350

Ala Trp Met Ile Leu Lys Gln Ile His Asp Thr Asn Met Arg Ala Arg  
355 360 365

Gly Gln Pro Glu Lys Val Phe Thr Val Asn Arg Ile Lys Thr Pro Lys  
370 375 380

Leu Ile Asp Glu Leu Ile Glu Ile Gln Thr Asp Thr Gly Thr Trp Tyr  
385 390 395 400

Met Arg Trp Phe Val Arg Ile Lys Thr Glu Met Tyr Gly Ile Trp Leu  
405 410 415

Thr Phe Met Arg Cys Leu Asp Tyr Pro Val Lys Arg Asn Thr Ile Leu  
420 425 430

Leu Ile Ile Val Trp Thr Thr Leu Ser Phe Gly Tyr Tyr Gly Leu Ser  
435 440 445

Val Trp Phe Pro Asp Val Ile Lys His Leu Gln Ala Asp Glu Tyr Ala  
450 455 460

Ser Arg Val Lys Arg Phe Tyr Gly Glu Lys Val Glu Asp Phe Val Phe  
465 470 475 480

Asn Phe Thr Leu Glu Asn Gln Ile His Thr Asn Gly Glu Tyr Ile Arg  
485 490 495

Asp Arg Phe Thr Ile Met Lys Phe Lys Ala Val Thr Phe Glu Asp Ser  
500 505 510

Leu Phe Lys Asn Cys Tyr Phe Glu Asp Ile Thr Ser Leu Ser Thr Tyr  
515 520 525

Phe Lys Asn Cys Thr Phe Thr Glu Thr Leu Phe Tyr Asn Thr Asp Leu  
530 535 540

Glu Glu Phe Lys Phe Ile Asp Cys Gln Phe Ile Asn Ser Thr Phe Leu  
545 550 555 560

His Asn Lys Lys Gly Cys Gln Ile Asn Phe Asp Glu Asp Tyr Ser Ala  
565 570 575

-continued

Tyr Trp Ile Tyr Phe Val Asn Phe Leu Gly Thr Leu Ala Val Leu Pro  
580 585 590

Gly Asn Ile Val Ser Ala Leu Leu Met Asp Arg Ile Gly Arg Leu Thr  
595 600 605

Met Leu Gly Gly Ser Met Val Leu Ser Gly Ile Ser Cys Phe Phe Leu  
610 615 620

Trp Phe Gly Thr Ser Glu Ala Met Met Ile Gly Met Leu Cys Leu Tyr  
625 630 635 640

Asn Gly Leu Thr Ile Ser Ala Trp Asn Ser Leu Asp Val Ile Thr Val  
645 650 655

Glu Leu Leu Pro Thr Asp Arg Arg Ala Thr Gly Phe Gly Phe Leu Asn  
660 665 670

Ala Leu Cys Lys Ala Ala Thr Val Leu Gly Asn Leu Ile Phe Gly Ser  
675 680 685

Leu Val Gly Ile Thr Lys Ser Ile Pro Ile Met Leu Ala Ser Thr Val  
690 695 700

Leu Val Cys Gly Gly Leu Val Gly Leu Arg Leu Pro Asp Thr Arg Asn  
705 710 715 720

Gln Val Leu Met

<210> SEQ ID NO 23  
<211> LENGTH: 38  
<212> TYPE: PRT  
<213> ORGANISM: Rattus norvegicus  
<220> FEATURE:  
<221> NAME/KEY: MISC\_FEATURE  
<222> LOCATION: (13)..(14)  
<223> OTHER INFORMATION: X1 IS L OR V  
<220> FEATURE:  
<221> NAME/KEY: MISC\_FEATURE  
<222> LOCATION: (15)..(16)  
<223> OTHER INFORMATION: X IS E OR D  
<220> FEATURE:  
<221> NAME/KEY: MISC\_FEATURE  
<222> LOCATION: (30)..(31)  
<223> OTHER INFORMATION: X IS Q OR K  
  
<400> SEQUENCE: 23

Asn Thr Tyr Phe Lys Asn Cys Thr Phe Ile Asp Thr Xaa Phe Xaa Asn  
1 5 10 15

Thr Asp Phe Glu Pro Tyr Lys Phe Ile Asp Ser Glu Phe Xaa Asn Cys  
20 25 30

Ser Phe Leu His Asn Lys  
35

We claim:

1. An isolated polypeptide comprising an amino acid sequence selected from (i) amino acids 529-562 of rat SV2C (SEQ ID NO:6), (ii) amino acids 529-562 of human SV2C (SEQ ID NO:18), (iii) amino acids 486 to 519 of rat SV2B (SEQ ID NO:4), (iv) amino acids 486 to 519 of mouse SV2B (SEQ ID NO:10), (v) amino acids 486 to 519 of human SV2B (SEQ ID NO:16), (vi) amino acids 543 to 576 of rat SV2A (SEQ ID NO:2), (vii) amino acids 454-546 of rat SV2C (SEQ ID NO:6), (viii) amino acids 454-546 of human SV2C (SEQ ID NO:18), (ix) amino acids 411 to 503 of rat SV2B (SEQ ID NO:4), (x) amino acids 411 to 503 of human SV2B (SEQ ID NO:16), (xi) amino acids 468 to 560 of rat SV2A (SEQ ID NO:2), (xii) amino acids 468 to 560 of human SV2A (SEQ ID NO:14), and (xiii) an amino acid sequence that is at least 95% identical to (iii), (iv), (v), (ix), or (x) and is capable of binding

to botulinum neurotoxin A (BoNT/A), with the proviso that a polypeptide comprising a full length SV2 protein, a polypeptide consisting of an SV2 luminal domain, and a polypeptide comprising an SV2 luminal domain wherein the domain is flanked at one or both ends by a non-native flanking amino acid sequence are excluded.

2. The isolated polypeptide of claim 1, wherein the polypeptide is soluble in an aqueous solvent.

3. The isolated polypeptide of claim 1, wherein the polypeptide has no more than 128 amino acids.

4. An isolated polypeptide consisting of an amino acid sequence selected from (i) amino acids 529-562 of rat SV2C (SEQ ID NO:6), (ii) amino acids 529-562 of mouse SV2C (SEQ ID NO:12), (iii) amino acids 529-562 of human SV2C (SEQ ID NO:18), (iv) amino acids 486 to 519 of rat SV2B (SEQ ID NO:4), (v) amino acids 486 to 519 of mouse SV2B (SEQ ID NO:10), (vi) amino acids 486 to 519 of human SV2B (SEQ ID NO:16), (vii) amino acids 454-546 of rat SV2C (SEQ ID NO:6), (viii) amino acids 454-546 of human SV2C (SEQ ID NO:18), (ix) amino acids 411 to 503 of rat SV2B (SEQ ID NO:4), (x) amino acids 411 to 503 of human SV2B (SEQ ID NO:16), (xi) amino acids 468 to 560 of rat SV2A (SEQ ID NO:2), (xii) amino acids 468 to 560 of human SV2A (SEQ ID NO:14), and (xiii) an amino acid sequence that is at least 95% identical to (iii), (iv), (v), (ix), or (x) and is capable of binding

**117**

(SEQ ID NO:10), (vi) amino acids 486 to 519 of human SV2B (SEQ ID NO:16), (vii) amino acids 543 to 576 of rat SV2A (SEQ ID NO:2), (viii) amino acids 543 to 576 of human SV2A (SEQ ID NO:14), (ix) amino acids 529-566 of rat SV2C (SEQ ID NO:6), (x) amino acids 529-566 of mouse SV2C (SEQ ID NO:12), (xi) amino acids 529-566 of human SV2C (SEQ ID NO:18), (xii) amino acids 486 to 523 of rat SV2B (SEQ ID NO:4), (xiii) amino acids 486 to 523 of mouse SV2B (SEQ ID NO:10), (xiv) amino acids 486 to 523 of human SV2B (SEQ ID NO:16), (xv) amino acids 543 to 580 of rat SV2A (SEQ ID NO:2), (xvi) amino acids 543 to 580 of human SV2A (SEQ ID NO:14), (xvii) amino acids 454-546 of rat SV2C (SEQ ID NO:6), (xviii) amino acids 454-546 of mouse SV2C (SEQ ID NO:12), (xix) amino acids 454-546 of human SV2C (SEQ ID NO:18), (xx) amino acids 411 to 503 of rat SV2B (SEQ ID NO:4), (xxi) amino acids 411 to 503 of human SV2B (SEQ ID NO:16), (xxii) amino acids 468 to 560 of rat SV2A (SEQ ID NO:2), (xxiii) amino acids 468 to 560 of human SV2A (SEQ ID NO:14), and (xxiv) an amino acid sequence that is at least 95% identical to (iv), (v), (vi), (xii), (xiii), (xiv), (xx), or (xxi) and is capable of binding to botulinum neurotoxin A (BoNT/A).

**5.** A method for identifying an agent that can block binding between BoNT/A and an SV2 protein, the method comprising the steps of:

measuring binding between BoNT/A and a polypeptide that comprises the polypeptide of claim 1 in the presence of a test agent; and

**118**

comparing the binding to that of a control measured under the same conditions but in the absence of the test agent, wherein a lower than control binding indicates that the agent can block binding between BoNT/A and the SV2 protein.

**6.** The method of claim 5, wherein all steps are performed in vitro.

**7.** The method of claim 5, wherein the polypeptide is provided on a cell surface and the cell is exposed to the test agent.

**8.** The method of claim 7, wherein the binding between BoNT/A and the polypeptide is measured indirectly by monitoring the entry of BoNT/A into the cell.

**9.** A method for identifying an agent that can bind to a BoNT/A-binding sequence of an SV2 protein, the method comprising the steps of:

exposing a polypeptide that comprises the polypeptide of claim 1 to a test agent; and  
determining whether the agent binds to the polypeptide.

**10.** The method of claim 9, wherein all steps are carried out in vitro.

**11.** The method of claim 9, where the polypeptide is provided and exposed to a test agent in a cell.

**12.** A method for detecting BoNT/A or *Clostridium botulinum* comprising the steps of:

exposing a sample suspected of containing BoNT/A to a polypeptide that comprises the polypeptide of claim 1; optionally, exposing the sample to a ganglioside; and  
detecting binding of the polypeptide to BoNT/A.

\* \* \* \* \*